var title_f20_4_20544="Dependent atelectasis CT";
var content_f20_4_20544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dependent subsegmental atelectatasis in a supine patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial computerized tomography (CT) scan from an eight-year-old child following trauma. There is patchy opacification of the most posterior aspects of the lower lobes. This finding is consistent with dependent subsegmental atelectatasis in a supine patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_4_20544=[""].join("\n");
var outline_f20_4_20544=null;
var title_f20_4_20545="Pediatric bradycardia algorithm";
var content_f20_4_20545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Pediatric bradycardia algorithm (with a pulse and poor perfusion): 2010 PALS guidelines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 490px; background-image: url(data:image/gif;base64,R0lGODlhDwLqAdUAAP///+bm5gAAAIiIiERERLu7u3t7e5mZmRERESIiIjMzM6mpqczMzO7u7t3d3T09PVVVVR8fH2ZmZnd3dy4uLoqKiqqqqg8PD8fHx9fX17i4uFxcXE1NTWtra/8AAP+IiICAgP9ERP9mZv+7u//u7sDAwP8zM//d3dDQ0P9VVbCwsDAwMP8iIkBAQJCQkPDw8ODg4KCgoP+ZmRAQEGBgYFBQUHBwcP8RESAgIP93d//MzP+qqgAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAPAuoBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5nQK8vb6/wMHCw8TFxsfIycrLzM3Oz9DRz7qsAtTXcNbYnw4IBUba2+Jo4eOZA7zfReXm7WDs7pYC6kTw8fdY9viR8+D7//kAVuq3TqBBKfoOKiJYT6FDJgkfEkLHS0LBNxMEQNBCgJeFLg14McgTUsBIJug2noookRHLLRB8nRSSUaUTCwIQCEkJ4IAA/wJfSs4EgFNnlaJZhDbheSTmgF0tB57BqcBITShIi2ScEFQkkaxUwFpRilIjqpdREaHVQnVIxpxmG8Tk9TSjgo4IGDDwNSElTl4InAIoICABkZK8CDQoOQGBWQAMFMA1OWRvrwkZCXRswKBj4Y9vcx6wzIvrEMlPY3KVDEGyggaQJTumfCBBYgeMBfTVuNcwgI4HBLN2DduC7dlDAQyYrVMyLwUjUQNQ3dO2V4qPy6xNW2g7lrbKfwK42vGb7QJ2x4vPyvNqWwkCnh7pKKGkhQaOzc8jKyRraAENJJAAZzkRQZgADoglhHTUSbZafACcJxRhQKGjGF88SWaBA4VNB/+hgwCght9+Xg1h4RHoGMagbnshANtOEAqmHXeSeHcFeJIdoB4EHP4ywFXoVMWeWVdFaBICLhYxgHUaKeWYBTgZxh9RBe4ohE+/6DWXSAqGGKNuXqamW5QACAWfLy6WyFNK6HAl3JcTkDlljkQc4FmBK07QIwIT6MgkLzaNYSONgAx6lABVealjTT06QASQiFJpVHuPpSiARUQE2UBNTgoAZYdT+veYT74N4dgAQnWZZ5gexgmqSPBhKgRZTCFpm6NviumqlCUuKICOQhCWF1KrWtAYL7X9qoahhPbB7BTgXQXfRqwJAYGxZgU5WJWUqtQjZY+K1xEEnd7nGAM9DiX/LE2PjfiUAxfOcyAD6xYRq5cP6joiulzmNJIF5Kr52Jkq5doqhwg4YNlQJ/ZXIDo63QviELYdYBdsP5rxbLN6bAzFliY14Fm1DZz5kwOQJurZbhsV6SFQRTjgHGvl9vRcr0Ks7HJnvWxEkXMjrUwEA7YRAOKqWALdk3Px0fqYZeoYTN0BjjnnaKbM/XazTkT/5OBfdO00WwIfzchxIx7vYVvZqviUKBSkOpL22XXMjQeZrEjnxJYEJJeI3XTLAXjgsQxOuBuGH95K4oov2/g/jD9+RuSSm0J55YJinsQAMF/B0CaXa/5OFIRhWvoRnw9BgHxGrO45PUu4rgRhgsMu/0TqnFdB0OeyyyN6IDYeCNu9T/TuRepJGD8I7p0jpA7ymIT+exfB/4QqAgpYZF0CI8mLqL9Y/mqyjq5/r+wQhEnGvZGFMWCyAxRxnz74vQALwLev0c55SoEOoAD+JYMZAbiimZj14jWRAVQCzTKPBULgfSZKQNUaQBjCHCB+I9me+3rBIeeQ7ynm01EBmFQEDYoMMAb6Xl7C0z4WmmSEyFKPSKhGFwBW8FdJ8h/qpvcHe2CpVOj7VQIGIAECyCpCXPHeN4z4G9YJQQJVKd9TlpTCkUAgUAlI4jcYsMIJQKCCv7GI8obAIQvoLwHfsEDEgAIB1pWRQw6A42+aR4Qy6v9wJ28DwDzueDvbLWkxQyTMU7g4Ei8SIYt6fN4UDSNF5RiGT9tCQhYJ86IULlEChBwPBPZCDwToSI16ZNsAjVBGQQohAX6yX0N46CzSIcg2namPySzivSeKUT7L4QUjQfiN2qRwJwOaZSJt1gs0akMCtywCz5ClP5iFxAIDpJpe7vTBCRxRmdR0QEwUcABtIkpH8/AmN4eZKQFKgHbE1GXJekHL5/Vyl8OsjRzROSthZgQBTkQnMsNXGF8K4Vu8gJ9t6lMAyfRtmb+iJ+eMgwTpsTIL1YMfUIzoE9hkL5H6FCNXyjgeePbDn8HSRvYqGiJafiSTIbXlb0wzBCiWKaH/1sidtTzJxYhVJSQilOBJJgBEALgUpxEMKkOo6CklAaUbB0AnSm1mUZP2sTpNjOcjp1gOkl5UCHu5WiR9iskVYpUhnjxCWK2FzJvCdAj4UYATV/nQjrlSq0aUmS7bmVFi2kmXHn1nCp8TR+ckwCJngh8764ol+xXAMRVrpomSdNHDFuZ8dzmNKgeD2F9h54L1S+RlfRpQE/Vsqy6UgFwLA9iAfjSvUP1hOUb71wNd6pdcDa0L6bW9ESHqhO1zbGLL0ZhKXqSteXCoFui5B/yoAz++dQQVATHGIQgXuFR4LhaIq4cJ5DESFPEGIHCSXLZC1w7S/S4/xHuH8JJXbuet/1t6a2He9SZhUAV9jt/cKxX6ZiMK3cAUAQZk3+j19w024iMAEABNIeVliGUiMAx5cT/nWGRJtnnNf/HQ3gnf7gg/NEIRD6kjBUBAu770JSRp98D75WVJuBmrhelQYQsHOI8Evh+YElzQbiIokn+6IMxQuWL19jgNNuKQfvnrYYL4zyj4DM90jihTHv9YcE8mhxTii6ig+WyFIZGPahvMwSZPNspsaPGEI3fY5C4XzHsQ838jpwCWZtd2aC5vnMmg5jn72M6jw3Mo6mxf4cr0EdBbCoObEGhwwFkP1C00iuioOz3nGQoLRPBSJrpWMCi2eJUuQqIPbeg+hoTTqAM1Of8VLYbyiVrT7CC1UbXAZ/oGGQGYGkCglPBnNNSaCc1dgqrJ+VUoKHp3p6ZzsIO4jmGbiNHRdfQXXmzA51BwHpbtBaXZtz7szIQwx5kLVxwbVgjfljDfEq1zuLK/G6czqY5RcSRH24+55E+FGzTtgsuzrUre0G3I4tA3SsfBEP7GOvvNiaPASISA/+Q4jvKMYvTowSa+72fdq42s5re+figcNhd3IbKn0Gr3+lCXRiAiEkoJIU4qZ9oUm4DJUW0eoPhkwE+hWgNQjJ+kxhRmV4SMN5ZkO9klWebEhgDM9ihhtYKRicCuKzJTKB8IUXHpS9/dIudoM/M8heCqc3k/hvj/xwaoVY9TNzVkKLPh7ITUihvZ44C8PoCuq9Xkt260sqkXhTNjlZro9GfuVrfOioAUtq4Dt7kR5OVLO5kAOm7duwavVdo5eR4mu1Rdk66Nw8qR2E/1peVvDGyoBl4buY4qOle3dOW00/O8hOpgDJM6dBK1AKUnYuwloPeNI2TudIdCN1Qi65+edexWpLRVMYm80V/dGklezsx3bHPlJCrnnIz7KGGunCSlFPpEt/cxnYrRcBht1vQ8bc48fLuyif/zOXsKUAt+/PR3HcHnB+FJKSN0Xqe0pJpdO9f1P4C9BJ/VuMcF8DUzA6Bbv8dZiEJprPVgvXBtoNd+3KYjhWcN/1x0KaNFboxWWBH4S10jGd+wJc0XW4FVSw5jO+GnV1SiDiOoV+gXVQxVBC3oOhkXfwgoWFVmf9vCV8OUcRl3JpEFUQG4BR0HCnGHErbnBH1RCkOYXkvYCd3ANk7whNvQhORFhUFIZ1cIhFnoX1toBVaIBUWYhV8IXWNoBWGIBGfYUMZWOWXYVm1IBWkIUWsoOW/IStWjPhHXWtaxKA0YGu7DfHokcQumSuFjEfOzQthBRxe3HHHkSXsHcAjHQtzzPkJEb5SkOXXIQ9WDdnqkEmEFSkVVfi0FiI/xiUZRBBV1dMT3DbXmdnWhAF+3d1pndZlkSLujElB3TY+TidNTPf/ANEwARXgDNXPDuGERAk7fEIxadQBM4wAZVXtEMHunlCh7135NxE+s507BkjDmhjm8+Du+iH8EoW6mYj+OaBiHhYxCQI6nxBU44Yzb53/T0TzvVxf7NUXTZnxLFUpPNX6zRodd6IWupIMEsWADMhuvgZAN4AARFlYFuT2ZoksIonTPoYiJQYwEkngxSFUVUYMMgRNzSCjfKDrhmApxSDgjiYmupApSCI4BKXcvOQkp6Y0xSQkzyYZBkTA1GQc3CZBQQBEWAS+6ZD92okciwRCStpOZo5RPMCgyBYsYAy6I91QlVm9MuZRXCRFSkDt7UUkQsFHW1w9qNDyBAkAe8jD/DTiIMmQSNAQhO9mTu4hhIBdyWheNFoEZzqUOBGZcR2BHCXA1Kzdgn6QTobhSWQmXjeOUQNGVQ/CVAzYTBOFFfwcZ1FR6qidjviBQl0JBBjVfW4iYiqOY0xiVDGABeUQQe/F10WhWF/SXX9VJXyaYjamLXQiahxNgHSmU/TQdrMNBvqJV2/hY5INC1maQtvUanrE+b5mVhMYFIdFdzCll0akEtjmdemSd74Wdf6OdO8SdhlCdgRM6u6Y6mZYFFIEFzfU541lOTpBkSpCeIZmXNumdv4UV4fAWylkPc2g8/GQRkTZId1If+vlpZohyxaafW3mEleEiZwifUCA769kd//TpXU7gGY3JiQeKaXUCRPm1E+QSGMHyP0awFxyRaeoZnyepHBiYPCa6n00Xn4IAnnRjKNSlSZ3mbgt5QLCxJU70dwLmSNS5YLICQBKgEtHETicXVRrEcDHUbs6mZEoibSwEHb/hYGSEpI3ZCxxZcQVApALEUuGDb8oyWre0X4XoSBNkjNMHZRN6YUaQYUdAXZaHgO3kPxblRp6CYlE1BP0pctE4dJ2VlzX6T54CblnFpwBSjYeURFNEmAVgpyFCVcrUD5wjjxtWQOB2bErimqtTi2lHD2+EIJeXfrczdSXWDZ0hooiKkQEyAHA0qjzZpm66knyan/oZeZhUmfrVo/9AZHdASqjASYKVQU1NZE1L02WU1nev1Q+CB3u+QJuqxzn+NEJRNaq3Vnqrg42JhFDVdE0Qqlc5JjvMiKw5c0vGymKyep1T5n0SFmqQ+kSsWY8bWkcgqhw8ggALd6iCyg6+pyNUo12I9I7VOHzDxFOa1a4OA5zyKHQLO23Wel31uI+Qx5qr51WqYxriV5WkikRUIlEmllMWy6ZtOijZ9AvAOUwgaIAH4HU5kZTp9FpU9nUIJaD7qmmVBSwJADPxQ3gK6Fe0pEvf4KQxdK7RWJFTGjSLp1UVKCssiwAIhh10dbMLkoHIIn7sBi+4JJE2mB0/iK6yKqN9oAAwWgZ8+QX/t1a2XjuydmZdYXBrbAte6Qq2hxm36Qo8dFu3PXS3eNtKX7u3fiC3zQK4TCm4NEK4y/m10pC4iru4jNu4jvu4kBu5xeC3EmG4lFubl5u5d6a5nIs4nfu5bWC5oKtsoju6c1YCIAACApC6JWC6rvsFKvALMfC6tCuAvvACtZu7WNACvbACuvu7VaC6vGADwFu8UYACvaACxru8TjADg8a80JsENSAALRC91nsELrC617u9QwADAoAC3Bu+vhu+3Nu65Hu+6Ju+6muHktu+7vu+zEA98Du/9Fu/xKCJiUk9AbC//Nu//vu/ABzAAjzABFzABnzACJzACnzApXsIbfll/w2sFvq7wBRcwRZ8wRicwRQcwYXQJ9XnD6E5wRo8wiRcwiZ8whx8CKBUn+Epwif8wjAcwzLcvylcCAwJhbOKki48wzzcwz6swDU8CFwUm0G8PDv8w0icxEpcxFwQAh7wAQBwAh4wAl2wJJ7ZcVNyBUwhwQKoxF78xT7MxFsQAizgAScgxVTMBTnGwlcgdL2Aw0wgFC0Chmb3nUcMxv6bAbygASRsAALAAXj8wmKsBSEgAiEQAmgMAE7sASFAAmIAOD4BM6YJnUmQxWZYxxLaxS+8ABsQAbwQAXycwHosABrgx4CMwaYcyCicC4U8Ak88xR/AAiRAAiYAxWEAOB2xVv+hEVaZsRkJhBxz7EJcURJCgxSWMXNmERMQUDTGIR6UKV/qcRf+spafmBPwUSvd6Dl3rMEbIAAGsL8G8AAKPMqhrMGprMolPMhZUMgAkAIeMMUiIAJC8AHyfMtbkB9IcCAo4wsBQiImMcfSohv20c8FYMy8gMwbQR22wRUSci7d4CLpkRl7lSC+oEYu4hP/CJOsBsMXQMr+SwG9QAF83AEC8AAPIAAZoAEg3dGknMoZwAG8cAEVEACjfNIC0AEBQNKA7McUEACpDNMc4MkPcABCvb8V4MklnQEBANIcANIUoNQkHdMzTdIm7c1/vL8djQEmrM5YwM5SDMuyTAIsYMv/j4YF56JMIMMARSInIjHHFUMlA+IVTmHQiZrMH3LXAxA3ipIykJHWYOEUHQHHGg1RL6wBAnABAuzHEZDTvpABnrwA5JzKIP3NIH0Ao2zZj63TPi0APf3TNx0AnozTj+0Ti10BnL3Unz3Z/bsAvIABUc0LGXABF5ABpn3K6czK9SwCU6zI79zIj7wFuVwEpyIUa/0q/1wgbx0lSpHLdI3QHvIU0oEaep0jfD3c/XKK2NYhQrjNGGzYiO2/FWDTh83Yp0zaNL3HpowBrc3YG0DOAQDTBqDZPL3ZgAzfqE3Z3tzNG3DeAoABqg3TOK0BMN0LGqDZ+wvfJ30Aq9yLW4Bt/yMRGSVRAPNSJPuSLgBtFvAxAULRDSbRKH/h3AYjIg6NJJuSLbeVDvMiFtZRnsmmySfc0eUcAKx9ARrgE4ht4OYd2X+s3v3N3u590vF91fPt2fhd5PrN3/7tze/92R1tAORs4DIuAJ682AvuklsATW88pSLhMknT1txyGS/1WGN1JmcC4njNKstEpXz9M9cdkacIgC5uwn78AEod3ja+2Td+1TQN4zxeylet2pVNzhgA46a92CTd2Vdt34DuzeZt2j393zc9ygvA2qQM5aDNC99c5SQpCJY8Bxmee0IYwwaA1KAcADa90uTNv6bN2eh91S8t1fztyTJN0ycdATCN6P/1reSL/s1HzQt0ft9LjtN+zOqVrufgPN6CjL+B0OlxsC+gvtHobMHuHe3/2804newuYb/a7gu8m79xTu2ivMfg3r+x7dHYvggpzNV8G+rj3u7uTsNoownqzgeGIwDvfu/tLqPpHghnfQZFIiNcoEaJMV/1ju8GH+36Lu+s4DJgkIQp0p3sfvBebN/4nvCZYA+66XRg7iHL/BPNDBRF4Rmg8RO+PDIjESQdoQBYLqJnnSzX8VlKkjVpXkgJ6C/Y4SlOwRiOsRE14/IE4CguDy7b8ubOxd0Sf/QzbPFceBhr4xYYDiYKDSbnURTPphP/UeEkri3wURWCcS4tUknoICb/TtQwCdbhJB7R4vHvTeMRI1IA5UIh4dE3OZFcJ0SbBR/I3cwLgNzrSb3kQV3SRF3S/G3TOG3j3WzZAz7r3g3TF3AAjK/g9s33Hs33D6DVX6z0lwAPeHNKykImIR4fWZEfRTLd0dYyRGIWDg0YHvwnZkcnV6Ld1G3iVaH2qOIVT1IukSdwqg8svVGedw/GJ33tAdDopw3gly7aAgDZyOLYyc9PB7DoB+DdtH3YGTDnS24A0s+/rC3O1n/58X7xRrD5RvJJHfL5AxD68zD6sF/6VnIVZ20ss5EssakoiOobse8zkUL75YL7rwUEACHAMkEIBAcAQ6AYPoUC6JRaHQoC/1ntltv1fsGBDBKj3Qg2YjJHYAhQ2u/2WKAJsA0HwSWLIQc60DT2AvT4DO/a/PY6KgLOkJD4wigrKaWsMjU3OTupMD1DRUdJr6YaEgQshiYEIAAkBCYAIAQGABRscW0tBBAA9BIAWl8BGo4YHBAQGgZch5+JAZCfUg9aFRoABmaHnAmGjgWSlxuknZ2+hWoHGpAYplUBrMUtehHgLYqFrDlBS6dgsTSQoBY6ZbKcSXMQjxw3cAzQsfOgDaIAi8oE2jDoECFEDQ90uICkgsKCJwv+A7iS5aeWL2F6UimEAYFIt5wh6cZu161cA+6lUgBPGk2bTeA5eyVNGrJeN4UMOP8iIMGqJ1KR/KqJZCi0V+gAOMilip27cfFW6XF1JO1YXpF0EWliZSZLgSjxfqHYQYueCAEqCKCQ6GEciBIxjNRg0aGcAxwLeSTUUEsEARUM2TnAIW/nLXVjhpYpmnRp0C3vlVa9OvTpUnc9e84ASQDnCpYFPMhAuPFhJJYvOGKcgc0eR5ARfawI1w1gOEiax87rmvVq6tWxV7leKnV279/pioYtnTxeieXRpw+zHXxL9u2rv4c/n/7o1urxWzqfnz96+fVD+Q/AmAQc0EAAC8xkvP4YbNBB6RI8UDsJwYuQwgvjE+/BDTns0BILMYwiROxAHNHEl0qEYkEPWWyxwRT/L4TxRJdmrLE9GaNwUccd+cPxQB9tBACuIYks0sgjkUxSySWZbNLJJ5nUkMcpqfQMSPpiGNKFILmk78ouZapSzDEH+hI+GIZEAcw1vTOTTQVPMuCvLCKIrqAH7CRogRXJ9NDN9nCIZIY3CbWu0ArjnDOAOvHCs89HPzwUChoiqUHSS1HElMREKzOgggt2M2AwwUgKYIGRgguMpAVwc+SB59L4FLo9L3qOLzkto2A3SPP7EzwVIolB02FJ8RVTPiFJYwsDhnQjAkeeDSAOA/i4wI1PM3A0gOAK4eOBB0wVAIMH+MqCVg440+CCBeTEIANuecXPWO9eiAQGYvG1L18p/wmSs9MADHjggDkFWCBcPxAS19FFIhnXDYQXgOMBDWiNNoAHKgiYTkfiVW9e71YQAId9SVaw5PsK8pdON96loLmCAfnLWoBBJTcLeLNYWFwtONjg3HQL1nhRjjv2j1gQBKDh5KWfmGmHG04AgAQWPmB6Ez7BUHnR5kTaNZIIDD7VOMBWxe0vncf9jWIsMLAVYHCHLjq9j7MrQQAVrGa6rhRSACAHE/LWBOuTtJXWYLkRXw9fAV4I/OS6SLghBw90ACAFDzwwgQQdTMC8b6sHJ0iPXQ1P3HQv6M4OBMcfr0IGD6r+QHMATPhAdtZDP1138lJn3ffWrPBgBABEwBxzEf9OuNwEGfLOfffnp/tdei5LAAFp60uYQngAZCdhig9YaF5HmAcS2rPC+UPfwd6nbz8Uu+HCG4rtLTdehg/sFx8lOBCixHwuyGcJjanvTnnKC628QEAt/O8zhzsJjKAUQQlOkIKRcN9KhtS4C9IFJadymQDh1oUAVmKABiSIAjvIJxS+7QsjJAgEN9i0GJKiBZFYwQy1g5INcOA25sKNnB4mrkj4rFWGY9S7DqAFhukqYKq6DLMEEIG17SljaksEdLbwANxocQ9lKA4TI5CrDJjNiWlAXyCQMAgkbIA2JYlEYBKygWxJAnWaKEBcTIZD9mnKBZGwAQ4/8YVkcQGJ7zL/2MxWdhFxCY1bB+BDwXrYwy744QAlDIC67NABDuzJDZgEBAfadTE7fYtsBquTqHbjsna9qwII1EJgsmWnJCwwhAkZlcHg+AifCYB0IswEA45wC8EBco+YQkEksgdIFZ3EiWhA2L8QpjGGkaFghqQA0S5JEZJYsplgE0g32ZizUboBgXiiDRqE9iwEVuA5CrOTnNCQAaFR6zely2U4A4FIAFpBGQdIwC3UIgAJBISYygzFDJBg0GXeqVx7eld0HpAGZmFAVDfDJsxENQkzDGYMGQOXzTxpLoGEFGARyMAYxxkucaKSlhtz6KL4ogeHeSE4FaVkzKSVxD1hoG3KuuTO//ZJBQf8cx7CFIIetCFDPSq0E5RqAVOvUBA/2GFlYmvDnkiFAXWhgVX1hNkY8iQ2y3iUbE8coiuhGE84XIBRWnBUOd1QnCfC7VkZgEOdfuNOg4xEMBnY6ga0GcZHkIEiF6DALtdYRyoEFAkDOIBbHKCigkJVE1naEmWd16BT9RJ6LboOURMwi15EVqkzLCam0KQmzE6JAuXq7Pg2QdScpIK0ptiXVIpF2U3cULeZfe1vFZcpTxxgKgSAh3gKQIVckPYoTYhsA2qhE1oYNUC61YRqVwtc7eIFhp1wxyqgqwTkTqEACFCAMAkw0GP4JBsAKIATmJFb686Xg32iSC234P9KS6zwt93lhDuoqwchSGCgBBhLgQ8clrHM4o53hEttYQEBfwohvWHBBxOSCgXiNrYTp6XvpXybhTnuwQ38RYkjOZvfEJu4s/4dggMiAWFgHEUCDRAwLAr8CibURMfjgICOEVCAOwpTAMl9wjEscIzkNlcBByiAMKhAgG7o6zsVtPKVsZxlLSfUNCfpwGAAg9/yMJAL+q0Ei6HnYk80QAETuDGBAUAAIh9AzlHwp3gJ4GRQFFnDcCnwQLcxDgHIWAjvFYBxOwwfD0P1SyEGBAX6J0qAReKjsLrkczijBbEFh2FEk9VVSXUBO0CRAqOOhAYctQFIbzcLas5EARDN5gH/3NEBYinwLUZb59H+eAlFvuMVrDIEKRdaAA2o8DaYoQAFRPa9U4AAoK9WmqMEmaAfrpBqkJXYLcxmJNcU5SCSOEBw7bSiXZgZthhoM5EaLKKDsANgB+FAc4oZuK7mZ3SfEWdfKKDAUGnuLcQi3V8PGAmkhfFxi9rcBCjBAdOe8lESgPBhrmYCTpCstauM7c7AEk+StCTCMMAGb/cBqIvEb8Rys7Y4SpJVkszZBS4Q6e3aeyV1FjZ1beSmZ1cb49lp9ElAmQVs4cndd/hoEPuntW25gVrypPcddhnHonNgYgEk1wYiIPN6w8RHNqcwzmv0pWAQetFM/XnKzMZuN0Ai/wJHVyRF35hfVDki3WpDYDhJbeo0plqKrJYW1yermgFAubQ9z1CX1dMzv8eL5tMDklgiawSeG+gowaZQKyTuc42XR5urXjykGi89IEEXCQkwcuE9AYHmrqIVkVAA6+GycCgoBRiHhoJZkkoNtxw685oYPBKKwYCxEEDGCADHJpjwC+GSxtGff23oTxEL4DNg4JrqnYD0cHwLZKMVovUFNBjsiwxDofu3R0Luz5KLVYDFCuY4vjrCkQAEOKAXFj9qEhS9eefv/zOA94SBI8sBJCxfrm8UbALnys8sHKD84gHClOIpvi8czk8IdE8e7ojwNOwoZuEY4msI9MDijqC2CP9A+eJB+gYgJ24h+aBBAWwCH0bh7PgvBqHvCZhAxn6NqJDsyZBAvIQNCQigGeavnyTg+KQs4JAguaIrG+4oF1zQLvJPFI7g9ISg/D4Q/GrP/qIiGvJNAokEHtQPFmTh9oyAKqbsHsZCCWgvHowMxqCNLWBMFVRQBbEBGo6vuhAvBvnP1d5w0J7gxo5Cz7ZBGAZvGpTAAkgwEBtA1oZB2QBu0GBMAC2uyAagvc6rweIM2gCiAKHwLJ6g9Xww8uACC7NwKbZQCHCPAtPPz6ag9aZMCOrPwsYhDaMwC08PGcyCAW5RDp+B/eyQ+fBQBv2PE2pwCBbu15Ssyfaw4IYAzrb/AdASwP7kbAIGSvaEpACkDwkkYOCYEYOeMBQOkPzCsBNlwcF4cBS9wvyKDRW9UBWcYf7E8AhCawguUAjUrwobkB+w0BbfIRe/7xzmQhRg8Bc/bwafQNmOCwEAERbkTxsQkgoGLxGJagIIgKjcS/7ggdeYoAAmMcO0ERNfoxs94QLhQfjMIRxZIQxjwR29QQv3wRQnMB7WcRVyQRQ9UAP5ociUIb6WwQHssReoSx/HgR9/wR9pMtruUCAXjyDD4RohgPowAcaESQepAgqO4gcfkgnEiwVpIhVSAQkjISG3MRNB0hMsYPWsUBy7YSavgiXREf1iEhY98sgkUggajiuO/0v4PnEdOlAdb1Eoz5EXqQxlkDIpg5FClAwKhvHwrk2hjqElbwTbtiwyJXMyKXNJClNCKk4eoYJExhKHnMHyHtPw5qvsYqQzRZP5TtO6SJNCNDE1sc01MYslqu9YTDMUBqAODcTBpFA0vE4xYdOg5KMuqUIJZhPEarMKfu02owI3B+S8/GE3/w/sNqHO+CzRflOh5EPZtMEZnJJYWtM23485AYTaWKM3ARI6w+M6gdMTMGwIIGAClpAqcHHaKnIH4+w2EwAHEcACpLIcQ3Mxp8A53RM+By0SJGDwhGL8DAwbFUy6jDD87ogHB+8I2isJG6DBYm8I+eEA8PIZ+KwqL/+0CXwh8/DtFiy0Q19BRPFPzq7RAWar90REPZVpJvYQwm5swLLxLH7sjjKsIQ0xzpYtEIXURw/xPzOOCibgFSoMH5Lz/RLAAY6hHAmgxxgAI4PMSoUMj6IiASDyBClx1uKCzzR0Hg5gEptGI7lU1izx2LY0suRsI3HBS5sGJ36BOpMLmIjCMW1LRpeqE9pzHQh0S6EBAQYgGQfN5o7xAAyV0NqkNg2xTF/vF5p0OTf0CWwuCagxzzI1Ia+CCAnMz6pPTI9v4QSwCZSgyJhxAHIUR5+AGVnUz0q1yarRvQ71FviMsTAQ9fj0guTjGbdzHAaO34agBhvy5pZxIQnRQL7/Ewp2UipeITktTjnJ1FJxbdAwssiuNUunQDn7CU6J7QqSaxDLS0KFQRLT9J868irO1UvHT1D5bAKEgTpXAU8nbldjKDghjjhdzwEcTKDqcyq9DioLLRWm0kuOU/WMAf9+DZgESlqpkcKg4kEbNAyLM9CAbx2+MlSTa6iaACFzAv8+1AdDlFXDgQmJCt/K9CuFpPSW7Bakz0UNdELs9V4D70ilTTpFQVrBpDq5cWY3aDUlZFlDwzxJQWe7hGfF0md5tWYbVWmT1mkdj2k1D2rli2p/57QqdkCE9mSIliW6dvmsFndCgfSkK2dxM2uxw2h1lTNzExPQ9iW+thOkVTm7/7Y6kTYww7Z5QkE73asoReFtWUNt99RmAQRwYyJuOUFt6xY9ezFvA+c9/nQlkUJIzhAa3kE5pVIKjHCgbtMZaqs/h2oWKs7YEqw/77O5/PXiAPQJJNbAiAAf+IxHM3diOTc/m6AB9jAbCNb0NHfBAjFBW1VlFzR1S7QabiEHCVYJhlcC9vBAwaHOdpcBWjRkDy1EmRBGgdZxp5Z1Y+wJngwxz0JDdWEQ5YFSCZVWaWGglIEBBm83idTCIOBJ44xK3xcAt0E8Y3R13RPIkksBIIDa4AzOECD80tfC2PdJo/TFVGHgfg1LBw9KixUKJMAJCAAcaO2B71Ndh7QQ69SCB/9tbp+XuuLRbtE0ESvxQ+NSSLTXcSCXDz0Qyr73VgUxFWrsNh8RfQl2B9V2UWvPKi6VsWqVUmlEfys1zhguHMvrEW/4BuGiTEeVQ5srIW8Qz5y4iKNiKuK1ER3AVakrURe1zh4RhO+zAa5xoEg4VVcVx4Z4hfVmb4P0vXaMFsBBhp/AY8HhfJ2hgL1BPCMYfuVX1watj23OTNe4aaEgW3GhFozMwIoBj6Vg5/Z4Qyc4YfVMGxq4xzTyiRWY9bI4LD54XSUYWQVZiwmZbh0rHYW1fM21S9N18ti4dTxBOAfYYrtChsXhdpVTLXJhYj9YPKXySU82G/7tXzt5CY4gLrf/tnW/wgV7wcjUIhV42UWfuLyoIgnYjCp+TWIdVkpLr5Mf8ZoRgCIVOCp3N4MfkWGd9z6NMAEG6mWp9wdbWXVfGZYxBXGtk4jlVjwH8Tezd55NY1js2R+OMxOUIdhygjxhs5/9WTyklm0X2pUJpDIleqIpGssuc2mN9KEHVzAHk9WU0jQYF0EGep4DsqO166OZT1upgIHnZWsfuqRNur8uuspUmrxcmjUUmmaPMqZlGmw34WOp7wgacnmBYSpOmVWLbHdzFxVYtnelC0Fv16e3V6M3mkB4euZmugoycgjOl7iMzYMbbsrezIxrmi4X2G0fmX8fOIHdQ9Eq+q3hmqL1/++qny+rF4vwblhIGk6LDc24xroaB24rdpClp9WIt1mqrS2nMaT56PpRPnqrKZBOjU2L3TNHay2Vs1QbJtkdKhl9s/Ww2/o0FTtGGrunQ1tuIyGofUF5tRji4KEFMfuaTQ8erTkXeHdiZwG0nVC0VbO06xqx22e0g0S4g/bzAoGqgBG4o5a3e6s/6EASXKukkEBgtACNBKAR5AAuQgU3gm4LLgBu2smZssC6dzC8dzBnkOBw0moO0mgLDkCbyCXFeMeuRS81iftHnLu9zwBumAVc7Apm2KBcDIAzIGJZckPowEzoLiMLCjwwTAoQaqML9CDBFUnb1ICXLhy5ByHrsv8JueeGvq/WvnubP/YDDhxhJBBiwrclDragwHkmwhNIo1xcIyA809xbMAwcVQwCCXZjPyZNV14ExH3nvmeEyLU2v+sgIa4bMkiOD+QqAsolvAdjvTugf/zAp1w8MAaDvDE8Mih8rMZKxHg8w7VAjZCAA5KoV4RcbJk7u/JjP86gA5hckSYhYCKBwFn8lZ58gQIoy3E8EGy8L3BcpPggEOCGDnq8vcucvD3caJS7vtuc0ZCcquAgiVA8C1R8CwKDD1x8khSDTih8xq+7xiV80AdrSMoA0cncCzr9wx89xCPd7CZ9sPj7wP87ibSFWfDcTjagoaII0/O8MRx8NwC91BP/fCQ4xjJYZsx93AA2INUto9HLA4LiutojSMSbm8ThQp+kWzDSfMAjIcqHJAMqwLo5ACE4AFRaHC7kaLyHJM0zfdP5HK8iISKGpNQ6YIvSXF6oeoOq53pAIJmwc7veJdB/0cg7Abv63ROABS6ERda1i1n2XSARnhN4a+EDBC40aOB9O82I5ZjuBeM9oYaQ4OI5vuN3p+I1oY8eXuQ5AWmQ4I8kHeVTnlhqSGlcnhOOCQnkB+Jp/nRUXkEEYFBynhMQKuhv5Od1B+mpAH4EQOGLvgpqQACeys2VHnGYfgpsIBIuK+qtoI9Wx+o5ZAyknUEM6cQ0yrGHJWSQoOq9vgpS/yvbW0i7uwBd8MKRwIDbK6E4+EIDnqPUzCAN+EoPHAjKvUCTGE9T6gUu3j4TTN7nu2AQ+APx0YNRBqFcXoXkymCqtiYL5ES+P4hXsv4JGh6ZGr8KBH7mvaDcgN0yOGMMDsAvxLursm4MLOPBKQAOPijflZ2X8p0RfCiKIo3s3yA64ArTJ4ED+OKmyrydNGDExu2HTOX2y6Do1kdT/l0AsOf0RRNr5KoNvqwMLiD2eUlUnv8y2qYMXMaRDEb5x4Av8v0NdOPRLkY3ZCr9i9+9+eCZMB0IIoHFJRMIdDjHZICjPAYykU3gcAk8HgGMYEExQDEUTOALPaPT6vVaAHjD4//yOb1uv+Px7jy/7/8DBgoOEhYaHiIOCrBdHJyZBTR2UDSBZQhocAhsChgwNXVYLXFcahxRdEQuVF1pcoJBMS0IGB09pEZUQEEaUFiRQYkicWjQRmFWRAikum7CskFHs+0lVhdSW2drb8txen+Dh4uPk5ebn2NzZy+qFdcem25QoUY6il48l4FVPGAYaOlzd+yAQCb41pi5RCUDhwgZkkEpdcRKhHwBDAjBEKFDMVMPKB3houGgtJIm0aRTp7LbypYuA6V8KTNOzJkw11TwtuEAJ4CNCiqpcGHTg0ubIpDhkKpUryPumuoLIJToGU6OpgrggCHDhVVDOBnhAvKMRgH/yhxtIIohpzOpQwVoKeb1JF2UNlvWvKv3kIMEBObk3asysOA77KR9qiusLuM1HQA2jixZMuHCiixjJtRAgYC/LDO7rAwazuFoShtDnax6NevWbUYnEg17tAIJEjzTnD1Ytx7Xvn8DDz5ZNu86xIvvJfD3NmDk2o5nLi18OvXqv6E7f4M9u0sH33Br515te2Hp1qU9qDDr5IEIps6n/xe5rEXK4v+QNxTCwwcAJzyMcN8czH2mzQQCQLDNgQkCkt9e5kFBhFnvRTiUe7vUVxcGRaxnUgSOXLQJBe8EAyEbEJFVhHyNPeabg7y9OEgILHhwwn8BChgHgbnNcSAnCVgQ/8iCCiIIAAQCDNBHjDaZGAkYk6BxEJSzdKKaAVR0KE0FIHVURipnPLAJXShCceVFkNXFQYb25ZjHkoGEIEIIIdwIwH4ehEBCmwXGceAEAAwggAJCFmlgofi1aaJAWQaw6GEP1PeAMnApc0FSrxwRwSrraVCRGJzMFcAGX0K14hmMHjFLpa6kQmamq8iXzAKfbhKqhBdUwJYAwKz25mi+/hHnCPwB+AELJJBgQn97kkaHn4AKIAEAByonwGacKMDAGz4igGCgDHbrAAAScAJBA94Q0MC5AjzLbZFHJsnZJtnSAWxoa3Q4C6/57mpLpFrktEpFBliKBRgHgDRLp6twAP9SF2DqcuYRGKWB6lcCA7yIqwhPnN4YTTgc6kFCZQCpi8waplecAKTgAYAiiPDGBzGjDEBMPm6SwAHTetMAHIEmAO1fCzaAAAIN8JQgAezSsbQE624yQaBDv4tkHEDXm+gajp7Btb9pmNwhpPJ8rWaqAlzwZS5HPAxFehODZGqE5okNxnqumn3RUCCuHUDbW/TrNwYmu2YvZobzsfJ/xR5LAgvLonwz00ULwMCQbxyw9CYIAMDZzkPCu7QF64r7cwLlrqtt5wJ8XnWSmXPCeXM5NiklJTkdYbvbkdrNDqQYZSCFAZfUMgsRYDjR6N+iftklPbifXbHvvUslxBHEwx3/cBNKyHXGQQSXvGZkiJenMs0iAGiny3nWbLOzTK9+wOUFCIAAAxbUHz/PCdJ/etCk/0xQDSDaJlTnuf0ZCUn0sx/+ZMcn8TRJQheCngRNQSWzoCFs08sABY5iAAM84SuNusAGOmWW5W2pTCIyAvTCtImIRc9gItRVJ0IYKwFUwITKsNVQcCXDwrUva0HUjeT+5IBuWa5QDYQW54ZELgadzmoAWNqfttWZKSIodVZM0BMTOIAlBsqBPBJQk84ThVz4QhrF4FWmQESdNEZjjWZk2xAfWMfDvQ9bQbocFgWVvwZojjMMCiMcGkCuTUDAAfISpBYBAMh5ua6PnBFjs2g3/8c09EQaF6xPeyh0ybm15ZLkE8wo7yiIUsKBXFUkpdY+6cpXitKU4ZFldFpCOdWx0pKw3CUvg4PKu/ySlnwIJmiIOZ5eIlM4tzCjMV+CjmdCM5rSnCY1xyFMOzQTEWXcUKjOwJMwdBCHaKBVxFxIhSFYyJPVsZgaHsZONXClm8LJ5jXrOUZ7VpKMbDBArdTgQigkjyckCigtgLchR+jOjO9EiTwRc87q0BOf9Yzot+jQyDkECpE+80NErxGNv1UphvVgm8hA1IXTGMxrAN3EFfgpAAqY4qUvHMKkDEArKmBEGSOalKa6gEOeaiAtL1wErVIxiw5e4D2LoU5HJUrLpv/W4aJygECQjiQtjrZyGnMJqQhJyjYY+s0rOCTcAzbAL15hBBhd2oAWqkQxkjSBChvSQFq5oh52zMIiGwmrCJM3kgUYDwvn5MJ5oOrUOx7nQArwn7gacKRNJIlaS0NaFCtXUQZoDkndmhe0Nne1Qw0zq21oaFdHylcoNIKkKIWUSkX1UBQtQAgPSwYXeDWpF64oF/y6nlAFQAV3LqJv6ekQ2QBX2MMiVx2JFZTQsFgAAJyuADirXP02Cq0EnS5Ib9BioAYlBwacbmdY1aVWocDVLBHUCAdJr0FTm9CJIcUpmGhCW1cBEbhy4KESC4BujdGhnBiBAr91xHr82gXinlP/FFwgLWsMm9z2LTdBDKifd74xgMtVGAET2FlFoyiBJGmRJ4KagOqmpt3x6nMNLvUt22DhQnGSc4RhCWc5N3HOCmaQpSF6aUztKwQJdYJWu8ptBTholg7RagqiGuoWwmlUdhS3A3Jd3nUebOXx/GFIC6xw6bYIBwtMYLMHqKgDJiCvpxXwDQM4pADEFahVovg+ZZxMB8SXzOrE87hX3vM1slykLgryDVTlIxzCW9FURgsA3XouHLjcZ/LeOdKqWaae+WzpBvk5iulyJJsJUGYleiNJ34JaFjurAJzpzIpwVpJoJe3qV1fl0rKOcx4ITbtWwzrXkXbwrLkT4cjhWtfC/+Ylr3vtnGKHJthsw9RqFuobroiIjYBjNnrsXCY0VdrY2r6nRJGtpGnoQqDNnjNw6EGWwAFHbtne9ra9vRJ3uwncejuCK0aEkaGMqAkr5MIKeXqqSVVAJF/JgEsv9NMwbcoYaJACWKedFTRgREThdITJZCrOigCO3769qVtC2Rp4s7uWyAW5YaYhIljl+wvAE14vAvwMLhzAYj4URVnjOhJTMOHhrt05GtKiBY3zaiT5SCsXwMBWGbpVCBiv7Yryu4WkUrrKIWc3ybdRdeOAeyRo0cmKytpb32rgxXcd5zcwQITa0lC2Xjk7utHg9DUQrmNelU/FfcxfMDAdILfFof8X4KJO1Vx96nqpJuELX3hl+y3cSW35tZ9eAcYfYQOUuMRdSRSJhkcgAnFJalXm8pEQHqECT6AA6C+Sir+eYUUPozsYZiuEmvPTHyB5u9upgPFeCT73Mgl8MeV9EaQ04/GceELwJYhDI1svVf6WSttW/Nu58KSbGgjnx/69iS81nq+s5ytEqNRBDIxk4+HclQsvdHvA6z7971a/zSSjble+f9jA4T37r0n/w7kf2588qPwhWv//Y5n6kVv/EeA8AeABGsL9WcYAFmADAhECQiBMsN8A0kddmIkDfpw8oQqV1YUCRmDNpMQO3MAJAIDjQI6lmQiVCEGLVMUmkEFv5YP/prjUqECGULgaB9ZF3UkPQw3HB/pgaM1BCqQAAOSACfRaBLFD3nQeElzI8Sif3MkRFmDfneFgY3DgBjJYSXjgDyYKHZDADeSAB+gAy7iMCZCADpiAywzhYSEh87ngEqYW3EQeLKyIGQgcFPSWLsSWM9CKEtRbBkzfJpCCC13B3CCVKbgUTPUWr+iK7VlCI+Qh0s0KJ4zIUU0IX/0hXWwhF5JRHcgAfwDAB5ghACiLKFpZG/5Q5y0YFEAE9uxXU8SfqFACfkEG46ncWMyC5V2MYK1VfeFEQQkBxeAhJehgSLCOwmxPWNmitdkFJzojt8VB+qCPy3iACJxAy5iADIwc/xvUDSatQhxeBCWAUPaVQt+UyVsgBbqZ49dtAAZoAgXoQgegTT4gGGypHRpsCSdsRVfAo94chSSGHSeM3e+FFTtq4jMipPvUQfqIop7IgbFsI75MjzeKShMeBBztF8gUwbk5QgcIAS2WSb5BXPJFYVfJQ5dwQFu5UaakAk+8YAQUAcwxoSRK3jEMpIApo0h2YEJyYQx8gwvMQfqQocvIwAdQozayoURiUNwtW7/A4AipEItVgVSCyVH82FvYVDj5oUCu2F3Z2KlAGU6JSDy84cQcRb8UnS1YpSQan1e+FBk8TPAdJE/6IAx8AwroHgPWRQdMIQY24CbS5WzgACfMQP/66aVfIuZOBuYH0gAn1IBhJmZknsxiRqAKcEIMQKZkaib6USYEvgAnwEBmtlMWToazaSJpgmUa4KQ0pIYWoibudSYEroAA4IAAlhcbMCVdsFNuSkMVqgGqpNCSjYMW5GYV+iaYMOM0xCYEgoAA0IBtjhY08KZJ7GZyLiF1SseHRJ5+edVEJF93UqT/LecBloAAqAB0thONrWIy6AoM7aE4fcRXvidROVl7/tQGANWOYYLF6SHA8ddRaACjcEEtFNd1wgMe6qPr+Q2N0dRM7c6COqgWjicCCsALoCcmgQHBrOfrWcTMXUEWfMWGUI9fdQXh6BwUbET3tBhBeugZbAT/o8QWggokePJXqDzMhvpNhl5Biz5o0p0EYE5oYYDABJaXvigoU2qcC5pMbfXLeggXP8DCw2RAb22Aq7hekmIClcJo8hWoeYWKpiwhjgIXlvKKDrrKRwVpmiZldHpk4mHB6/WlDz1obX3PIhjYAlDabBmDgKko930kDAFYGZhVaQzodobngZqXSemCpPBVm8ppBrWe3ZkEkKpppQ6TyR3ZjlGAELCFe/rbku4KW3RQk12fG2pPkonlJnRP9/EUqqKKdgqng/5Ne/ScCyaibB3Fpizf1yjopFrqrz7VZk5GcJbEdBIbsMKE4SnrsjJrszprNBHCYQqranKnio3FriEr/6Zl63NE67R661xuKwCI2CYwGjSGawJ267eqK5qe6wEEDTadqzXkh14e57p+Ta5R6jWNa5LMTrxqU7q65quZZq0Opz9ZZzTE2Dh1BWPkqz3xBC7lk7+iqyL86GsOW5fSKKSyRnqlXj8ppsQKQLlGrMRGK8BiEoN2QSOSalZwnD9NiqSgDQZo3E494ko2gwEYqQUVFICeAcae1hncLBYQBSBqpb69lBGAqPeYlDzVazvFKwTszAEcTb/qhlTV37xOg47+LIClJEDJFeeBTcYIzMuxDkS4ioYazHrUXH7d3DD0rDdEDJWllcGs3C2GpMthAba1jTjx4Mdua0YhgHjZ0f8dyAsnWNdUSZFmpJkdwAvVmSwPGukC5KMLmuPeNdzX1E1AvlA89SMenhOkrAfbrYU3fKfPUllxjc05XYk7vlQFGKQaxCEHNi0mkSy8+gFn8KstLS4AYi2bqt1euWTX0pt+9akM1U1NUl44FmKZOITwdEjmbd7f8ZyBwlfwDEzznh9GQJ4tYFt6rWLGSmjtClEf4G6fCApjedG6hFmhYFbOBAlnaM5fqG+3JEgDkYsFwMv8Foq7boKnjdzjtmCmdkHB7UofCpk/YJsG+UtbHoNFGJlZ4Cw7aI9+6tfXxW03GdkFYJwLFUVXGi18YluMraLz+a34jiweFC5zKVZz5e//JozOojVAAiRAA0wY53DGnyzNAKzLC4cs/nAC/iLJDlNOAdDPX0zN/1JsdE4GBVjsb24kPJmjvYavCUNjhbWZHJQvHAxJDadvmnWLBYwrJzBA+U6NFn3xEglaEHuxAFgAm3kWGwKwl/KSuaEEVUjxj1Lx4NpBFnvZAnVx5SgaG/PEu8IBGXeGGbMxGv+xtnwxuVzVg/XuHUtyw57iH/AxAnVRCwPyF1NOkjhAupQv7iKyBSiyJjNyItePtuAvEp+SJLsyJUOyJX/DAAmApvmMKQdykLQvIq1OFP3JKJeyGm8yG4tr4eZut8VxY8To7FbBheCZpRgrwirDwarG2flq/x6fMCDYmiBcsg9GsmpsQKR6CIiYkxpAQkmcKT+kIl2wYIqQ1jelSjqh0yUmbCzSLjbPEiFscyB08wd+s2RwBVy+ZnC210pSycGe6dtEMzQooVni4D/lzpPMokQno7hdgrS9Bj4rpEazWhK306QIFSUImX0BRBdw0FZ6HPPQ25fwZm6qCtqwSvWkCNIa3RisGJoUla5IG0g9Q4c4CtfErlecMzTAcnIVteN6NIZWpMyeVMiUgUkhjI6SAVO+zQ/VnMaCJcYwn0zHAktfSVywTkYm419NJ0/PTQzNAgXtyt5GTDhPMTYfdbsls/aVdGxd8EiY1wWABOrmQ1WvFu+gQf833s13gu0DXEDBoIjcPGlZk5ZP+9d+GsF6BPUcvnUeY0e3OJDVAkLjCkJGZQcBHPMhDAB4mOu3RafqLcCd8qV5bYkWrNz5qfTvZQD/nZ9LT+RgB8NY3AJ+gt98CS+9cU8XMLZ59fRh6I7ucGxUHJ1yajR0jKt4afZLnIvI4gFo64V1V8NoG8dcr15d61AXgG1YcdCIhBNsE2s5391X/ONZG6/GfMMzmAx+BtVR4LSTrTMFr6jQzhSO4VjCXrSo6F+sNTcgLE23eMZmCYr9srFjbc7ONJDmVJXVCBJnKIDP7DKQxMGEiQd2J4J2j+9NREYxtOYaMBwawKpwuCJDV2v/L9lzM+LzcVQY/VyxFvmwC4cyKh+NHzfuDa+ODsswDedPoW2CBBQAZu8MaBMAIU9RkvgR6wBAAUTRAIx2oDjAY1W4FVf4GPNyRiWAtjxW4kIXiCFAG1vFk1eWuHKCtHg41TYIY2xSb9qxNznzK7lQ9d2ZNVc2FaeEFXeZml1R+dJ4kDvagUgAGi/ajlvNkWwYOOAS/bwBArzO0RCAAvT5ktuMqAUNpJvOcw1AhXdO7nqHBXQ6HDCA/UwLBAxAAogLhwNK0KS6jgyKhj05NvBEA6y5Hl+qK99xXDvVcVRWzjhSmqHxoEeLoYcsoieJog9yHTi6d5ROm7H6G1h3yIqr/6pfsZp5hhtLwC6zTpULygGEcQLYhrQfc9EUgAJw2GZZu7g4+gEUrgPcemnnuq7bK68jcx/IuLjEeCA/lyLfOCnnz7IjewJNQCcDwCdbl6MrmqhJemhbOrW768L/jGd0unVJwKCci+CmeqnjUqqrSwKEtgQkwNGE+rRkuqi5QQL8Cf7AO2lns2nT+7raOz4RB7nghtOYmiIzeP04eP2cDr0MvKIDALczyBsofJHzvKXLwbQ/V8QjPZKs+ZcfANIbWplnVLRcCwKAvBx4B79qjgyjeS27AZe3Wby//LzH/LfOvD3RkyKr36sjSlKn/bSu/UTdhdsLHuBSt5vM9dwnZv/d2x9H0xp+JGaeKcbyaibgC5Pi89k/pwFPJBjinwRclURMByKPeW4kbEL0oWhfjgLdczTjbwOrmz1GuTw3OP4ZSAEFgERiVAfGFQNLg0RtAY4p3B7wmDM1D5vom9JxULtlRHs1cIa4TABuSG0ckP7py0HpW13fT4IoPDfro83lP0lNTWUGeCTakEqcX898nXM3ssJKA85KXj4mlAxVvKfdKEN8dckNhj5+7L0pFbkCJMmElQ4BwFny5wHzcysQAIRDYrEoCCSVSo1A08xknAFph3oxBCpIyiOguWA6lMDjkTkIMAevdLE8XAIYtfIQCSwumWSH0//j+FPKiNgIiCv/86JboMhKwqDACHBcsrzEzNTc1BQw+gQNFR0lLTU9RU1VJfI0lRCAdRiAVWAAEFCAPQBwyBWQKJrFtRU4SAAWKsAVSCA2liAYuE2AfcXlhcVtUFY+QGgAGFAokoAwFlKQdhCwHSLwBR4gAChAEEDY7YWFkAcwLlh1qtUqJJkiZHMCJkmiAAbIINozBQoFKxfexCmEUMMSP3kE8EnywEqECkoqNaQQZ5IdOQH8QKHipMJBKxwQPuKUU+fOSwMD/gQaVOhQoD5JCQDIgB0AaLekDUgAAAIwBwjaAVBqq6kACEWU2YLQlauQaE6ZJnCwDqCQdRaUSQOQYJdcIg0QWLAL/1BcuHlECHTN2g+BNG8NIPTle0CBA6KhjKIqeMlABJAXDjhMgrkh5UgdEmWgUEHKAZgvp2CqJOVQBg6UZxI6HScCzsx4METo0GTjg4dznGDhGVz4zseNjR9HntwxZIDn6EVF6i8qtWy7hDgvAH3tEGVCoN5aWzZ6P/AMCFTv7p2AhahE0mQD1oAdXb9wi8lbx/iWA/rh7FlQjpWfIluiiQNMMuC9AziwggoKYDmkg2yygEKzSiSEhbbqtLgAFg4wyMCiJBbIhg86elPiNgEOOnADWB7AYIsMOXzxCwHeGC5H4YoLsEcffxQIMgCzkmqe6M6Z6hMiDwPPq1YUACY6AP/E06svpCQYR74D0gPArnSKIGCCZAQABwIFvgFTGgsEkGWewfwzDDFx0thOOR5LIVBHS07Sk5MOvOgzUEEHteROIA9FFEhDjbBGFlqIaS4qfWIhQphamiRCGVoYk5JKvoRAqh5miuESgAnQHGKdqxJQ8xcjzoPlqXlExYcXX/iZJw3r7ByQUCUs8zVYYYftc9FEj0WWKGOTLfW4spJFdFlQ8iS2WmuvrVZaaLfldhRtE222sTXB6dbHb4/ANl1119Xz3HLf5dZdeOelV8CAqGU3kwcqIDFff4WVt16Bewx4YIOhLRjfETuMYKMl9Fhxowo6FKAkPTHYo98d8biC43//y6Dt2oIPJlmokYeSEtmUSw7FLv3sJUgT4MawZGYyOijJgJZ0NOAQjYPTRYsVPw4pZGtPZjlpyFAxLBsxU2l2ZVHIK2otqQMK9yeqSTkAMZhVURimn23kY2yGlHjgIAHSFiCMAGyaMYAI3uhXg9kiyQbHnsygJO0AXISlAkY8AskjEiswAJaGAxDgwYrzULskwCuW8XFIHLeCxAcv2ChxWDRYIPJNkFa6dG9RUUABcAoYx+Q6p/b6XqtfN52sXb9ORWGNSVzJoxHrmCOCA5fge4s3ZtN5kgeyOOAhEu1+g4OHbsxEAJ3vmGyJDcjY4JDuH7b+C85d+iN8nQO4oKSz//8mY3lLBBF/ARLfeGCDJvROH6LRa+f/OG2VItcQLGWLd1TDH/YQwAC6M6noQIAW20BKMdgCn2gQQC7wCUcCqKE6BtzKGmxahgRptYsKXtCAk4LAAm/FCl/s4oO7yE6s+lFAVzEQIFUJIO4gkwmxEaiHSQCDxYiXBY0t73sge9sjSHSBBpEkCdTDRMVcZIDs6UxxeQgD8H6XhMoNjXq8Q4garDg09y3BiWXgV0G69xpIhLF3PelfHFFmhHVQijvtGQKRmkKAWbEpTNzxBJPAIw5wpOMtwejLO17mDzJBxQF2OcBehiClBGYQAG8qjCLdQyZB0iOQsQPVUxBABCxdEv8un+KjJx1gJlABZAJPM0LCZJYFmm0hCTbbjMMs4b4iUpEyhTCAFEAyP+DA735yC1nFwJCBydDhQB3gGG8GoQSNgUGXjHsDNNEnRGe6BA8ied8f7qex7h3zlkIUWhTluM4BnUIpi8ROVMqSH9YJgAAM6A59roQQCYSLPM9STDbaJAS5rBIXu6BkpPIDKgcA1Bds6k8+bzdJgChDFghEC5sEOI95QtQ60bHKtHqVCYgtzpZYjJjcEIJOXhZkeaBRHBWnWbcL2O8gBzleMoWYvQcojmNp0NsWM5ONQ2RjbpC7Yk9XhAcZcRNzvvvbITznhNBd8aSFYmdWc4e6xdCjFkv/YVJHXzaV7oQFK0ghJCCNIMlnJUBMaxpoXHb1HQEAqEnneNMAvtHWt7Kpk2UFZZMmkFEADdaUG52SOvwKGKRYoHWfkCXRklCICqQkJ014Y44MACieQFGyndBqaPGEiobCAgFiGmBisVFaZuDTEwzYYAPR8xgG2AMacBEGNeIqF2FIsFFHisoIVRsOWOgWhSrcByuKCxBYaZAeCBzADBXrANiOqgD8WM69JJsNzmqCRHG7GLCAFtTPwlG05xUpegV2tZ9khUzZjVl55TvfYqnXvpO8L73YC7VsnBK+YKNvgAVMnPzal3QFjmNkBxxF8i5YOJsd1IERPC8JT9h0Cu4J/8dC9E2jNaS7w/JsjpR6iEv8yV8QFlSFLdwtFa+YZRguVDGE5rGPhfjBnBGvEmqULxQHqsUuTta39pvVZ2kVxktYmxe6wGHGOS5nXmDb2g4ShsG9Jspsc1uKHEc9pZ5BA477g+cWpwQGFU0yHy6D2rA8ial2lw6woEAGNNe2znE3wkDOqpBph2elHVnH15sNk82HBwgXj3p3o56VvWA8ZC6BA4C60WSi4AjNiG8jHUHbI+p35ksYOqcG8jAmnDm/MtiPej2uL5/lqK0PruMZL5wSPA4Yq3KQZQKTiocGtTElWBCgAWkQggSAMYFsXOUWLWRKdZ4TK/Eg24Z9HmkUK/8wRZ5mIdGEhjIRXWqAKjO5l2a02I2O2DMM2CQ0XaRxmZFoCVSbuZdsRLUGlFoxcm4A3mjO0Y9VfSg9g6orpBxHKi36xzFR169UsYojIQmVBjQgHcBmSpTsegRRAvywZJFGJb/DSky9ONo9qcAyq41NLWAbid9+nN9aamYyizPSv5yNEiZjTUxIGmMHinlm0LxykOnmbd3dXkzSmIRyTuHRd953//qNKb0WV7X0zMU9EzsBYFBHF+SRi7C9IwGIax0qv8hhdCzadGYsFON3nc5H9zwwPz9xp4J+w2sKrW0ze44C3t52gQ7yIPq9iJnZyBlRdwmhJOQcIW/kufsAF4H/7paU3mr0HpzxPRx9J91cQmolNgorz+kOIUneQABAkoRYuTK8AayyaC+QIYRaUdRUhH39xVULXKkwdu3r/biDdU9mEm/X8vz71m/DU1zOr7a57UhAXxi4WxL2GhznQQCU7PJA5TKDucR/LrMzHimsUIMat69X23dPX6VKoryV/z2v7jtkVbwT2todf/zni/70I4f+8QK/KTRVyffHV/7/J5r7q7/GEMABTBTxA8CcsDGSUpj4K0ADDIoHhMAfQUCemTxfGZvRaTBMyEDhwBvLUYIu2sBUm8CDkcCfKLJpyT8gq8AE7IQRtIQODA74SYPCKbmjKUGS0Rari5VT2BpV/0hByKKdrJkw8VsRCIEz34AzZqKy9Ck0NZsyDOi2NHuRKFyCicmQfpmMveODNiM5uImzh1EbJPhAK/gyD3mbJVwC8QqxygmZK7NCLwStHDSYcyFC2AGKIIylFXQxI8yCDYgAKfSsbhqDSii0RTs0brs2RRCanCKeBvGdZgqRkJMxCIu0MOQT9KE7Y7KISnMIPshEKALBKzyNkEDET6vEC2QcOqxD/sI4C8I1RqqGOnKVCeI+GkIGB+pBXVQdbiiGK0mkCegOqNigMukvIkAhWlSdrpOABoCVUYohCSI2WDA2Csw9JHsDFLsReQO8wnuIuYOq5ZnCxKONRlgb0EECFP8jiXvDpskRgN6jg0nolzPal3JrnGlDiN5Dn+FZwCcKKnJkxzlkxfCjI4EygvTQpCSpiqtIgwb4QbWQjinpI1lAi8RKK0PiP6TID3ryBIXDB71ijBTspFSpK2ZUhgCqFQsYpboKsmvUsWyEtAUIOikoiT+JOXBEuZJQObpbt/fZAC0EFJLwuaO7RBv8lSxInLdxOb2ZjE/EBBr8iEbjgJKYGBskx6FERHUaSIJEBYSECx48gICKhYekPbHSusT6oF/gkuiIBqrzpE+Rq7NMwf4wj+pgRlO5hwGgxbGkhmY8QJf0x1DDJsdDHMpoAsTJtnBESjjDO5YLCcVBR8F0osX/8wLqgZtRlJEHmYOnmqqSuEx0+kCLuUlYyJ8hUsy/UZysNK+tpDBXHK7RI6i+koXHmiQSKr78MD1WSasxcb3sCKlh7AveSoCGYxUi6KRS0pLUg5I8YpPWKwLnVBTAdMFM4AB9nE5Hs06sYs3W7MpWeJblyy02qa1a9A5auE02cbh7KE5dJJWBkBIF6AvgJKgDSE9m8K/jsgdqaL7o6ycMisbhRCDV+Uv4u05NKL/Mms4D3Z/thJcT/JG8MIXTmygjk84CtVAfY9AGRa8JoE3H6DUDq9ALFVHKy9B3cdASbScCHdEVbRcUZTEXTZoWZNEZrR4Y3ZYTtdGlUVEa5VEF/8zRlvzRVtzRHiVSrQzSaDlStgvRIu1RHLXRMILSKJXSKaXSKrXSK8XSLNXSLeVSLR2QLgXTMBXTMSXTMsXSJEXTI0jTNWXTNjUOJ3XTOJXT+oPTObXTO+1DPNXTPV3TOuXTPwXUBAvUQSXUHCwBEAABAUDUEijURnVUVVOBMIqBR6XUSkWwMHoBS9XUTQ2tFsiGFeDUUBVV/klUWLCBUUXVVD0YFMgGFVDVV4XVd5kBWIjVWrXVY6kBAWiBW+XVXlUOF1BUXxXWYQ0KGBAAFCDWZFXWUwDVZXXWZzUCRoXWaaXWarXWa8XWbEUZM+XWbvXWbwXXcBVXL9VWPvPTcv8lCHS1r6YDpXNVVx1919DSlfSK1xit19D6Enq9Vx3c1zxDoHbt15Jx14ANiNDjBei8BYI1QYWNI4W8CzXtkUnJoVOwh2oMhVn4tzjKBf9qv3sIrYFlWNLyBVjCr8ZQimzoilfgWFSoWFPA2INZk1EKhY0FCqWQ2TwLWfRqsVywK579iZYthZc1mJgVBZptL4+l0JwVrZ1lyWkciyEgNgXwPsagWQcSk5btrVFqmh582a3lv6zFCljhPyFYE6cBgJh9Bcf6hQQYB2PoNcZwW2pECJJ1RtOqpLpkBrdA2vPYhd5iLJntraeJug8lLtMKBfa4B2qUDufzH6VdWuTwWQD/MFqovYZZmIeqFYCrZYdZoM3zAIjve1nPjQu0uoYhoIaJ+4TTK4ayhQW1pQVlmAfLtdkAItoicCBp2NjTG06bldy6WoeomAVpuF3eJbaUzdzeFZPziK7SbRl7KAD5YIc1iYo06FCTcdyPhVyW7F2OLd6zGiXM1VwGeA8FmAAG2EsZ4orzTaDxLd/R/QWObQCnTaDa3d5gCyMEqKPT2gX6FQLopdr1hVIGmAUJmAUx4UGu4F39PFtmqF/LZV+LJVsGhl4GeIX4sCNlud6kNY7InVwh6F5l+N5KstpLWooBaLULJi4IqKNFCodWcwAONSB3GIuNpV+jreAisIBT0QX+/+0SStnYNMCj/kUABDgPW1Bg5hwlBZbeBranFjZII1jiCb5h/33TDMbZ4+DgsfXgsXgF4wWGXAhfkmSTXPg3CLCAlyVjITBjMX6ZGx6C3KWGAahh/otZW7CAjB3dLUFaIqDZOJ4+dfA1qaCFLRbQAShfj+3eVxATmp3cFRbaCcLfk2WAJabexrXidaqwk02uDsZL6gjk6iqg8HVaumiADyIAR+mKUs6GUx5l+kQICMghlWSGOJ7jUxLL+UUIuIAVkq0uXZMGvH3asj0lsksAC+Ddwj3e3qUOMWllXqtGbwghuPXkibXeS161ZOneQOVkI0AAPC4CII5OaxZUZMlmQP/d5kxZCttdZQi2P3EeZ3dWGXgGPnmOZ3ounZMJXmKbUFPg4YE559J5ZHHZY/3DBWXwZlCx53tOXcUlheSzC2Bg3bwkBaINaCLoZ9ZLZ+WgWaAtl4teq6ctWHaY4AW+WZdlB2KDYJBNaFEojpEmBb0ylVFak3HgD/Yj6Yke6GP5Z27x6GAAaaAY6Z4Ghb+Ii4NG6JX2OG7Ohrad5lGYaXSQIL+9Dnug6hTGS9M6AE3OXGLjIzJpWdfNaF4QWzmeW5JO27pNXGmoWOhl3GRLLsrFarOuq1yQALZdXHuS5mIra7i+h74dC9ayh1+GlUvh6vOYvvGkBbTtQZt1oLtobNT/ZWmkTuoiCGoGrmRReOqq+IbgFeQBUIrhpOif1hQHqF35PWxlqEjKPl0jUN0DiOg7rqSNDuvzAIbzINmDjIXXfigFgF3iuqd7oN2cRmc2QePYTqDD1uz4RYjDruxvINrZTYPNbuLRkmx+ZW3FnWIUhmKEUAAAOWAIIDaI9tiXZQD2jF6kLeeKDe9PWOIhUO7+ql0qlm1b+Lp9oGIjKG+EmOQ9tuH7zd8J2F/hzu9iw1j5BuD2yIUDSG+RVtznhoUG4F2iFWodqm79WuilyG6NOlzmJSgJolzxHqWXDewJLm2QVm/ytGgGluGuoGGkNXC13lxtKN77fs7jpsZatt/V/yNbHV5d4R5xaixwHz5wqFZwE2fwpXBwMolwj53wkq1wJf0E513g6eVw9q7yqAUHQ6bk8eYK6C0ATXEtmV1w10rtulhtqB4A1SXrm+3jSjpxjhoL277uULlx/qbje7BjPNZPEKZsWPhyIB8LBfbjik3uMSdhgEhyCGfyRS/pyH5yKP/oa4jbQMbsKveP4gIQa8iFEB8LS1HcXTb0WzY2YJbj/KTlPe7lOCZh8/WFNFblty7PENpvNh/bWybrY+S1ZI51XxDgseigWZYgvCVsI6fvxPbYk1V0mWZ0U1DpRz/qe62KsOZOZ7fweO2t/uBKap92bcdgbtdQb+92cH9RcUavZnK/UXOPQHQ/d3W/F3YPsnGF93iX93mnd3F193vH93zX933n9373938H+IAX+IEn+II3+INH+IRX+IVn+IZ3+IdP0yAAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PALS: pediatric advanced life support; CPR: cardiopulmonary resuscitation; IO: intraosseous; IV: intravenous; HR: heart rate; AV: atrioventricular; ABCs: airway, breathing, circulation.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission. Pediatric Advanced Life Support: 2010. American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. &copy; 2010 American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_4_20545=[""].join("\n");
var outline_f20_4_20545=null;
var title_f20_4_20546="Nasal foreign body removal button battery";
var content_f20_4_20546=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Nasal foreign body removal - button battery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 329px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFJAfIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqerQrcabcRuOChq5Uc4BgkUjIKnik9hrRnAaZxbR5z8ox79aw49TTRvF+o2k8RaG7hSbAboeTn2zWzp7AxsmGUhjgH0rF1OwN/4zij2bisCM4HUrjivMxrfsJtbnvUbONpbW/VGiulySI13cRN5bsCoXkgdqwdSsVfWLOK1UB3YErjBPNddf6hcafZPHtcYHzcZOB0FZXgaP7VrdxqFw26GzQ4Y+vWvFwtCNarFwenVdjR15Rg5y+Rp33iGKz8YwaPLaFiwURSg8gnrVa2eQDV7iUgyGV4w3YBDgVkrpdxqPiuLxHJOGsFcMETmQc9MfzrRthJcaPf4Vo2+0zOFYdi2QT7V7lN80zkUVFfmeIMRJqUzNj/WNzjrzWnASHQ54AyDWRJlL6aKRTGwdsg/WtFWhSCFWz5h4wpzuNNvU+mgvdNUXakbgAxHGOnFTD5syjcoxxuXg+1S6N4Y1S/Kzx2zCDu56Vv23gBnkb+071nUqSBG3CmmoORz1MVSp6XucxFIZN7RkFE4JHb613vgbzLPTL37S8Q82dyEHOUx94+lJFpGg6WscYnhjaP7qu2S/rn1qHUBJf2cmmeGtPmE8q7WuXBESg9cNVwtFs87F4r20eW1lc0BqM2k+FW1G2fdL9oKJnlShPTFc/wCKvFOtwauqCR7WMIrquMBwRkn3rsbjR7H/AIRFdKvbgOllGrzuh5BT1rkpNe/t3ULJ5NJjlsIXWASByeMcZPvjNcs9LK5wwad5WNnTNZuDe6Tq17qCw2WoQ5aBjwGzjj2rqJ4rWa+MCbkudgk3pwMdq85v9U07W9Ont9VsmsYtPIa2ktxuI+b7oB46c0mq6pdab4htb/TDLLA0KiIScB1PAz70e0aSsDpcz/r5HpV3G09ubbU4I7+0bGVdc7T61xlx8OrL7S9xoGqT2MpBISfMi59PatePxPdw20Et/pNzA5kEUisPvFuhX1HrW3c3enxXMcFzcQxTyjKRs2Ca1VVSVmYezlB6Hk+rWHiLRpWOoWjXSMu0vajeAPXAqgL9AhjaZY2wMxSDa2fX8a9vljcnaGz7E4FZWq+HrLU4z9vso5kz95VCsP8AgQ5qXSi9i1Wa3PMI7hGjTD9Rhgp4U9uaeJouYkyxPr0/Oulk+HlgzsdOu7iyOc7AN4z+NUrjwDd7CYNUUP2VlqPYdmWq8epjowDnLYxwCO1OEjhgQxYDjNTt4V8QQsVktYXQ8B0mHP1FV7nS9QskKzxSr7KM1LoyRSrQfUlS4JkOTx16cVJHcIAAzKzf3hwfxrLa48iQ5POPmDg9KYLyBm3NKgAOCOnFZuDXQ0TTNtZlG3cwIX5QFfn8+9TSTbV3GT5MgBfT8e9c/Bc237xY5YyP9k5FPUsZI2DhoxyVY8k0rAa0l0Fcpv4PXnGKfb3bFGzGxGflI4496zElUqVBUsOQSOlP8xyCsgVdx4w3OBzyKBmrFqbzW2508sZZSo6n3ppuZGYIzKxI+63HPb9KofaE+YTITnHK+9PRlMuXG/aPl9V+tArFlry9DEFoQQcY44opvmxnkscnn7oooCx7vRRRXvHhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVDO4jgkdjgBSc1NWR4nuPs2j3DAAsw2gHvSk7IcVdpHG6Su6Kd+cPMSB6VQa4mj8YvJaAMYo4Y2Yf7XGPwresB5VoiNwY0LE4445rA0lgtnda0ke5TMTwfvYPArysdVlCneHl93U9ykko8suw7xfdX0qzB0jjupcxqsWcsnc/WotHs0TQF0C8ElldTKNkr5xJznqPy5q7ozyX93da9qUZS1jTKgjO0dyB3qS/8Tafc6bcPHE95ah/LkAGCgxndj0rnpQUJSm3e/wCJLbsoJbf1YxrLWda0/wAZLpJQNZxfKYihEar/AHg2P61uXhFlqdy02TYXwCpKpyAw6j0qneyXOqaEdJhvWaa4jSe0nZc70z9w+4rT8PR2ttog0i6aGedd3mQyOCXY9a6k3CWjM7q17eTOa1rwXputMTdTLFMvCTQEBsehpNM8O6BoTo0hS4mj43uC+4++O9bmjt4e1GzvGEBtzaMVnWU4Ix/MVQvvEdnov2KHQ7WBYJlEshKZyucH8a0lVja7SNI1Ztezi36Gsx1a6CJaW8dpaqOHmO3A9v8A69U3it1trm41DWbjUEthuMMAAH096xl3+J77U4otQuZLNP30SuhKgf3RVjw94U1ITsZbhrazys0ZU/OXA4+grB1JSlYVrK7dhND1qy1BJl0W1i0+WHMkpuFLMye3XBzV3wprOs61aatcny1iAZII1GCrD0rrLbTrezhdYYI0Ev8ArGxjee5NQRyaXYIbaNra3iPBRcBcnrV66Iwbjq7HE6Fb6pLHciWVku3iZDC3zF8j1HHNcwWurKCZbKSTb5o3oq5IccYOK9Wj1XR9OU2trII1BL7IYyVyepFQWOp6JavJJaQG2Mpy7RwHLn1NZ+w7Gyr76HN63p2qap4e0+eLRY1uZm33MMZxt4xuOfaqMGla5NoljbLYHYLhxl/vLHxjPt6V37a1pyqHM0gB/wCmRpsur2nQSHPUYHardG5KquPQ5Lw3f3On6rPpGvOskacwmRWYIewGOxrKn0n7W9vcvep5cUximJDFlJbI98Yr0JNSso5DIXCyOOWI+8Pc1NDcWSzSSRNCssgy7ZALfWpdJsaq21Rxl1rNx/wlv2O9u2s9O09yfNRT+8XaMAk8c1seH/FUN88rXDtbxPKRD53G72Hatm/jsdUtZLWeRJI5QAwVhkgVBqGkaXf2UFjcBfJtxiNVYAr9Krkd7ojni1ZkseraZc3xs1uYnvVyTDzkflSyTWvlLIrAxMcA56U210WwtrwXdnbJHPtEZcDJwBj86ot4dtEuHcySrGzFjEG4zVNy2JSgaqxxPGWS4AweRmoo5JArfZZIXb0Iz/OsmPwvAuoC4juJWhKkNExPORxj0xUZj1XS5jBY2aXG7G2V2GR9aFUlHoDpQezNqW3e6GJrGylBGCJFxn6YqpNpWjGMC+8ORYU5BTpn86r6xrOp2NpbFNMZruU4fadyqPwq6+t266ZdXgWUratsnUoQVbHOAeoq/bdGZ+we6KF1ofgq7O6fS0RsdQGH4cVm3XgzwlcOosjd2BBGRCfvfXNdNFrVi+lR6ktwPsbkAPjoT2q6nlXS74zHMD1YHdmn7WLewvZyWtzg38B6OzsLfWtTAUYIG3AH5VFN4EjjQvY6/O3THnKOPyrvUNm0vkqYGkXnYpGRTTd2R83LQ/um2yFuApPY0m4PoUlU7nAp4E1JsbtXsXQH5W53Y9KF8F30KgRMWkDZY7gFcfjXoBsbVi4+zKCw/hHT6VBPpUE2xZGkbaeFY8D8KThBhz1F1OG/4RTVf+fZP+/g/wAaK7X+yo/+ecP/AHwaKXs4B7SodnRRRXpHnhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzXioC6nt7VSWKnftHr2rdvrqOytJLidsIgya5A3Hnb7u6Y7SNx5A+Xrj8qzqOyOjDQcpX7GD4tuZobOCxt9xnu3CFUPzBARux+GamOmw3eqxaBYF10xEE07q33R2XPcmszTb6TUtdi1aXIjANtbIB1HPJwQfQZzkD6AV1Wm2cOg6Dcea4W5l3OSzfM3ov1/z715tWlSrtTlqou//AAD0Kk5QfKt/61+RL4iljtdDktrTaI1xD5YPKKe5/KuAgVPD9hdXELBmuH8ja/OeM/jW5/aB0eCbz4Bcm6w20nOPrUsP2DxBZ2ljLZiNY2Mo56MP7vr6Vi26kr3sVFezja19S1Z3Fza6Rpt7cwxRqynBCgeWMfKB6ZPGK89vbe+t/EZFxbyRajdsDG/YbvT3FdT4dS+1h9a+2kx2ZZiIuf3Mi8gLn04rptNtINQsbHU9TiX7RagqszN0x/F+NaWdSPK+gKapPmXUoHSJLm9vbG9hCRTBJDcKn3wqgMhPYk81oQ+G9MtbJYmhxBG29HkblRjpu9KxNU8aS3cklr4UsmvJVJD3cuRCnuD3NZcGj3M5abVr6e6uHO9gGIQH0AHatlTTWpEY1Ja7HWPruiaXH5dpJGxA+7brnP5VSPiPUrwH7FaJaxf89JjliP8AdNUJotM0e3El7Pb2sfbdjcaxbjx/ocKsLa3vLh1+6do2H8a0UVEaoc215ehuy201y/mX13cTueVEblFH4CpktYyOYA+evmLuzXn998QdWm4tLa2tk7cksPzrnrzW9Wu9wn1KbB7LxUurBPRnTDCzW6sey+SIhkCOIL7AYqN9Rsof9dq1nEB1DOBXhqg5JNxdFj13Stz+tOWCB8+aGb2Y5zQqt+hf1Z9ZHsz61o23La3YELwR5gNRnWNFkJI1WxPuHGa8fWC3XAFsrZ/2RThGqNxbov8AwEVXP5D9gltL8D10X2jSkKmoRuO4blRU4ksHIP2u1yeASQMivIVyV+VAB7ULGpcBwcezGjmD2HmevR29mzkwXcAkHXZJ0p4s4znFwGbjkN/WvIhDEOAZgfUMaR7dWBCzzKf+ujD+tHMw9hHuewpYMXPl3VxkdQsxp5sbuIYSeQDOcsd1eLiKWNsi8nGOP9a2f51YjvL6Fv3F7cL3z5hOaOcl4Vd0ezW76hCvyXDuxzncowRjAxjkYyT1weOOOWnU9RhwHiDgeleSwa9rsBzHqtxj0DVqWfjrVrbAuIkuV6Euxz+lDknuQ8I+iR6bH4imVD5tm8WOSc8YqdNcs5QwlMSF+GSYbd/+NcFB8RbWVQt5psqj+8nI/WtS18W6FcR8Hy5lHCyIDzTUUzCeHce6OovrLT9Qt4baSHy7VG3eVCNqt+VY/wDwiTwahBNpF/Olk0n76ESFfk74PrUsF5Z3Q3QzYLc/e7+1WPPv4UD2zJKo9eM/lUSoRlqhWqQVjGvrLR/COtW17qMl5NHJkxyITlXz0I/i4q/rmpvPpiXuiLby2k5zPG8IZgR3YdjVr+17S8xbata5xyBOuBn/AGTVzVEurnS/+Kdkt7a4ZlzuUYZc88euKxnSautgU9Vzf8Aw9OuNR17w7ef6RJbmKRDHMPk4B+YZpPDfiDzdKv7efUk+1xvshaRec4/8e+tZ/i+XU18VWuj2shjt7iOJQUXC7j94nHFV9fjsmlu9KtdPC7GRnmBw7uoxlayfuddjZJTW2+pTlvfFplci4JBJ5CcUVbXxPrsSiMZAQbcGIZ4oqPn/AF95fM+39fce5UUUV7x88FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAGRQaSsHxXq50+1WG3b/AEqb5VwM7R3NA4xcnZGX4pvDqF+thbvmGEh5vQnsK5/xTMZLWHS027r1tjZ6JGBksfbjFX7aEWduzynj77seSf8AGuWSG917WUjVmjF1lSQMNDCDz+ZH61x1ptr3d3sexRgqUfQ2vA1ilxPHqUieXbw/ubZe0h7vVfWdbuW8StprpGFkfZ8yk8djW14njltdEg07SoyskpEUZUf6sDnrUNxp8t+7Wc0Lw38EEUiaiepkGTs9xXE4JR9lDZEwnq6k+piyWt5N4lGnzQtAFTzNxGQVX0Pv6VvWWiMmrWkxcixjBYKp2Mrdz+JrcllWCyE97KiiKMGWQ8KOOT9M15v4h8SX/iSYWGgiS30jdslu1HzSH/ZPYVpGlFO4JzqWijqfFviSCJpNO0MQvducSM+SFDZz0HOMDv8AxDrzjmYtEvJLWKzlmmntFJfyFOFJ6k4qaKy07w1YSXl42D3ZuWc+gFchrXjm6uzJHYRCCEjHJyT+Iq29bs7KOH5Y2j951eoeJtK0ZmtQQ8kJ2mKHGARx1rlNX8b6jdErpiiyj6bx9+uSbLuXdizMckmnAH/Ci7N/Zwj5hKJJ5DLcSPNKxyWdicmnLFJgbRir1namYjA5rft9LAUFhk1DV9zZSZyfkOMZyfYVNHZOWAbhRXVyacijOPyqubfaTkUKy2Fa+7MdNPDDAH41IlggYDkEVspbg9Mge1TrZjGMfMe/SmmwaRhtaquNin/Gp005mRWdeT3PYVtJaooyM8fjVpIVKlTk5qr9yX5GBFpOc55A7DipW0teAgCt2Dc1vrZllA49ueKa9kvyjccrzRdC1OcFgUHMe4nuDxUZtAnBzkfrXTCwDr0yRyOac9gNuCuT7UrroNPuck0Hz5VMY5NV/LDMcZIHtXWPYBj3qL+zhjKrt/rTuFzmHttoBxgHsKaLQs4AHPauqj04MwJwvsRU7aeu0nrjt60WfYfNFHFyWpydy/Me1V5LN9oyvXoTXcPp43ArjJ9aiksdw24B78ClaSKbhLqchbJe2zh4J5IwPQ8V0Nj4qvLKRPOUsndlPP61d/s/ZEcIMEcj/wCvWZe6f97glcdfSqUmtzP2cJbHdWGu6brEaxXaIzY5Y8c+lWZba607E2mzNJAvPlMclfpXlEMUkM+MtjGQR2Ndd4b8TNY3CW2pSFoZOBIR09jVpqWjOarhuXWJ6bo2qxahEvAS4XqGUZ+orzzxLZWw8c+VNcG2t5mXcpzkepBrq7qJYdl3ak7gNw28ginatpdp4oslmUKl2owsg4yO9Z1abtoccGoS9TIbx1paMVOkPIVOC+V+b3oqk3w0utxxqK4z/dNFc/JMd6f9XPa6KKK9o8cKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopruqIWYgKOcmgCpqd9HYWzSycnsK4WJpNRvXvrrPPCD2+lT6rePrepBE/wCPWE4yPWqHijWItE0sbVBnYhIoh1YmuepM9PD0eWz6mN4y1TDiwhdj8u6QqenoK6zwjpiaHoj3F3IftNwBJMz9Y1xwPpjFcf4L0a4v9Ua9vuXVxJLu6bh91fpXf3guGuraKMM1ty8jjGCc/db2rihUc71FtsvTq/ma17Nqn239Sv5upS6xbsiwvpE8ZBYH5omx1FTW/l6LpMsuq6i0trCxdppRghT0X3q1c3FtYWUt1dyrBaQjc7twAK8wvJ7nx5qHnTq9t4dtm/cqM5uT6kelXGNnczhB1HZaf1+Yl7qN54+1AKFa18NwtkIDhp/r7e1a2t6nZeF9NjZ0QHGILdOM+5xTde1u08MWCBUT7UVxBbrjC+5ryO+vLm/u3ur6V5pnOTuP+cU5SPRpUklotCfXNVvNZuWuL6U7M4RB0Uew/rVJV5AAwvt3poBY5/h7Zq5b27MRsQ+xqdtTo1bsiNIzkZyKvWtsZDyBVzT7DzDukPQ1qpbBVGFx71DkWoJDtMtBHjjmtyOPgEngdMDJrOtwd21RzirqyjhTkGhMUkwljyTgYqs9vk8g1aaVR3Jp6SKwJPSmTqVobc9wM1M0BA/nViOSLOM5+tTuiyAbRmmJsyRGS/JP0q9BGdozgAVMtrlverf2ZkiVtrYYkAnoSOv8xTsS5EZVSvTrTjAH2hR1pNq469KehVcDNCsS7k8FiHUhRgdjVmHTsIxkIz29s0tpMMfN0/lWrbTRx4JKlT1B71vDlvqctSU0tDHbTlGT83HQAZzSDTWROOe44rdnvYBFiNdxP8XpVGW+bfxkjrxVuMURGdSXQzJLD5uFJAPXFOFkGwdnP5cVZuLzdwVCEdx3qo1zuXBkY1DsbR5mV5INszbQPTkZxUL27tHjA+gqyJYxlievaozcpjKMDUXRaTIWt9wAIwOlUZoEBKqpXGTzV+W+jjHPWqj3qzgrtwe1Jq60Lg3F6mTdWa54UEHnisu8tN6BCvU/KcdK3JmYEbOD0qlICx2knA7HvSUbLU25r7G54H1h5S+m3JIaMfusjtXR6I32G+MLEGGZ8Kc/cb0/GvNLu3ngnivbUHzoGDpg9cdjXoVtcR6hYR3C9JMMzL1V+5/DmtItTVjhxVHlfMup1rRozEndk8/eoqGLVYhEny5+UUVPK+x53MdTRRRXecIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFJmgAauS8X6g0kq6bbMQzD96w/gra1/Uxp1oShBuH4jXGefWuTsoTAJJZm3u/zvI/Wsqk7aHVhqTm+Z7DZXt9K0yWWY7YYR82O9cDvudU1GPV7yLiRzFaQE9V/vfh1q3rWonxXr8OkWDj+zoW3SSdN7Dtn0rppPDs1zHb6jC6xeR8gU/dX/d9j615VZVMRU9jT2W/+Xz/I9OdSOHjzTerNvRrKOztUIZD1G4Dkk9aL3W7S03IgaaccKi9M+pPasu3tZiHa5uCVJ+5HwB9D2rlvE+oym8bQNDB8+cZupcZZE9M/1r0FhvZR5paLseXHEOvNU6erfXy7jtYu73xPq6WU7CPTY33lUPDt6n/Z9vWruu6zb+HNOQrGplIxDH2X3prNb6Bp7SzlBM43Pj1x0+leWavqc+r38l1cE7c4ROwFc12lbqe9SopJLp+ZDe3M1/eSXd4xaaQ55PFRBRIduTx1NABPB5B/SrltEBgjpULU6WhYINzgY5Hb2rZtbc8EcdqrWkTbhjkmtyGEIPfqaJdgjoLaxlUOBz1qykZ2+uOuakhjPlgjANTqvHIIJpDbsVVAQkZ4HP1p/JBKrwO9TCHcSCMe9S7P3YVBs2/rVJENopmRvl24x3qF2eRiBkLkZxxV1o9gGANx5z71Xuf9aewI6A1SC5Su742soCjcuSduM5FMh1+eFfMa2DKc8ocCrEtk0qlkfBC4H49c1lm0uooirKpQ9SD/AEpS02NIxUviZ0mneI7C7+SUtay4ztcZ/WtATmQfIcqehB4NeeShDnfGzMePmGKl0/VbrT/kfdLaqeB6fSlzXJdFLY9DjZWHzE59MVKVUqORWNp+oQXiB7acyoBkqR86/h6e9XVmBGFPWquYuLLrXKxgqMGkW9YZ2HhayJ89AWY54wOBUKmcZG3HoD3o5kHsrm39uwCWPNPj1AbsnH1rFxIy8Bc+h9al8voTtT3LU3UsL2K6mlcXyk5xle1VTcDHKmqE1zbWwZp7pMj+EdfyrNl8RW0e4W0TyA93OP0pOTZSppaI3ZpS/BUAexqoSzgBFbcTzXPy+LLhTut4oY+w3KGqrc+LNTkJxJbp9IxmkmaKm1sjrorZmIaXI46DqaVrR2DIsbLuHQ1wraxftJ5vmybm9BgVPFqesSKQt03PGWHP50O/cr2cuh2/9nzkbnBbPHCGmNaAMBI0MZ7l3C/zri1k1bG59RuEI6BZDVaaylmYG5uHkB5/eNuNTZ9xqnI7aQWyMw+0wqp4PzAmpvB93bpc3Fq8ySQSnCL6nsK4X7AqIADjnqBUaeZHJvtGCyowZf8AeFVFcruE6LnFps9YaC8RiqzMAvAAFFR2viyya2hMm4OUBYFO+KK67nium/5D1uiiiuk8cKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACormeO3haWQgKozzUtchr909/IIkJFopOW7OR7/lUTlyo0pU3UlZFaW6kvJ2uXAyxwuew7YrlPF+oXFxNHomlSAXFx8kz/ANxTWrr2qJpWnmSMEzv8kSr1z61m+DbC6g3yXMIkaZ92cfNg9cZrzq9eNNqMnZs9unTVKm5Lp/V/kT+G9ATRRGzQGFNnyTHmR/X5enPNdGLo+QiInlW8Q2pFnOB/WmXM5muUij/eQ24xvboze1OEsMKSz3EipBEpZsjjjtXoYTDRw1PXd6u58/i8VLE1LL0MnxJriaHpvnrGZriQ7bSEDmRz3I9B3rF8L6Z/ZtnLdXLiS6um82WU9iewPoOlWfsP9oao2q3rbnZNsSD7kER7AerCsbx1ra2Nl9jt2AlYYIHYVjWrc/vdOh7GBwipx5er3/ryOW8c6v8A2jqLQQPmNPvMD+grnR1xnGKaMsxYjLHkk1IAVAyvJ61xPXQ9pKyJbdQ2CehrRgjDNgDAqvZxFmyQVFb+m2q7suDnFPYNySxh2EECtGJA4YPzz0poUL1OABUQlQ5G7k9CKS1Bl7AU7VOAR3qQA7hk8jpVE3XmFBkHHFSxzjcoY47VaRDNOPG5gRnNPUfLgjjsapJMNwCnpWjCxKg7cgim1oZ9RPILYB+6T6VXuLVQB8uV9vStJH3rtTpjvViK3VsFlyOmKI6kuVjnFiePg/c65xTJISeQDt9K6SSyGGOzAIwM+tZ91blEwwPy9u4rRppBGomznZ7ITAoVJXOQQORWVc2c1spWeINFnhl7fWuqYMeQNrUm9tm11yD3xWbjc6I1uXQ4NrcoRNbuyZ6FTgmr8HiS+gUC5jWZl6Ofl4/CugubWGc7WiXI6Y61kXOjxyY8sbQOeanlaNOaEtxY/EysQ0sLKD2HTNPfxRs/5dw/oMnJqqNJZZGZlUduKsLpSkbSAARjOKXKO8UQv4pugSYYFViDg9QKz59V1W+BWWYnnJCqBW5Do0SrnZk5H5Vci0SLO4qCcU+XyJ5oI5CK3nkmETLMzt0+XP41ojQTnczM57kV1trpyqME5z0GOgq61pEirhcFTSbF7XXQ4tdEEkWIlyRwRXOzwGC+khII2N0I617FZxxbMMNxz9K5vxX4c+1RNeWm0yIvYc/SrinJGft1GWuxzlnbrJGNxLemKviAKuFGPrWdaM8a4kPzfxCtDcMrg4GPzoaN79hwU5yfzAqJ4Ym+Zh83rU3YcgCkMZdSFI4NNWJuyqVy+FGeafGgVuFCvnrirKwrjIyXPFCjHDcjoc02gUrFJ4IixJZsk0VbML54YYopaml0fSFFFFekfEBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRUF5cxWls88xxGgyTQBl+JdWfTooo7YA3EzbRn+EetcxqTSyWm+VlVQuZWGFG1R0447UB31C9e+uMgtwqH+Fa5zxRNdaxe/2JpePLQb7l89v7tcVeqopyex6+Eo8iv1GeG0bxFrw1O5DGzt2At0xwRnqex/Gu+llh0y2Dyxf6RIdkaKcEgjrnnGPp/8AW5/wjbz2ET2ZiRIEQM7j+FfQ+9Pa5Gq373CqTDGPKgOOo7n61ll1GOKtiW7rocmZYjkbpxLdlAIYoVkkUb3CBtvzDPU4H51h65PJd6i+lwqG060xLPIjqzNKCdqEAnaQRyDzUninUbq2mtNK0tt+q3S/ePSGLu/16in2GnRWNuILN2eIcl26yP3c1216vO+VbIjA4a1qkt/61Kt/qEdhpb3Ejdcsc9ye1eQandvfX0k8jFtx4zXWePPEEF3Gmm2C8IxM0meOOij9cmuMVPmGa4aju7H0VCHLG4qr0GcetX7WLzcErxUMMG58k/hWxZwAbdnTvUbGxatrT92QOlaMAKBhn6CktsLHkjv+dOBJY7aW42xJCW69TTAsccm/BGBnkVMQApLnntWXqTNNhFZgB3FWibX0JFv7Nm3K2HHYrjFXEnjmUPHyM1zU1mmCyyNu+nWpNAmkjunjIJVuPpVJpicXHVnTp94EdTWvauPLGTwB3rKjXnC8ketW4icAihsiUbm5bum8g8ccVbh+U5U8Y5rJgflcda0oCcgE8d6aOeehdUsqBTggknn9Kr3FsZDnALEd1q5BhgQ3zY+6KnTcW6AMehzXSkcjlZ6HK3VgyMCBnPpUQtJMYLNjng12MtkGRieGPORVN4V3EEd6lwNY12cs1oY+ide9V2jI46H2rrLi23fcYE9M1jz25RyCnSs3C2xtCtfcyfJ+Y8Zx3xUzbSo+TJ9CaupGCff09aGgD5Krj61FjXnK8W3j5dp7gU/bx8pJ571K1sEHy5Dj8hSiJwxwwFS4sOZDo0bGfu+9LHGWySc59anQZAVhgkcY70149+ACRt6VLiw5iNcoQGwVz1qxCyj5EzlhjbjNV3icjK8gdRSqGQryQcdutNXTuKSUlYxNZ8P7mZ7aI7u+DiuYu7W8gOSDx/Cwr0ETyrIN5LJ7UtyttdD98vJHb0qnJMcJzhp0PPomlIy0WQOoDdKsCVlYDGEPTmujvPD8Lo0ltMQeuPWsG5sbi34nQMM/fXoaFZm6qplmCaLBD8H6UrxRjG1lKketZ+AvBzk9BSojNypGD1xTKsnqi7hfUfnRVbYf7tFLUfu9z6Qooor0j4wKKKKACiiigAooooAKKKKACiiigAooNJmgBaKKKACiiigAooooASuU8R3T3d4lrC37iPmQjoTWt4g1JdPsmKkGd/ljXvk965e0jMUJMp+c5Zyx6etY1Z2VjqwtLmfMynr+pR6Jpjy8GTG2JB1cntWZ4PiuNJV7me3lnvb4qzIQN2SeSPYCodCt18XeIJr2clbOzBFujHgsD3rq7m5TS4Y7ieJZL2QFYgOqr2ry71MRiY0ox92zdzvxNaNCm+bcdrUyWcT2lmWE9wxJx1yepPtWPeahb6DpJuZ0WSTGxYl+9K/bA9aEcrBNf3riM7d0sh5CD0rKsYZNXvodVmgVIkO2wglGR7yMPr0+te3WlGlFUqen6I8XCUniZ+0nsvx8h/h6wu3uJ7zUZANQun3SbefKj7RfXvVL4ieIxp1n/Z1g+LyVcMy/wJ3z7mtbxNrdt4b0okHdcyZCIDyzep9q8Vvrua9uHnunMk0hyx7fSvOnPl92J9LQpc3vS2RCudyqCc5xz1NaFvCzckfWorWHc4B5NbVtGpGeMdOaxO0Za2uWHWti2g24GORT7WIYQFQD3xWjFEELHHtilcZXCYHSlEZGT/KripuJHAxTjCuPlB+vrTJuZjA55qpdnGcY961JkCMwKnFZ1zGrE4ptaDg1cx5Tndz2qfw0oe4kJ5I6U25QorDGKZ4cm8rUjG2cSdanoaPU6pRsI96sRkDk9KY6gMBxgfrSou3IxmtEc7LKyYbdxWxYfvAAOh71hKCGArX05WTbt6VcdzGotDVAMZG1jxxnFXIS+BkjJ5BpUVXj+fjinxsIxh+R/KulI4HK5Zhwz7XB2nrUtxpyFN8Q3R9fpVdJEdvk5Pv6U8XDx/MjFT0wO9aRtbUwkpX0KV1bFT+7+VageEuvz/eHXitJ7gNgOiuPYc00rEnzK5Pqvek4p7FqbW5ivZBu2fYUotwgw64ArbiUSbsAcdM9xTHRHDLjjFLkQ/avYxmj3HqOaPKCnGePQitRbNQBkoQfTjH1p/lxxjKAfUnrU8l9yva22M1InQ5jj4xgE9qYLdsMFTnrWkAmcn7vUkHmiVoMgRnOerY6CjkXUPaS6GYLVy+GXGfWkmtdrhXXI9RW1DJbpHhpW3dOlVnkh3H5SyE8EcUnCFhxqzvsZL2ZzgLjjANUZ7N4VLFSP61vsy545HX3oaHeB8+e+DUOknsaxrNbnMW5eMgEHb3qVmCpk7XXuD2rbezj5/dqSe+KhWxjIyQqkdeah0Wa/WEzDl0q0uU3hQoP8PY1kz6HLGx8k5A7eldHdw7JP3fJ68VGN4C5LYJzx1FZu8dGbQk3rFnJ/ZrwceS/HtRXWeah6hyfqKKXMjT2s+yPXKKKK9M+TCiiigAooooAKKKKACiiigAooooACM0UUUAFFFFABRRRQAGmTSLFGzucKoyac1cd4r1Frq5XT7Y/J1kYHpUylyounBzlZFSS4Op6pJeMoaGI7I8/qa5nxjfzzXUWh2DYnuWBlkB+4hrU8Q6qnh7QzJ8pmb5YkHVmP+FYvgrR72e6ivrphJfXLZkRuCkY64rza9Xlaj1eh7VKKpx5nsjptL8Px6dlo3eOwgj3vjqzCqplk1K7a6kUp8uEHTYn1/rWlr16juNOgclEI8w5++fT6Vy+sT3V7djQNHZVJ/eX84P+qjHVfY9a9LDUlg6V5atngVqk8dW5Vt3Ip5R4hvJLa2bGhWTbrhwcfaJB/CPUZrb1HUINJ0yW/u18tVj4Qc7QBwFFQ6VDa29mRBsh0eM/uweNxH8ZPqa8x8deIW1rUmjicixgOEH95vWuSpUavJ7s+gw2GSShFWS/r7zI1/VpdXv2upyRu4RCc7FqnbrvYHP/ANeoB+8brk/yrSsoiOOma57dT0E09Fsi5b25+TZ+IrXs4N5G3lR1Bqlbpsky3XGK6GzhxGmPqfekzS5LCpCcL15BqYsScqOe9SMCCoBwQOBT9pYg9/akhXHovyFh2FSBd6D26YNMTJYencVcijVQNvzA96uKuY1JWKFygaI8c+tYs6EbtpAOM4rp54wq8YI9aw7hD5pBBI6dK0SuhRlqY9183cZxzxWVaDOqRgEc9Oa2NRjKN8vesGQvDcpKMAhs1il0Ou97M7xcmPODxjmp4ZFB+bGfpmoLZ0urCOWM/KRg89xVYO6tuYj0pxkYyjdtGtujJByOa07CVUWuXaYkA9MD0q5a3ZYbVOce9aKVjGVPmVjq2vMrjtTzdL5IGM85z+B/xrm47vkgnJqVbvJwDkVp7RnO6NjYFwVxtJDLyPerUd3uPzEg96x/N6HHH1oaVQc5wxoU2hOkmbRnIO5SM9jTXuj1bjPpWQlx5Z3hh+NS/aQ5DMv5VSnch07GkbraSO+cnFTLe5BGCawnnzzt5pvmsfvEjtwaamJ0jbebcSQCAe9RtKhZgTx7Vkl3TkSEDHenfaOe34UnIapmg0uSQMggUiTEgZz/AImqDXGDnPI4pGmLjg4HtU3uVyWNFZDyNwI9zU0Z6EncP5Vkb/nGeeKeJZFxgnFNMThc1JNijeSePxpqu0inaPl96yWmkDkh8nPIoM7kg7sfjTUrC9mzSM+0lHJHOajdo8Ek85/GqQm3/eJJHc1G0h4INK5SjYmd975jPtyaSSQpj16DI4qJXOR0z6ilklD4GRkUmWkO88/88k/Kim7WoqOWJep61RRRXoHzQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUZoAKKKjnkWGJnc4VRk0AZviDUjY2oEIDXEnyxr/WuQtkWGKa7un45d3NWbmd9SvGnkyF5UDsBXL+IWuvEV02j6YM2sa7rp0P3ueFH481x1qqinJ9D1MLRaV2Y1qlx4w8TR3pieSwhfZbqOhK9zXoDTrY2r2OmL5tzIT5jr/DnqAaz9FsGh0gw2k8FrdL+7dlOzIHUbTzn1PesO9m8Q2m600tbEzkMylSDnnipwrSTrz1b2VtvmY41yqzVGDSS633JtY1GTTLNfJiE+p3DeTbRn+Jz/k1c0zSRoul/wBmu6y3tx+/1G6J4B67QfaquiaTd6fdpqOsy/a9elXEEZ5S0HcgetUfGmof2dYiyjJ3yfvJpDzv9B9a0qV2488jowWDjF8q+/8AX5fmc/438Ree7WtsNtug2IAcfU/jXBSMchRzniprud55TI3J7CnWcBaQMRnnoK5Ipt3Z7EpWXJEsWVsABvz7EVqW1v8APt79aksrQllDBcfSteC3wu7A4NDkOKCzs1yGYAk1rwoE5PY8AVCgwpC8Uo3DbxznipKbLoXcMk8/0pEHPGNpP5U6INt+Y8+npSthccHBpkXGsCpyO5rQtQGXkc9ao9SARkDmr1quRwB71cDOoTzIGQgj6Vj3kTL8y9BW706H2qrcxbgQQPStUYp2Zyl7EJUPXI6Vz+oW+EPH09a7G6tPvEVjXNt8/wAw5PrWco9TqpzWxW8IaiEZ7G6bajHMbE9++a3LyDD5UFTzxXG39o0chdBkdR6g+1WbXxHdwhUu1E0Q43Y+b86jla1Rd7s6HcwjAZefX2piS7ZOFIFSadqml3uCLgJx91xitB47QYKsGA7qcimtCXJN7FaOXzlAJVfepo5PLc7JWOBnHagvYjhpkU+7AYppn07b/wAfUYX1B5oTE35FuK9JxvC/NzmkecyZ2Zx79azZtR0qAhWusZ67UJqa2ubGfP2a5RsHH7w7efxqrsjlRZFwwBBHtmrEM8bDbxn1NV9mG4UMBnleaQkbSFXJByfelcHFMuM21A3AX3PSkWQbRhgR796z5pMSMqA4Az8x61EZZQRwSB264o50HsmbRnZRt5xiomnc54XHeqUVxMAdycYxzT1mV2JZcZ9qOYPZ2J2nz6Z96PNYDPHFQbuBsDn2zijyZGPQIPrzSux8qLAuiq8JkE85pxvRjnI9MGqzfZ0BEtxgD3phl00LuE6kDvnpRzi5IllbwFvmxg9hS/bMH5AKoS6npEPW7B7fL838qrNq+lgfLcbvouKLsajF7I1GnZiRkA+9IsjtGdpxnjOelZsepaZI+EmyT3I4q011YRKTJcxqCMZHNLnaHyxJDJIFGG68YqeO5G1d4YknAUVTTUdPxhbpSW7HpUgnQhTHJExHRQf6Uvadx+zRaJkycIcfWiqv2mU/8s3/AO+DRU+0K9m+x7nRRRXsHx4UUUUAFFFFABRRRQAUUUUAFFFFABRTSzCRQEypzls9KdQAUmKWkNACEheWIA965/xNMztHAHUIwLMBnPGf8MfzxTvEOrm3KWls3+kS8Z/ujvXC+MNZfTLJLe3laW/nwqqeWxWNSokjswuHdSV2LrN1e3V62h6JtW8YYmdjjYOmB71o+GLJtF08uA0EzZVi64JIPOc9s5qjoWkHS9NimV/O1e9cPyB6Hv1A5/zgV0Tzo8ccUrEqCN7Jkln5y3J5zn9O1YYeKrVedr4f1Lx+J5Iezi9H+hTuIrOOOS6vpI3HLuwGOvvWTpBh06OTWDAfOuiYrW3YfNs6FvpW3p0ul69Jc6bcWkzwWWXluA5iiD5GEypyx6k56dOc1Xup47m4F0VjWOFTHCRnG3PXn1/CuirNvZ6GWDw6es1/w3/B/Io3F0NNtpb2/lJmf52Yn9K8g13VJ9Vv5ZmJVHfKpngVr+M/EEmpXrwW7EWyHaB6nuaxbG3MkvzDrXDOXMz6GnDkV3uV4LJpHzitmwshGM49xWvbWKrGpI4rRtbAyEbEZgO4HFJXewOUYaydjOs7cjBIq75e0KuPetKHT35+X26jinvp0zDgKf8AgVHJIz+t0duZGWpJOMcnOKekoBIBySPTvS3djcwtvMTlBzlef5VnCRFx5jYIoUe5qqkZK8Xc1VuVUfNncODViOTzF4ycdKxXOXB6/wBav2khUY96Cmupobc5wvzetWIflIOcnpioImywOatBecjtRFMzm+hfswjum8jjJ9KW6h3cjgEZx6VDCcZP5VaibLZbknrW62scz3ujOaIAlCp6fmKzNR08FPlB55BHauujtI7k5TrjNV3tMo0UgIJPHFXy6EKrroebXNsy7hIpOOhArJuNMdslWUJ3BPNel3Wl4B4yCKxrjS05O3GfbiocWdMakThZtMjKgD5mHUilit5oiwEsmQOF3cV2E+joOdjM2Og61nSaU8bHyyHz0PrWThJHRGpCRzTQkviRS4680RwxB/mGQPaunOnTkD90WOM9O1IdKkIObdjkZqfeLvHuc0yIXwvJ7EDio3hCkBu44OK62HQXkXdJAUU84HU1Vu9PVAVWCckHgEDIp2luxc0JaIwIri6t3DQXUgx054/Ktmy8X3cHF3bxz8YLqNtVX0xpdwVGU/SmSaRMifLGSuOB3pXvuN0+x0J8T6VIoE6zI/8Asx5pp17RQPlkulPf931rnDpcx6QsPrT4tMIXlCHzjnv9KLIjkaOnh8RaLIMNLcDnvHUFz4q06A4treWc/wC0Nornm0x8n5M57ClGlvvXdGwUUWQezTZeuvF11JkW9nHAM/eLbqypdZ1CYnfcD3CjFaSaWx6R8etSx6WQSUUZPtT1LUII59o724TzB5kiH3qoUkU7WLKD1B6V3lvZGMBccj8K0hZ28q+VLGjJnk4FOxLkl0PMRbcAoOGPbirFvbRjPmEk8nA6V6DNocEi5t8KR7Cqb+GAZG8pwjEdRyDS13H7WHY49oBj92rKKRbYtkEHH8q61vD1wgyHUj3qJNJngLIkRLE9QMg0a9BqcGc3DYs7BVR2yDkgcCpBazwSqY3bcx+96V0a2N1gkIR61FJC4I3o3p0oSbG5Q6GeEvwP+Pqf/vs0Voi3GB89FOy7EXXc+j6KKK9I+PCiiigAooooAKKKKACiiigAooooAKKKKACqOr3qWNm0jH5yMKPU1c96427uDqWoySMSbeI7UHTms5y5UbUaftJGeCIo7nUb99rBTIxJ7DnArmvDaJPql34m1tMp5R+zROOCuOPxq54qWTXtUt/Ddg5xxLdOBkBeyn0Oa2YrOa/1ZLXUIFj0zTIQpP8Az1IHy159Tmqv2UN/wPVc40qer0/G3/BF0yGWJPtt1mOedT5KHkQxnv8AU8VU1WaeSSPT7Ev9ruRgOvSJO7/j0rWv50VZLqcskMKb2I6Ko6cVmeF9RT+xpPEE8b7718QxdflzwB+PNelGEaEFSh/XmeNBSxNV1ZK6T/4ZFp7aHSrSDRNO3LGo33MoPLk+p9TXHeP9dS0gGn2pxLIMNj+BfStzX9Wg0awlu7th58rFvLHVm9APSvHb+6uNRu5LibmWU5+g9K46kr6RPoMNSS1l0/FhAgdxium0bT3kcMANo6k9KzdC0mSVhNNkRZ49W/8ArV2lsojjCqAAB0FTCn1kZ4vHcnu09yxBbRRrlgHI6E/0FXoGzGAc9cAAYxVSNyCOmfep4gVU/Mdx6mtloeNOcpu8ndllThiDgHHQcn8aF3GTauGJpIV2gkc59sfrT1ViV52gHOO+aCB5YKmeWY8KuepqnqWj2OpKoniw5GRInDAn/PerRgDuS5b/AGcEjH5VYiQLEikltowCeTjrRYqMnF3i7HA3FlcaTdJb3cge3kP7qfGAx/un0PtW3bWuFB9a3NQsINQtJbW5UmKQEHHBU9iD2IrkfDt7c2t5caVqTAvAxCSYxkD/AOsQazdNbo9XDY9y9yobkce0jcaswssi5UhhyOPX0qKeJZ4ymSOchlPII6GoVYQkXQUiWEYu4l58xO0yj26EelEIX2Nq1d02uZaM0m4AxwKltz82V/8A11DI6yorowYMMgg5BFLATuHv+lHUvdXNuyZVYhsYz+VX7m380eZEMg8EVgrJzkdR1961LG8KqF4IreElszkqwa96JXnhMZO5cntmoJLNJB8wAHqtdJJ5FzF8w+b1qhJZlSTGOvA5qnAiNXvoc7Jp5xiNyQP739KjTTow247mkPGSRiug2BW+ZcDofal+yIeVAwTnmp5TVVWjCXTYwhUqxH8qibTYkAESsCfQ1uyQ7WwMcdx3qJ4h/d59c0WBTZiS2ksakqPlPpVKWBn4dDyMZ711BgwgJYZJxg81CbeM53HknkntUSVzWFSxy5ssrsXhQMAetQy6dlRkYwe1dc1mhGMDp1pj2cBAVlOD3HWpcLmirnMR6eh+9jIHWkbTY3yWUdemK6eOyjjOFQn0Lc1NHZDnKH6ihUxPEHJx6WrZ+Xao7VL/AGUrY2r+ldglhGq7iMfU4qX7JgcLz2we1X7Ij612OQGnY4A46YxTl04DqDz7V1QtFzubd+dOazUAHfgehpeyD6yzlDYJg7hjPFQtp64G049vWusNsuOQrY79KryxQgsAvPUUvZWGsQ3ocs1u4BIHPbFRnzhjgj0xXRSRI23GAD3NV5kjJ2xg8Hkk1LirGkajb2MrdKvVj7huRSqZXJ/eHB9auGDHzMVAJ5zUTRMo+cqT7CsnobJ3K8AMUh+Uc9DV7Edx8s8IYY9KqIAowucHq2amt22luWA7VF9RvYh/sW0bnDjPPWirhmjUkFxkcGijnl3Ises0UUV6p8wFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYnii+e0sligYLPO2wH0Hc1zGoXqaNoTSn5nKlYkP3pHPp/OrGo3J1PX5cHMdsQi+3qa5+73a544g0xVY2+mr50ij+J/8A9Vcdepypy7HqYamoxu/Vkng4R2unSwSN52t6hKWLIfmCn+InsK7GcpBCtmhLpGBuc87yOvNZvhu2jt5r/UnHz58pVx0I9KkuLlLO2mnnO1FBdjnjNLLHKdBVZ7s4sxqJ1XGJxvjmefVde07wxZEqLoh7xlbGFB+7XS6k8MEyxqFjsNOTAA4UMBzXOeE3dYNS8S3ca/bNRl8u0J5IQcZrN+IOoNY6LDp0T5luWzMSecdc1c6l7vud+Ew/Kox7fn1+7Y4zxPq761q8lwWzCDtiU9h60/wppZ1fWYbZtywAGSaRf4I15Y/l+uKy4olYZb731r0HwFAtt4Y1292/vJPLtVb2Y5b+QrOmry1O7E1PZ0m10JHKvKXRAkfRFHAVRwB+VPRsk469aiAJ4w34VLGB079cEda1b6nzxNG3FW4mGeevvVVAOOOasRgcZANSBdjOe9Sg5HAyaqIsbD7i9emKsQhEGFAAPpTuIsKOhPWpEI9KhUkfSlzKOvln8xQIsI2eD3rgPH8jafqsV1bKDcAJLz0OCRj8RxXdxMxOSBn2rzXxzctca3dhQSsIihB/HJ/nWtKHM3fs/wAg5uVr1R2NlKstvFIn3ZFDDnsRUkyOwWaBhHcRnMbHp9D7Hoa57w1fE+HoZH5ZXCcf8C/+JFa63Qde+BXO04Sse3Q/2ij7xBDdJZlJUUx2Ez7Gjb/l1m7of9k9Qa2oyMknvWSyxyGQSgPbzL5c8Z/iX1+o7Gm2dxNazy6bdtunhUNHIf8AltEfuv8AXsff61ckpLmRnSbpS9jP5GwX4znkUqTFD1IOeoqh54AyWFKZ0L5Bz7Vlc7OXubcOpOikAkj3q7DqGW+8ckfgK5YzkEDoKdHc8AgHGe1WqjRnKgpdDsvtSuMEA+vHWo/tSBMFwPUVziXpYAgEEe9O+1sQS4HWqdUyWHNx7qJvu5x9KjMybQzZwfzrIN0SABx7UG4Y8HGQOtLnLVE1d6EAl8A9PakJTJwMmsozNgEYpftDAdM+9JzGqRpZAOcnNCEs33gQvSs0XRzkjBpDc9dxwDyMUuYfszXMjBsbgBj0qxBMgADORWEt0M9R+dPNyzsMnjNCqWJdG5vNco3BcHJ702a6CqSp46CsQXJJBzTVnAXHP4Vftifq5qR3+3G9Tg+lSPeB1JJBrCluVKjvgZxURvEB6qp+vFT7ZotYZPZGtcTvIoXOEHQ981X3EHJbA6c1lzainLJJkjoR1zVKTVlJZVDk1lKqbww7WyNwsp6MPao2OVyMA9Sawf7TcoNqjOeaQ3c7twmB3qfaGioNdTWmkyOWyDUEl1tXJYbR37CqCrPKfmIRcU9LU4AZiVByR61Dl3NFBLqI9208ihQFUdfenT3CWlo0skmCOQP730qrfaraWI2qBLOOir2+tYU1zdarciSfCQr0RemfU1KbkW4AwuZGLmRsscnmirgwABk8UVpYqx9FUUUV6h8YFFFFABRRRQAUUUUAFFFFABRRRQAGq1/OLaynmJxsQsPrVk9awvGTldCnCsFLcClJ2RUFeSRzuhqiwSyzjBcmQsecZ5rK8Awy3J1nWHU+feysyEcEIBjj8RW4wFvobYXdiDr6nFYfhAIfAWmTvPNFKuSCg5b94RivLxDTtBq9/Ox6z0ptr0OmDLDpthC5PmFPMf1JNcl8Q52ksLHTIn2PqU6xkdTsz81dnqpDag2Nu1QF4/hrkJwl/wDE3SIJQPLtrSaTHocDBxXpVF7Okox9Dx6D56/O+mpoXlvFBfWumwKFgsogGUcAN2rybx7em48RTZz+6+QD0NeqiYyx3t23MsjEAnrxxXh2pTSXWpTO7h2aQ5b1rjqWT5T6TDxsvRfiWLJM4Y5NeueHdPMXw9uj1aYrcgewcr/7LXmNpasAucAe9es+AbqO8s7eyfmNbZ7aQ+mXyD/48Kqg05NGWYqSor1OcVGYgDP0FSRQkHLce3f860b+xl069ZHUqVbgkcVVAOevX9Kux4VxWRdzeWcqO/pT0HahAyNGYwBk9KfGm0gu2cH7o6YpWAcowP5U4OqsFLDcecZ5pZlCO4jztBOM0rRJHJ8uCpAYNnOc+tAEmdpAkIYt91V5x75qUBsfK3584qINlSBjDdyOlBkjt0LMcepJ60xC6jdCw0+SYLuZV+RfU145damJpJoFZnnaTzZnB4PoPrnn8K2PH3jZfs8lpp2JJHynmDoT6L7eprjdIt306S2e4zJMzefID1JHTP44renNRTS6/kN038TO/wDDyvBZy2b87LhY/bIRmb9WArYJwcDIxXNrfT6ZNaRxos08YLSgjO55Dlvy4H4VabxI7yrHJbIJe0cR3OfwH9awr3nPQ9nASjSoXm7K5vLLj73UU7W8z+FH1RDm40ecbSOrROBuQ/marxaZqF5bi41OSLR7DqzyEGRh9O1Y3i3xTpraG3hnwqks/mt+9lOMMfXNaU6TWrOTGYyNVpQW3U3Fu0cKysTGQGAx1BGRSNeH5eAvtnmufi1W0gtYrd/MaSGNYyRkBiAB1qM67GpwlpvY9y2DiuKWj0PfpJyinJanUC6dV3BiT1weKnivG4BjB9fpXKx+I02hXtPlHq241JH4jtkYnyW9xmpuynBdjqBdrnoBx0BwamjvI2OZDjuFI5Nc7B4gsJl/eIIyeMkZNWIdV07LfveDxnrRdkumn0N37QpxsAyff8qPNIO5sjHQ1lrqdioys8a44BbrU32u0wWF1Ewb/b/pRdkcluhZa/RSFZyCegx1P1pqX6so4YknkVRae0wWM0QXHd81Xa9sQADcIT/stijUpRXY1TdjDPuKgHG49BUqzCRNwfJI4APBrnZtT0+P5PP3L1xnIpsOqWIQBZWA9h0oswsjpDMI+pUfhTDeJlwhJwetY8eqafkA3JIPTNTvqenopY3MRA9DzS5WPTsXTekMflZzkcYqIXlw0ZMQK9yDWe3iKwXcRKxwM5xTD4osMsSrkY/u5osP5Ft5LktnedzDlQKZ5U7KOCM9NxzWbN4thH+otsj/AGmxVK48R6hOMW8IiBOD8u7j60KLLTZvyWrqu6dsL1yxwKr/AGzT0yWnGR1wK5mRb+9UCeSQoDwGbpSppTEgyMcVXKF0a03iaNGK20GT0BY5zUY8RX7HZFaqH7EjHNV4tO2njb9SvSp4rXjG9iM5z3zRyoLX6Eqa1qZCmZbdMfe+XJNR3F/e3KbMlecHHQ1IIEXIwT9anhiPJVAAfWlyp9BrQq29pkgngjvVyOIMcI20jsehp0UYGd24+gFW4kjU52nI7Hmmrg2lqMFtx1FFWPNxxtH5UVdkZ3ke80UUV6J8eFFFFABRRRQAUUUUAFFFFABRRRQAGuf8arnRs4ztdcj1FdAayPFEDzaLcCPqq7vyqZaoum7TTOb1CYf2I5RQf3WMDpWJ4dt47TQtPs3+coPN3qSQfmrXsyH0xN39zNUPCKRRySWty4/0diwB5yvJ/nXl4hPmhK9rNf5HsNfupHQ6g3mXkjgYyeD7Vx2nSuPiZrESBWMenhw3dTt6fjXY3MjSyQzdnjBB7E9zXJ2IeH4qXhKjy7zTyee5Ra9Wt7yjbyPFwmlSSe9mHiif7D4XuSvDtGcHuCa8e0qPdcbmIJDZ9jXo/wARbtv7OjtVHzM3IFcJpUR8zBAOK8+bvI+poRtD1ZsxIdw7riuj8H36abqsDTcW0h2S89jxmseJBheMYFSlc1nCXK00aVYKrBwlsz0vXZ1tZ0tNWHmQSD/R7zj5x/db/aHY96xprActauJUH8PRl+o61QttW+36MNK1Ahwn+od/T+4f6GuG8SadqVoCml31xGITnys5Kew7j6V2uUZrmPmamHlSnyS/4c75Q0RGchweMimtl2JY4Gc4HFeNt4z8UWAEaagJ8cFZ0BI/OrX/AAsHxC0WT/Z24j+JOazbRX1ap0PXWbPTrQGVAWYgY7ngV43L461yVCJLu2hPTMcYrImur7V5D9ouL++B/g3lI/xxRcf1WfU9X13xzpGllolm+13IH+ptxvP4kcD8a808ReNb/WFKyn7Nbt923ib5n/3j6VJpuhX18i2cChI8/wCos0ySfduldvofw2NigudRe205By0krCST9eBWig2C9nS1erOC0bSpnZb6/UIAP3Sv8oA/Gus0TQr2+nEtpaSXMrMGMjLtjAHQAnsOvua1r3xB4Q8PuVsIH1nUB0eQlhmqVxq3jLxKgSLbpVgegA2cfzNaqklqzCdWVWWn4Gje6Hpelb5vFGtQxs3zG3tjlj7E9azF8WW8G6DwXoSJkY+13I5+uTT7Hwbp9vIJdRlkv7nOS0pIX8u9a7W9skeI44vL9FXbioniIR0Wp2UMuq1dZvlX3s5S50zUNUlE/iDUprpz/wAsYjtT8TSpp4iDQ21ukSAfcQdfqeproWit89dnHUGojbxBDhy2enPNcdSvUnvoj28NgsPh9UrvuzB+xMxH3FPfJ5FOktkVhtJKrwDjqa0yqxMUFrOcnqEJqxFE8rBEtJSexMZ5rJJnbKrFa3/IwHQADeh3ZOT6VDKseRsV8DqSOtdbJ4e1N8FdPYg/NkMKYvhXU2AZrFkTOPvDkVfs5dmZvFUv5l96OPdB0xxjpSpb4bcTge3Wu5t/BksoXedjkElCM/rSDwPOEDK6K3XawPHtQoT6JmbxdDrJHDiJ+Rkc+tR7JUbKvz6Cu9/4Qy9Lop8kK/8Asnioz4J1Pc4ECyAA/MOM+lUoT7EvE4d/bRw+yZmJbLdh71GQ5fbgg9Olei2/grUpFBSyB5xliBip08I60vXTkXHQ5BzT5J9hfWaOykebNbyZBCknONoFNEcpk2hTu9MV6ivhHVWP7yCFB3OOlNk8KatG48q2ikJ9OP50/Zz7B9ao/wAx5sLOc/dhk/KpF0u5I/1TEAenWvRB4Z1U7d9vGp9Caf8A8Ivqwbd+5HoTR7OYfWqPdHnP9nXAH+pfntirlrprEkuqovueTXex+E9UYhpHskAzywNPbwpfAMDdaaq9cLnk/nR7KZLxlLucfDp0cYwACTzkip1syvO4kHsBXUt4VkClpdQhQDj5DTIfD9mh23GsNuOT8ven7OS3IeLp9Gc+kIUHdwKCE4JJxXS/2BpJTcmqyYHXBHFMWx8MQqFuL95HPHzA0KnfqDxkVrqc9uTJwcehpsk8aNkHPHSumih8KI5VrRJiMENJnAqybnwxA2Ft4d56kKaapLuQ8cltH8Ucal1HkZ2A++anF9GPlcoF9cGuxGtaCQEjhLem2IkfyqSPX9KiH7uznZRz8sBx/Kk4RW8hfX29ofj/AMA4lb5BJtjUSDrkA8VP9tUEZhb5uBgHJrqJ/HOmxws66ddHadpXygCD27U1fF6O5EWjlMDLF3QYz35pqnH+b8jOWPlvyL8Tnt8x/wCXKb8qK2X8caUrsDaxEg4zkUU/Zw7h9dqfyr8T2Siiiu0+fCiiigAooooAKKKKACiiigAooooAKa6hlKsAVIwQadRQBwZgNhqM9lKSQSZIx/eU+n0rn9Qkl0nW472LAhk/dTZHBB/pXpGt6YL+3BjIS4T7kmOfcVxt5aC9hktZ0ZJ14aM9/euOvR5k0erhcQpK0jR0+RLqxkRSxa3Y7Vz95OxFYMyY8em5yAlvpkuVz13KO9WfDd3cC3m0+Ep9stZCCrjDyR9h9KTVo4Y31C+lULeTwi3ERONgxiqjiF7Oz3icv1aUMRZbM4LxmZJvIIPysMqfSszToNp4Ga6LxMFa1tFwBtUAYrNt4wqCuV6H0cXdE0Y4p2cH2pCMCkwWPFSUPB6024AuoBDPu+X7jqcOv0P9DmkleKABriWOIdt7YptvJc30nlaPp9xeP2cjagrWEJv4TjxNWhblqu5xOuaTqitIR5d5H/CZIuce5FYtvo88n/HzDDbZ6ASFmP0AzXs//CK3SRCXxPrEGnW+MmGA4OP51k3Pi7wf4aJh0SwOpXi9JpORmuqNG+54tSvGD9zReZzfh74fXmoMrW9gzL1825JC/lXVz6N4X8NwhvEOqRzyL0toOx9MCufu/EPjTxe3k2xeztGPEcI28fhVrw/8OBPN5l35t5KTy38APua05Yw3MeepV2/EluPiS/Fp4M0RYc/KJXXLH8BVD/hHfEPiGYz+ItRdVPzGLfjj6CvS9N8HQ2sSo00drj7yQIOf+Bda02g0/TYQIl3P1Bc7tx/Gjnlb3VY2jh4L43dnD6J4TtNPKLaWu5z/AB7Nw/OulTRJ5DiRliU9D1/SrsWqXl1GV0+zkRc44XofpTLm11DzUW7mWJ5OCgPK+mfSsJzjFc1SR2QXJ7sEkUp9CtGKi8nlJHQR5QU2PSNGiQlGmY5yBJJuq6umYMjyXLyPH1weKr24NwP9AtGnA4LgfLWH1mg/hV/RGjlU2cn94iW+kq+BZI2R0ZdwpGWyiOYLe0GP+mWWH4Vq2On3mwNfmC3hB4VDktnpk9qmu9OsYXJlyrMjOSOu1etaKqrdjHnd+5Qj1GGDPzyKTwTsOKm/tmMlfmfaepzSQ2+l3clrBb3TO88ZniYchkBwQffNNksrALNKl1GwiYJKj8bW7A+hqJ12l7uvzEoq+qt8hr6tCwAhtZ5OepO2mnWEDcWj/U9qXUZ5tOtpZZNIVUVflLTkc/Sm2Oj6hc2cVzNLEjSDzMZ4APSsXWrvRRX3/wDAKXJ1/L/giS6w8BAMJUE9lzmlfXJd67bXr0DDr71JHplvdXbltVjNxjHlxnNLcwaRY3iWl7LKJpFDAsx5/wAKTrVFfYpJXtb8Cv8A25dhJD5ceQehXpTotWv7hsK9rGSMqpYEkVcFvor3jWUUiy3QjL+UJDlhWb9s8P8A9m/bFtJGKSeU6Jnehzj8qhTq3u5Iq19oki6hqAkIMkTduSOKJItWkzN9rjUY2hVnArYOmacskMa2cjrIdrsHOI+M8+lYsup6Ta3s9lb2Ekl1CxHJJU4561oqko/G/wAyUnPSCK5m1JgFN+MA4wOf1pzR3hzu1sJjqhXcSfQVe1LxDbQ6XFeW1rHHKzASxSRgFR3p+raisdvci2tf3y2ouY54oQ+OQMY9eav26bsheznuZllctalTcXMrFuMsOKgmbU3ldrbUYpA54225JA9BWvqWryCxurXybey1BAptvtCgiUeoz3NUtU1y+0W0sFvIoReyESN5cYVdv9046GspVZKFlL8Co025XGDTr+S3H2p7h93QnK/pRceHJAEWWzuCX6FJcf8A6q2r661eOS91GxEV1atAskdvuywfHQfnVLSZdc03w9eG8nt7m+LebBGsm5gh7H6E0pTlzP3nb5f1qCi3Ff1/VigvhR/LIj028JzwWvB/LFKvhOZh++iEJIOxPM3M/wCNWdWn1OHwm2pXN3i9SdZAIjlShP3aLqS21KePWZNY8iB7dolhztMcmOT+dW6sX/w9vyEqU+/4GM2jpaaotvPpk1xNt3YW4CBF7lq3pNEY2sMmj2ttdwSY5Ygn8+9Wp187WreOaPzYrjTHWSeNzkrkVgWlzb6bbXs2m38zQafbrAvy4VzvyWx+OKJ1FFWu2vXUUabnqt/wNR9EedpYEvdF3bseUYQxQj1GetTJ4ejYeU1zYM33CPKyd3tzxWHqumz6lqWn6jpdu6x3QR3dRt+Y9TmtK20uHXri61C3lltLhVa2dB0DqcLIPekq3O7qOw3R5Y6yNIaTplt5ha6liFuv7xYn2hfcimapLp2nWUIudSvVt3IWIxT/AHiT0FU7vwV/ok8kmpSNdzY3SudqkY6Ed/Wpxpuhx6JBYSajavJbghZnYEqxGCcdqdN1VtGxMo0tG5XElv8ARLe5kiuBdfaUTdtlfhl7HPvVE3/h3UXm3aKbiFE3FvKLFse9P1CPwwsNm99qkcos0CsytuaUDpms3W/H9usaW/hO1YMBhpWiC7fw70c9dvWVkWqVJ6Ri22bC2/h8qDF4ZhaMj5SYMEjtxRXBt4j8WMxY6hACTnGwUVvzsf1SX8p9E0UUV3njBRRRQAUUUUAFFFFABRRRQAUUUUAFIM5ORx2paTnPUcHnigArJ1fR0uyZ4SY7peVYdz71rd+lLQ1cabTujzvUNKjvJv8ASENteoMhoztJ9896pajHPFbSrezi5YKEjJIyMj2616Dq8ljHCHvpkiEZ3K5bBU+teU6/4n0OG4eDT7ie/kJ+WO3Tdg/WuWrQ5lZHfSxa05+hR8QgNb26/wB0AHFZuFjg3Oyog/ic4FaFnoHirX2DJbJptq3IkuOXx7CtCTwl4Y0KIz+KtYN3OOSssmBn2XrS9hrqzplmSirQX3nKpfpcSiHToLi/mPQQr8ufrW/YeEfEV+u+9lg0i37qPmkx9aq6n8XNJ0lDa+E9MRwBjfs2DP8AM1yM2o+NvHFwfLa4WE8FYFIX8TXRCgl0+886rjqlTRy+47S4/wCEH8Ksz39z/aN8OT5jbyT9KwNS+KWo3oNp4X037PGRgMq4P5Cr+h/Be7aIzajJEZcZCOxJJ98VqP4UvdFiVJLRY0bIDW65HHr3p1Jxpq9rmdGlKtK11E8/XQNd12QSa5fyYxkIWy2PpXTeHPCVhbyhYrVpWX+JxuJPoB0zWnojNf3jwRBVWHHmk9cnpj+tehaZa29lAWt5C0zD5pX7D0Fcsa9Sttoj0nhaWH6c0u76FTT/AA/bWqJNdnKoMrCPlVD6kjk0641yJCYbKLzHPyrtGAT68U69drmDE8jQwO21f7zD19q5nWLtrG3e10y8SJIj5Tv1lcehNTPEQpS9nHVjpUHWdzbna7JAv50gcgfugfn/AMKgv72xtGSKSZJyRuRmPNcdcTSyRyLBeee0QVx8p80KOuD3x6Vh3L2DzK0+rmGRxkB7Z9w/CueaxNR+9Ky8v8z0KWFor4n+DPT9L1tZ9Tigt2RmZcqM4ArUutJuby6M0uoSqxGGUKMfhXjFrqUVjqImgmFycZM8cLIvH+yea9P8IeMk1aWGG5RY3lztkXgEj1HWnGjGMeV6/jqcuIoSg/aQd191jWtNG0+N5Wa4kuJov9YHOMfUCrmmanYXNlI+nzRBIsqy9Nh7Z/Gue8QzXGn6re6ppS5wqxXiSAheRwR+FJHo8UMMg0uNJpL6LEyyuCUHXj2zWXO4vlitF/SM/ZRa5pPf+nf9C3Izt5Ol63dytd3bebG642IRyFU96rwanq2pNdWkUMPlxloXuW4K9smqGhtc2ltNLrMIW3slBgEo3FHJwMY6DpU0E/8AwkehX9rBCsNyjiWTy/lV+5+lZ811c15bN6f5Gne6b5dxHNLLGum2cG6NoiNySe2OxqrZPB4hsbmK4VLbdIAbheN8nbPv0rK0rw/q9rqEVu0f/EruE2OytuVR/jWjYWml3kK6Mjypsl84SBsFmB7flRrdXWjDRLR3t17EOuX0lzaz2p2maxK291JKTsIbgMK1JnvIL2OGV2XS/sXJ6IpAADA9ay/F+nTWAvNRaeE21zcQMFI7hqn8U38t/De6WDHG6iKSJ2cKDkZKH610SvytP+tzGKTa5V/Wn5MyNP0e7s/EjXcu028CmWKdj8rAjqMfXvVW0lm1+USSXXnanYEMFYDbLED296feajc6E66YJN0MaBXil+bcTg8H05rZOm2+l39pqENuLXTbiBludvWI7Tg/nXOrbG7bWv8AX9MrWy6ZZ3U+t6BuvdSRgZLVukaN94g/Sr8sZ0C3uL1reO4ivLqJ8YyY1K88Dvk1SaO20vw3GfD5kulvWKyTMpLsfT2FaWnvq9h4cga0EFzdmUAwvztXuPrTTs7MlrS6721/rQqSvcWupeJr4rLHtjXYAThjx07VUk1W9gu7KGxhgSeeFZ7iRhyFPQGtewfV212+tL6ItZFTNhxkJxjAP1rDhsrbUo5buW/lgvLaNYZtxyroDxj3NTJX2Ki19ryN66uNMvNNhn1iOPc0vlJIOMN2OO9YWpTazo0KRpMJnvT9+Nc4UHAH5UyWxk8RW1u1vKlnb6a5iXzuRIXPGD0yMVra/fX+iWtsIUMcSxYY8Ha2eufeizcbsFZS5V9xm3+lxax5V1fXb29xaQr50X8QTPBHvmrcOqWl7p66hrFopgspGjsjnJmHct9KkttXi1TQLm7FjPJNIBayyoRv256+4yam1HwfJdaXY2WmzlUijO95ATk46gUJS5fc1Byjf95p/wAN+o1Iha+JLLVIr5INMlUERs3U46YqraaLd6b4jtru+1CGKCeZkjAYkvkE7a0L3wtbw3OnyahexRWdomPIZsEnv9ATSapqHhWzijN9dCRVk82IRHzGBxjAxW8aMm9UYutFbPfy+4qaVbW7nVdGuNSjaW4LLAi5JQrzn0rGuYra8udHtbVHuRJIIJ8LwNnDMPY1q6LrSTS3U3hrwzcSO8mTcSyKNufbriq1zqPiC1uY4lm0rTImkJd44GLZJ55z1rOcIRiudo0hVm5PlTb/AOB/wx2s9qtrrcFy7iOGO3NtGu4BVUnqfespz4YsLC6snkt0t7h98sYydzdetcxdaQbyMtqd/JfPJklWfjr6elWNKSztJTBNGrQMuRtOGQ9jzTniqUtEtTONCpa7ZoXHjm1SNINHsLiZVG1DjCAD0rMj17W7p22PFZMxyRbrkt9c96XV2DWyy7wHQ8Aeh6/WrOla5Z21nNZw26lpQGMxdRiuSWIq1HZe6dUaNOEea3MzIn0KSZ1aWeR2bLMWkYZP0zTNK8Lxam8e0ruYlSoY54+tWtQ1iARsqJM7vx+7GcVShupDcJJDFcQlepXgGs/Z13bmv95opw5Xay+RqP4V06zuSmDIw4JIyCararpKW2xo8NGSFwBj+VXbbxHLZwyxRW7O0vDFkOV+lUrnUXkZVaKZUBB2iMnd+NaLDzUW23f8iY12pK235mkPCcJGSoyeetFUv7bI4EF1gcD921Fc3scR3f3j9rLv+B7TRRRX158yFFFFABRRRQAUUUUAFFFFABRTJZY4ULyuqIOrMcAVyGv/ABG8P6OGU3IuJRxsi55+tAHZVFcXENtGXnlSNRySxxXj8vxD8SeIZWh8M6U6xtwJSp498mnJ4B17WB5/ijXGVDy0MTdB7npQ2luCu9jq/EHxL0LSi0ccxupx/BFzXMN4s8Y+Jvk0PSzY2zf8t5+Bj8amc+BvBMIci2kuB1YnzJM/jXI+I/jRNPuh8P2ZQZx5jDPHqKFd7IG0t2dSPAJkQXfjPXZJx1KB9kYqC98c+DPB8Pk6Pawzzrx+5Ucn3Y815clv4w8bXH7x7mZWP3RnFd94X+CLfJLrU4TvsXk0+RfaYud/ZRy2vfE/xL4jlMGkxtaRMeBCCWP407Qfhb4i8RzrdarI8aNyXnYlvyr3/QfCGjaJGos7OPeP42GTXQAADAAAp3S+FE8rfxM848MfCTQNICvdIb2cc5k+7n6V6BbWkFtEsVvEkUa9FRcAVPRUt3LStsNCAUFARg8g8EU6igDmdQ8JW09wstm6Wj7tzFYtxb68irK+H8R7Guc+/l4/rW7RUezjvY1VeaVkzl18LzebG0mpeYkbFkVoenHQ/NyKxbr4ceeJ3GpolzM+9nFr8vvhd/FehUVnHDUo7I2hjq8Phlb5L/I86PwzAdXh1Zo3UcMIOf8A0Kq1x8LJJo28zXN0x6SvabmH4769Ooq1SitLDePrt35vwX+R5fH8KmVAH1vefX7Lj/2eprT4Xm2vI7hNZ5RgwAtcdP8AgdelUUeyh2B5hiJKzl+C/wAjMl0pJomSd1kVxhwyZDfhmsXTfB72esNftfq7MCPLFvtAHbHzV1tFRLD05O7RjHEVIppPc41fB1291dS3es+ctwPmQW20A9sfN2qvJ4Axo72dpqslvNISZZ0j++PQru/rXdUUvqlK97fmX9brWtf8Ecb/AMIfeCJIl1yVI1AXakO0EAd/mpbbwSLd3kS//fHIVzDnaCO3zdfeuxopfU6N72/Fh9crd/wRzM/hYT6CunTXQkZWDLLJFuwQePlz/Wn33hW2vvK+0+S+EAkJh5dh0PXjHpXR0VfsKdrWI9vUve5zM/g6wuNQjvZ8vcxrtGR8nTAO3NVtJ8Hz2TTLc6s15bzLtaKWHjrnI+Y4rr6KTw1Ju9h/WatrXObt/DT28dxDFeqlu4xGiw4MZ9c7ua53Vvh3qN1olxY2PiZ7KaaVZBcrabmQDqB846+ua9Goo+rUr3sH1mrZq+5zFl4ZuoIoVuNXlnaNskmPG8bduCN3PrTLTwfDaCRIp0aGVsyK8O4sOwzmuqoo+rUu35h9Zq9/yOS1DwXDeQwW/wBqaK1jZmMKJhWJPB69q0ZPDltLpX9nzSNJbldp38kj65rcooWGpLZA8TVdk2Yh0Wa2txFpFzBZAf8ATsHH5bhWPf8AhjxDfIY5vFKRxn/nhYCNh9GEldnRVqlGKskQ6sm7s84b4XQyQstxrF3cuw5ecF8n3Bbp7Vdsvh7bWkMSxTWyyx8CRbQA49PvfrXdUVnLC0pbr8X/AJmixVVbP8EcXB4LubWaaSz1l4TKckCDI/8AQqrXXgCa8mD3esmQckqLfbk+v3672ip+pUNuX8yvrte9+b8jgk+HgVMf2o+7GNwhwcf99UifDmIDD6k7Z+8fKwT+O6u+oq1haS2iT9aq/wAxxUfw/s1ADXUr44G4E4H51YTwNp6gDETc5+aLOf1rraKpUILoL6zV7nPReF7aIYjZEA6bY8f1pP8AhGh/DcqOc/6r/wCvXRUU/ZQ7C+sVO5zy+GYtxZ5y2fRMf1qQeHYxwLiQD0/ya3aKrkj2F7ap3MMaAoGPtL/l/wDXorcopezj2D28+4UUUVZkFFFFABRRWTrXiLSdFjL6lfQwkc7S2WP4daANagkAZJwK8k1j4wo8pt/DmmTXcx4DuDj/AL5HNZLaZ4/8XjdqV0dNsn6oTs4/3Ryfxoem4t9j03XvG+gaIGF5qERlH/LKI72/TpXAah8V9S1ORrfwro0sjdBJIu4/kOB+dWtO+G/h3RkE+sTm9kXlvNban5VHrHxM8MeHIzBpaROy8CO3QY/EilzX+FFWtq9DOi8J+MfFDCbxDqptYT1iByQPZRwK14vCPg/wrH9o1OWOeZed9y4Y/gK8v134s6/qrNDpqC1iJ42DLVl6V4P8TeLLnzJhcSBjnfKTgVSg38TIc4/ZVz07XvjJo2nRGDQbTz3XgbVCoK851Txt4t8VSmG3aVI2PEcAOa9K8MfBGztwkmsTGVv7i8CvUtF8OaVo0YSws4o8DGQvJppRjshe9LfQ+efDfwe13WHWfVG+zRnktMdzH8K9d8M/Cnw/oqq80JvZx/FL93/vn/GvQOgoocmxqKRHbwQ20Qjt4kijXgKigAVJRRUlBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFNl/wBW30oArahqVlp0JlvrqGBB3kcCvPtf+LukWbNDpUMt/P0BA2rn+deffGH/AJDZrL+F3/IdX/ep7E31sdl/avxB8XnFnAdOs3/ixsGPqeTV7S/hTZq4ufEmoy3kx5ZEbC5+p5r1Rv8AUp9BXF+Pv+QJc/jWfO27I05Uldla51/wj4KtzDE1rC6jhYgHkPtmvPfEXxru5zJHotoEB4EkvJ/KvJdW/wCP2X60/Sf9aK2jSVrswlWd7LQ3JbnxP4uugkkl3cljwig4/IV23hf4J6nd7JdVZbWM87WOW/IV6H8Fv+QW1enUOVtENQT1ZxHhv4a6DoqqfI+0Sj+KQcflXaQwxwIEhjVEHQKMU+iovc0tYKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The right angle hook is advanced behind the button battery and then pulled forward to remove it.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_4_20546=[""].join("\n");
var outline_f20_4_20546=null;
var title_f20_4_20547="Exposed medial wall of orbit";
var content_f20_4_20547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Medial wall of the left orbit (lateral wall removed)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 495px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the proximity of the frontal, ethmoidal, and maxillary sinuses to the orbital space. The lamina papyracea is the thin bone wall on the surface of the ethmoid air cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_4_20547=[""].join("\n");
var outline_f20_4_20547=null;
var title_f20_4_20548="K pneumoniae sputum";
var content_f20_4_20548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    <em>",
"     Klebsiella pneumoniae",
"    </em>",
"    in sputum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <em>",
"     Klebsiella pneumoniae",
"    </em>",
"    under high power magnification (1000x) in sputum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_4_20548=[""].join("\n");
var outline_f20_4_20548=null;
var title_f20_4_20549="Perampanel: Patient drug information";
var content_f20_4_20549=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Perampanel: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/18/7462?source=see_link\">",
"     see \"Perampanel: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F15594703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4031542",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause or make diseases of the mind worse. It may also cause very bad problems with how you act. Ideas of killing yourself or murder, forceful actions, fury, anxiety, and anger have happened with use. If you think you have any of these problems, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15594705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or control seizures.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15594704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4031544",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to perampanel or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15594709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15594710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15594711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698697",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are new or worse after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15594707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15594708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15594712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15594713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87121 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-4E1BBEB838-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_4_20549=[""].join("\n");
var outline_f20_4_20549=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594703\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594705\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594704\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594709\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594710\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594711\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594707\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594708\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594712\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594713\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/18/7462?source=related_link\">",
"      Perampanel: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_4_20550="Infectious tenosynovitis";
var content_f20_4_20550=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Infectious tenosynovitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/4/20550/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/4/20550/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/4/20550/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/4/20550/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/4/20550/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/4/20550/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/4/20550/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tenosynovitis refers to inflammation of a tendon and its synovial sheath; this condition occurs most frequently in the hands and wrist but can occur in any joint. Issues related to infectious tenosynovitis will be reviewed here. Noninfectious causes of tenosynovitis can mimic clinical features of infectious tenosynovitis; these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/40/27270?source=see_link\">",
"     \"de Quervain's tenosynovitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19141?source=see_link\">",
"     \"Trigger finger (stenosing flexor tenosynovitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomic placement of tendons, their sheaths and the adjacent bursae has important implications for the clinical features of tenosynovitis (inflammation of a tendon sheath) (",
"    <a class=\"graphic graphic_figure graphicRef77271 \" href=\"UTD.htm?29/32/30215\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=see_link\">",
"     \"Finger and thumb anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extensor and flexor tendon sheaths have two surfaces: an inner visceral layer adherent to the tendon and an outer parietal layer abutting adjacent structures such as bursae and muscles. In their normal states, the visceral and parietal layers abut one another; in the setting of tenosynovitis the space between the two layers may fill with inflammatory or purulent fluid.",
"   </p>",
"   <p>",
"    The visceral and parietal layers of most tendons are tightly joined at the ends to produce a closed compartment encased in a tendon sheath. Many tendon sheaths lie in close proximity to adjacent bursae. Therefore, infection in a tendon sheath can spread readily to adjacent bursae as well as other tendon sheaths. For example [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infectious tenosynovitis involving the flexor tendons on the dorsum of the hand can spread via bursae to the volar surface of the hand",
"     </li>",
"     <li>",
"      Infectious tenosynovitis involving the tendon sheaths of the wrist can spread to adjacent bursae and tendon sheaths surrounding the ulna and radius.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Spread of infection from tendon sheaths to surrounding soft tissue can also result in compartment syndrome and tissue necrosis.",
"   </p>",
"   <p>",
"    The ends of flexor tendons are overlaid by retinacular structures that act as pulleys to facilitate movement (particularly in the hands, feet, ankle, and wrist) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, most extensor tendons lack retinacular structures, so infections of extensor tendons rarely result in loculated or well-localized infections. Thus, extensor tenosynovitis may be difficult to distinguish from a simple soft tissue infection. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tendon sheath infections develop via one of three mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Trauma with direct inoculation (eg, laceration, puncture, or bite)",
"     </li>",
"     <li>",
"      Contiguous spread from infected adjacent soft tissues",
"     </li>",
"     <li>",
"      Hematogenous spread",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infectious tenosynovitis may present as an acute or subacute infection. The mechanism of infection and the causative pathogen dictate the nature of the clinical presentation. Most infectious tenosynovitis presents as acute infection via trauma with direct inoculation, although any of the above mechanisms may present acutely. Subacute presentations (eg, those with a delay between exposure and the appearance of clinical findings) can occur in the setting of infection due to mycobacteria and Sporothrix. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12469?source=see_link\">",
"     \"Clinical features and diagnosis of sporotrichosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=see_link\">",
"     \"Skeletal tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tendon sheath infections may be monomicrobial or polymicrobial. The microbiology of tendon sheath infections is closely linked to the underlying mechanism of infection, as discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Trauma and contiguous spread",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost any organism can cause tendon sheath infection. The most common pathogens implicated in tenosynovitis due to trauma are skin flora (eg, gram-positive cocci such as Staphylococcus aureus and streptococci) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/2\">",
"     2",
"    </a>",
"    ]. Lacerations and bites are commonly associated with polymicrobial infection including gram-negative organisms. Tenosynovitis in the setting of diabetes is likelier to be polymicrobial and include gram-negative bacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Types of trauma with specific associated pathogens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cat and dog bites &mdash; Cat and dog bites are relatively common causes of infectious tenosynovitis. These infections are frequently polymicrobial. Staphylococcus aureus and Pasturella multocida are important pathogens, either alone or together. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"       \"Soft tissue infections due to dog and cat bites\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"       \"Initial management of animal and human bites\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Puncture wounds &mdash; Puncture wounds due to thorns or woody plants may result in fungal tenosynovitis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link\">",
"       \"Mycology, pathogenesis, and epidemiology of Fusarium infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12469?source=see_link\">",
"       \"Clinical features and diagnosis of sporotrichosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravenous drug use &mdash; Intravenous drug use can lead to infectious tenosynovitis, with or without upper extremity abscess. Such infections are caused by skin or mouth flora, including Eikenella spp [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link\">",
"       \"Soft tissue infections due to human bites\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fresh or salt water &mdash; Wounds associated with exposure to fresh or salt water can result in tenosynovitis due to M. marinum. Many other nontuberculous mycobacteria species have also been associated with infectious tenosynovitis&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=see_link\">",
"       \"Soft tissue infections following water exposure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hematogenous infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathogens associated with tenosynovitis due to hematogenous spread include N. gonorrhoeae and mycobacteria.",
"   </p>",
"   <p>",
"    Neisseria gonorrhoeae should be suspected in sexually active patients with the triad of tenosynovitis, vesiculopustular skin lesions and polyarthralgias without polyarthritis, even if microbiological studies are negative (",
"    <a class=\"graphic graphic_picture graphicRef71303 \" href=\"UTD.htm?18/49/19219\">",
"     picture 1",
"    </a>",
"    ). Rarely, N. meningitidis can also cause a tenosynovitis similar in appearance to that caused by gonococci [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=see_link\">",
"     \"Disseminated gonococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tuberculous tenosynovitis may manifest as rubbery masses overlying tendon sheaths that enlarge gradually [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/10\">",
"     10",
"    </a>",
"    ]. These lesions may be only moderately tender and lack typical findings of infection such as warmth and redness. Such findings may progress to tendon destruction and rupture before a diagnosis is established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=see_link\">",
"     \"Skeletal tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immune compromise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tendon sheath infections in immunosuppressed patients may be due to common or unusual pathogens. Common pathogens such as staphylococci and streptococci should not be overlooked in such patients. In addition, unusual pathogens such as cryptococcus and Histoplasma capsulatum are important considerations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardinal signs of infectious flexor tenosynovitis were described in the early 1900s [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tenderness along the course of the flexor sheath",
"     </li>",
"     <li>",
"      Symmetric enlargement of the affected digit",
"     </li>",
"     <li>",
"      Slightly flexed finger at rest",
"     </li>",
"     <li>",
"      Pain along the tendon with passive extension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of 75 patients with infectious flexor tenosynovitis of the upper extremity, pain with passive extension was the earliest finding; tenderness along the tendon sheath was a late sign of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/12\">",
"     12",
"    </a>",
"    ]. Severe pain and tenderness following a bite or puncture wound should suggest the presence of tenosynovitis regardless of whether it is associated with all, some, or none of the above findings.",
"   </p>",
"   <p>",
"    Fever may or may not be present; among 75 patients with infectious flexor tenosynovitis only 17 percent had fever [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/12\">",
"     12",
"    </a>",
"    ]. Other findings may include subcutaneous purulence (due to rupture of tendon sheath) and cutaneous signs of ischemia including skin necrosis. These findings have important prognostic implications. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Infections involving flexor tendons progress in the following stages [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage 1 &mdash; Distention of the inflamed tendon sheath with exudative fluid",
"     </li>",
"     <li>",
"      Stage 2 &mdash; Distention of the inflamed tendon sheath with purulent fluid",
"     </li>",
"     <li>",
"      Stage 3 &mdash; Septic necrosis and destruction of the tendon sheath and surrounding retinacular structures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The stage of infection is important for determining the approach to treatment. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Anatomy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Infections involving extensor tendon sheaths are unusual. Since extensor tendons typically lack retinacular structures, patients with infections involving these structures often lack the typical findings seen in infections of flexor tendons. Thus, delays in diagnosis or misdiagnosis as an uncomplicated soft tissue infection may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of infectious tenosynovitis is usually suspected on clinical grounds and then confirmed by microbiological and histopathological evaluation. If there is associated cutaneous purulence at the site of tenosynovitis, specimens should be sent for Gram stain and culture. However, in most cases aspiration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsy is required for both diagnostic and therapeutic purposes. Specimens should be submitted for histopathological exam and culture (including bacteria, mycobacteria and fungal organisms). Histopathologic evidence of granulomas should prompt histologic stains for mycobacteria and fungal organisms.",
"   </p>",
"   <p>",
"    Plain radiographs are usually normal in patients with infectious tenosynovitis, but such studies are useful to rule out bony involvement or the presence of a foreign body, particularly if there is a history of trauma or a bite. Ultrasonography and magnetic resonance imaging may also be useful to confirm the presence of tendon sheath abnormalities and for preoperative evaluation to localize the extent of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4392?source=see_link\">",
"     \"Musculoskeletal ultrasonography: Clinical applications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1991?source=see_link\">",
"     \"Musculoskeletal ultrasonography: Nomenclature, technical considerations, validation, and standardization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blood cultures should be obtained for patients with known or suspected pyogenic tenosynovitis and systemic symptoms or signs such as fever, chills, or hypotension. Tuberculin skin tests should be performed in patients with suspected tenosynovitis due to M. tuberculosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the management of tenosynovitis includes surgical intervention and antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stage of infection is important for determining the approach to treatment. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In general, during the first two stages the tendon sheath remains viable. Stage 1 infection should be managed with tendon sheath irrigation and drainage, with or without debridement. Stage 2 or 3 infection should be managed with surgical debridement of the tendon sheaths and surrounding necrotic tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/12\">",
"     12",
"    </a>",
"    ]. Amputation may be necessary in severe cases.",
"   </p>",
"   <p>",
"    Surgical intervention is also appropriate in the setting of associated bursal or bony involvement, and is mandatory if a compartment syndrome is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=see_link\">",
"     \"Bursitis: An overview of clinical manifestations, diagnosis, and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microbiologic data and mechanism of infection should guide selection of effective antibiotic therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pending definitive diagnosis, tenosynovitis associated with trauma may be treated empirically with antibiotic therapy active against gram positive including staphylococci and streptococci (as well as methicillin-resistant Staphylococcus aureus in areas where the prevalence of this organism is high) and gram negative organisms. A reasonable approach is to combine",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (500 mg orally every 12 hrs or 400 mg intravenously every 12 hrs) or a third cephalosporin such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (1 g intravenously every 24 hrs). Treatment of water-related injuries should include activity against Pseudomonas aeruginosa. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"       \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=see_link\">",
"       \"Soft tissue infections following water exposure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=see_link\">",
"       \"Pseudomonas aeruginosa skin, soft tissue, and bone infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of injuries associated with bite wounds depends on the source of the bite; the approach is outlined separately (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"       \"Soft tissue infections due to dog and cat bites\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link\">",
"       \"Soft tissue infections due to human bites\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Treatment of tenosynovitis due to hematogenous spread should be tailored to the nature of the systemic infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=see_link\">",
"       \"Disseminated gonococcal infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=see_link\">",
"       \"Treatment of Staphylococcus aureus bacteremia in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of therapy depends on the underlying etiology. In general, 7 to 10 days of therapy is appropriate for uncomplicated bacterial infection. Treatment of mycobacterial infections generally requires several months of therapy. In addition, patients with involvement of adjacent structures may require longer duration of therapy (for example, bony involvement warrants at least 6 weeks of therapy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=see_link\">",
"     \"Skeletal tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=see_link\">",
"     \"Hematogenous osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among 75 patients with infectious tenosynovitis involving the upper extremity, risk factors associated with poor outcome included [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;43",
"     </li>",
"     <li>",
"      Presence of diabetes mellitus, peripheral vascular disease, or renal failure,",
"     </li>",
"     <li>",
"      Subcutaneous purulence",
"     </li>",
"     <li>",
"      Digital ischemia",
"     </li>",
"     <li>",
"      Polymicrobial infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who presented with stage 3 infection had the worst prognosis (amputation rate 59 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20550/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/15/10482?source=see_link\">",
"       \"Patient information: Tenosynovitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tenosynovitis refers to inflammation of a tendon and its synovial sheath due to infection or other causes. The anatomic placement of tendons, their sheaths and the adjacent bursae has important implications for the clinical features of tenosynovitis (",
"      <a class=\"graphic graphic_figure graphicRef77271 \" href=\"UTD.htm?29/32/30215\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tenosynovitis develops via trauma with direct inoculation (eg, laceration, puncture or bite), contiguous spread from infected adjacent soft tissues, or hematogenous spread. The most common pathogens in the setting of trauma (with or without contiguous spread) are skin flora (eg, gram-positive cocci such as Staphylococcus aureus and streptococci). Pathogens associated with hematogenous spread include N. gonorrhoeae and mycobacteria. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of tenosynovitis range from pain with passive extension to tenderness along the tendon sheath. Fever may or may not be present. Findings of advanced infection may include subcutaneous purulence (due to rupture of tendon sheath), tissue necrosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      compartment syndrome. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of tenosynovitis is confirmed by microbiological and histopathological evaluation. In most cases aspiration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      biopsy is required for diagnostic and therapeutic purposes. Specimens should be submitted for histopathological exam and culture (including bacteria, mycobacteria and fungal organisms). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of tenosynovitis includes surgical intervention and antibiotic therapy. In general, early infection should be managed with tendon sheath irrigation and drainage, with or without debridement. Advanced infection should be managed with debridement of the tendon sheaths and surrounding necrotic tissue. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Microbiologic data and mechanism of infection should guide selection of effective antibiotic therapy. Pending definitive diagnosis, tenosynovitis associated with trauma may be treated empirically with antibiotic therapy active against gram positive and gram negative organisms. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20550/abstract/1\">",
"      Tsai E, Failla JM. Hand infections in the trauma patient. Hand Clin 1999; 15:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20550/abstract/2\">",
"      Small LN, Ross JJ. Suppurative tenosynovitis and septic bursitis. Infect Dis Clin North Am 2005; 19:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20550/abstract/3\">",
"      Doyle JR. Anatomy of the finger flexor tendon sheath and pulley system. J Hand Surg Am 1988; 13:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20550/abstract/4\">",
"      Kour AK, Looi KP, Phone MH, Pho RW. Hand infections in patients with diabetes. Clin Orthop Relat Res 1996; :238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20550/abstract/5\">",
"      Baskar S, Mann JS, Thomas AP, Newton P. Plant thorn tenosynovitis. J Clin Rheumatol 2006; 12:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20550/abstract/6\">",
"      Gonzalez MH, Garst J, Nourbash P, et al. Abscesses of the upper extremity from drug abuse by injection. J Hand Surg Am 1993; 18:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20550/abstract/7\">",
"      Mateo L, Ruf&iacute; G, Nolla JM, Alcaide F. Mycobacterium chelonae tenosynovitis of the hand. Semin Arthritis Rheum 2004; 34:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20550/abstract/8\">",
"      Anim-Appiah D, Bono B, Fleegler E, et al. Mycobacterium avium complex tenosynovitis of the wrist and hand. Arthritis Rheum 2004; 51:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20550/abstract/9\">",
"      Chin KR, Miller BS, Koris MJ. Serous flexor tenosynovitis as an associated finding in meningococcal septic polyarthritis. Am J Orthop (Belle Mead NJ) 2002; 31:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20550/abstract/10\">",
"      Skoll PJ, Hudson DA. Tuberculosis of the upper extremity. Ann Plast Surg 1999; 43:374.",
"     </a>",
"    </li>",
"    <li>",
"     Kanavel, AB. Infections of the hand: a guide to the surgical treatment of acute and chronic suppurative processes of the fingers, hand, and forearm. Lea and Febiger, Philadelphia, 1912.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20550/abstract/12\">",
"      Pang HN, Teoh LC, Yam AK, et al. Factors affecting the prognosis of pyogenic flexor tenosynovitis. J Bone Joint Surg Am 2007; 89:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20550/abstract/13\">",
"      Michon J. [Phlegmon of the tendon sheaths]. Ann Chir 1974; 28:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20550/abstract/14\">",
"      Newman ED, Harrington TM, Torretti D, Bush DC. Suppurative extensor tenosynovitis caused by Staphylococcus aureus. J Hand Surg Am 1989; 14:849.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7654 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-794AB5B1AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_4_20550=[""].join("\n");
var outline_f20_4_20550=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Trauma and contiguous spread",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hematogenous infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immune compromise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7654\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7654|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/32/30215\" title=\"figure 1\">",
"      Tendon sheath anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7654|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/49/19219\" title=\"picture 1\">",
"      Gonococcal skin lesion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=related_link\">",
"      Bursitis: An overview of clinical manifestations, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12469?source=related_link\">",
"      Clinical features and diagnosis of sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=related_link\">",
"      Disseminated gonococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=related_link\">",
"      Finger and thumb anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=related_link\">",
"      Hematogenous osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=related_link\">",
"      Initial management of animal and human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4392?source=related_link\">",
"      Musculoskeletal ultrasonography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1991?source=related_link\">",
"      Musculoskeletal ultrasonography: Nomenclature, technical considerations, validation, and standardization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/15/10482?source=related_link\">",
"      Patient information: Tenosynovitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=related_link\">",
"      Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=related_link\">",
"      Skeletal tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=related_link\">",
"      Soft tissue infections due to dog and cat bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=related_link\">",
"      Soft tissue infections due to human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=related_link\">",
"      Soft tissue infections following water exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19141?source=related_link\">",
"      Trigger finger (stenosing flexor tenosynovitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/40/27270?source=related_link\">",
"      de Quervain's tenosynovitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_4_20551="Naloxone: Pediatric drug information";
var content_f20_4_20551=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Naloxone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"    see \"Naloxone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/10/31907?source=see_link\">",
"    see \"Naloxone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2980444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Naloxone Hydrochloride Injection&reg;;",
"     </li>",
"     <li>",
"      Naloxone Hydrochloride Injection&reg; USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote for Narcotic Agonists",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended as part of initial resuscitative efforts in the delivery room for neonates with respiratory depression; support ventilation to improve oxygenation and heart rate (Kattwinkel, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Opioid intoxication (full reversal):",
"     </b>",
"     (PALS Guidelines, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. (preferred), I.O.:",
"     <b>",
"      Note:",
"     </b>",
"     May be administered I.M., SubQ, or E.T., but onset of action may be delayed, especially if patient has poor perfusion; E.T. preferred if I.V./I.O. route not available; doses may need to be repeated: 0.1 mg/kg/dose; repeat every 2-3 minutes if needed; may need to repeat doses every 20-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E.T.: Optimal endotracheal dose unknown; current expert recommendations are 2-3 times the I.V. dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Opioid-induced depression:",
"     </b>",
"     I.V., I.M., SubQ: Manufacturer's labeling: Initial: Usual: 0.01 mg/kg/dose;",
"     <b>",
"      Note:",
"     </b>",
"     This dose is",
"     <b>",
"      one-tenth",
"     </b>",
"     of the dose used for neonatal opiate intoxication (full reversal); may repeat every 2-3 minutes as needed based on response; may need to repeat every 1-2 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"      see \"Naloxone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Opioid intoxication (full reversal):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PALS Guidelines, 2010:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.V. (preferred), I.O.:",
"     <b>",
"      Note:",
"     </b>",
"     May be administered I.M., SubQ, or E.T., but onset of action may be delayed, especially if patient has poor perfusion; E.T. preferred if I.V./I.O. route not available; doses may need to be repeated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Infants and Children &le;5 years or &le;20 kg: 0.1 mg/kg/dose; repeat every 2-3 minutes if needed; may need to repeat doses every 20-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Children &gt;5 years or &gt;20 kg and Adolescents: 2 mg/dose; if no response, repeat every 2-3 minutes; may need to repeat doses every 20-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     E.T.: Optimal endotracheal dose unknown; current expert recommendations are 2-3 times the I.V. dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer's labeling: I.V. (preferred), I.M., SubQ: Initial: 0.01 mg/kg/dose; if no response, a subsequent dose of 0.1 mg/kg may be given;",
"     <b>",
"      Note:",
"     </b>",
"     If using I.M. or SubQ route, dose should be given in divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous I.V. infusion: Limited data available: Infants, Children, and Adolescents: 24-40",
"     <b>",
"      mcg",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     has been reported  (Gourlay, 1983; Lewis, 1984; Tenenbein, 1984).",
"     <b>",
"      Note:",
"     </b>",
"     Doses as low as 2.5",
"     <b>",
"      mcg",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     have been reported in adults and a dose of 160",
"     <b>",
"      mcg",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     was reported in one neonate (Tenenbein, 1984). If continuous infusion is required, calculate the initial dosage/",
"     <b>",
"      hour",
"     </b>",
"     based on the effective intermittent dose used and duration of adequate response seen (Tenebein, 1984)",
"     <b>",
"      or",
"     </b>",
"     use two-thirds (",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     ) of the initial effective naloxone bolus given as the hourly infusion (Perry, 1996); titrate dose;",
"     <b>",
"      Note:",
"     </b>",
"     The infusion should be discontinued by reducing the infusion rate in decrements of 25%; closely monitor the patient (eg, pulse oximetry and respiratory rate) after each adjustment and after discontinuation of the infusion for recurrence of opioid-induced respiratory depression (Perry, 1996).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Reversal of respiratory depression from therapeutic opioid dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PALS Guidelines, 2010: I.V.: 0.001-0.005 mg/kg/dose; titrate to effect;",
"     <b>",
"      Note:",
"     </b>",
"     AAP recommends a wider dosage range of 0.001-0.015 mg/kg/dose (Hegenbarth, 2008 )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling: Initial: 0.005- 0.01 mg; repeat every 2-3 minutes as needed based on response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Opioid-induced pruritus:",
"     </b>",
"     Limited data available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention: Children &ge;6 years and Adolescents &le;17 years: Continuous I.V.  infusion: 0.25",
"     <b>",
"      mcg",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     was used in a double-blind, prospective, randomized, placebo-controlled study (n=20)  which showed lower incidence and severity of opioid-induced side effects (ie, pruritus, nausea) without a loss of pain control (Maxwell, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: Children &ge;3 years and Adolescents: Continuous I.V.  infusion: Initial: 2",
"     <b>",
"      mcg",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     ; if pruritus continues, may titrate by 0.5",
"     <b>",
"      mcg",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     every few hours; dosing based on a retrospective study (n=30, age range: 3-20 years) with a reported mean (&plusmn; SD) dose of 2.3 &plusmn; 0.68",
"     <b>",
"      mcg",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     ; monitor closely; doses &ge;3",
"     <b>",
"      mcg",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     may increase risk for loss of pain control and patients may require an increase in opioid dose (Vrchoticky, 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Available routes of administration include I.M., I.V. (preferred), and SubQ routes; other available routes (unlabeled) include inhalation via nebulization, intranasal, and intraosseous (I.O.). Endotracheal administration is the least desirable and is supported by only anecdotal evidence (case report) (Neumar, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Opioid overdose (with standard ACLS protocols):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V., I.M., SubQ: Initial: 0.4-2 mg; may need to repeat doses every 2-3 minutes; after reversal, may need to readminister dose(s) at a later interval (ie, 20-60 minutes) depending on type/duration of opioid. If no response is observed after 10 mg, consider other causes of respiratory depression.",
"     <b>",
"      Note:",
"     </b>",
"     May be given endotracheally as 2-2.5 times the initial I.V. dose (ie, 0.8-5 mg) (Neumar, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous I.V.  infusion:",
"     <b>",
"      Note:",
"     </b>",
"     For use with exposures to long-acting opioids (eg, methadone), sustained release product, and symptomatic body packers after initial naloxone response. Calculate dosage/hour based on effective intermittent dose used and duration of adequate response seen (Tenenbein, 1984)",
"     <b>",
"      or",
"     </b>",
"     use two-thirds (",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     ) of the initial effective naloxone bolus on an hourly basis (typically 0.25-6.25 mg/hour); one-half (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     ) of the initial bolus dose should be readministered 15 minutes after initiation of the continuous infusion to prevent a drop in naloxone levels; adjust infusion rate as needed to assure adequate ventilation and prevent withdrawal symptoms (Goldfrank, 1986).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Inhalation via nebulization: 2 mg; may repeat. Switch to I.V. or I.M. administration when possible (Weber, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intranasal administration: 2 mg (1 mg per nostril); may repeat in 5 minutes if respiratory depression persists.",
"     <b>",
"      Note:",
"     </b>",
"     Onset of action is slightly delayed compared to I.M. or I.V. routes (Kelly, 2005; Neumar, 2010; Robertson, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Reversal of respiratory depression with therapeutic opioid doses:",
"     </b>",
"     I.V., I.M., SubQ: Initial: 0.04-0.4 mg; may repeat until desired response achieved. If desired response is not observed after 0.8 mg total, consider other causes of respiratory depression.",
"     <b>",
"      Note:",
"     </b>",
"     May be given endotracheally (unlabeled route) as 2-2.5 times the initial I.V. dose (ie, 0.08-1 mg) (Neumar, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous I.V. infusion:",
"     <b>",
"      Note:",
"     </b>",
"     For use with exposures to long-acting opioids (eg, methadone) or sustained release products. Calculate dosage/hour based on effective intermittent dose used and duration of adequate response seen (Tenenbein, 1984) or use two-thirds (",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     ) of the initial effective naloxone bolus on an hourly basis (typically 0.2-0.6 mg/hour); one-half (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     ) of the initial bolus dose should be readministered 15 minutes after initiation of the continuous infusion to prevent a drop in naloxone levels; adjust infusion rate as needed to assure adequate ventilation and prevent withdrawal symptoms (Goldfrank, 1986).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Opioid-dependent patients being treated for cancer pain",
"     </b>",
"     (NCCN guidelines, v.2.2011): I.V.: 0.04-0.08 mg (40-80",
"     <b>",
"      mcg",
"     </b>",
"     ) slow I.V. push; administer every 30-60 seconds until improvement in symptoms; if no response is observed after total naloxone dose 1 mg, consider other causes of respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Postoperative opioid reversal:",
"     </b>",
"     I.V.: 0.1-0.2 mg every 2-3 minutes until desired response (adequate ventilation and alertness without significant pain).",
"     <b>",
"      Note:",
"     </b>",
"     Repeat doses may be needed within 1-2 hour intervals depending on type, dose, and timing of the last dose of opioid administered.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F199436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 0.4 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 0.4 mg/mL (1 mL); 1 mg/mL (2 mL [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F199421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endotracheal: Dilute to 1-2 mL with NS; follow with a flush &ge;5 mL of NS and 5 consecutive positive-pressure ventilations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation via nebulization: Adults: Dilute 2 mg of naloxone with 3 mL of normal saline and administer via nebulizer face mask (Mycyk, 2003; Weber, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intranasal: Adults: Administer total dose equally divided into each nostril using a mucosal atomizer device (MAD) (Kelly, 2005; Robertson, 2009; Vanden Hoek, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. push: Administer over 30 seconds as undiluted preparation. May administer I.V. push as diluted preparation by diluting 0.4 mg (1 mL) with 9 mL of normal saline for a total volume of 10 mL to achieve a concentration of 0.04 mg/mL (APS, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion: Dilute to 4 mcg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.O, SubQ: May administer I.M., I.O., or SubQ if unable to obtain I.V. access.",
"     <b>",
"      Note:",
"     </b>",
"     I.M. or SubQ administration in hypotensive patients or patients with peripheral vasoconstriction or hypoperfusion may result in erratic or delayed absorption.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F199505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS; do not mix with alkaline solutions or solutions containing bisulfite or metabisulfite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Fenoldopam, linezolid, propofol.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dimenhydrinate, heparin, ondansetron.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) (see product specific labeling for details); protect from light; stable in NS and D",
"     <sub>",
"      5",
"     </sub>",
"     W at 4 mcg/mL for 24 hours; do not mix with alkaline solutions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Complete or partial reversal of opioid drug effects, including respiratory depression induced by natural and synthetic opioids; diagnosis and management of known or suspected acute opioid overdose (FDA approved in all ages); has also been used for the prevention and treatment of narcotic-induced pruritus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F199507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Naloxone may be confused with Lanoxin&reg;, naltrexone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Narcan may be confused with Marcaine&reg;, Norcuron&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Narcan [multiple international markets] may be confused with Marcen brand name for ketazolam [Spain]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F199504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions are related to reversing dependency and precipitating withdrawal. Withdrawal symptoms are the result of sympathetic excess. Adverse events occur secondarily to reversal (withdrawal) of narcotic analgesia and sedation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, fever, flushing, hypertension, hypotension, tachycardia, ventricular fibrillation ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, coma, crying (excessive [neonates]), encephalopathy, hallucination, irritability,  nervousness, restlessness, seizure (neonates), tremulousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Ache, hyperreflexia (neonates), paresthesia, piloerection, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, hypoxia, pulmonary edema, respiratory depression, rhinorrhea, sneezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, hot flashes, shivering, yawning",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to naloxone or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiovascular disease or in patients receiving medications with potential adverse cardiovascular effects (eg, hypotension, pulmonary edema, or arrhythmias); pulmonary edema and cardiovascular instability, including ventricular fibrillation, have been reported in association with abrupt reversal when using narcotic antagonists. Administration of naloxone causes the release of catecholamines and may precipitate acute withdrawal or unmask pain in those who regularly take opioids; providing ventilation prior to the administration of naloxone may decrease these adverse effects. Following the use of narcotics during surgery, naloxone may reverse analgesia and increase blood pressure; carefully titrate dose to reverse hypoventilation; do not fully awaken patient or reverse analgesic effect (postoperative patient). Intramuscular administration of naloxone may also reduce the risk of cardiovascular effects due to the slower onset of action.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In patients with physical dependence to opiates (including newborns of narcotic dependent mothers), naloxone may precipitate symptoms of acute withdrawal, including but not limited to agitation, body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. Neonatal opioid withdrawal may also include convulsions, excessive crying, shrill cry, failure to feed, and hyperactive reflexes. Recurrence of respiratory depression may occur if the opioid involved is long-acting; observe patients until there is no reasonable risk of recurrent respiratory depression. Larger doses of naloxone may be required for the reversal of respiratory depression due to partial agonists or mixed agonists/antagonists. Naloxone is not effective in reversing respiratory depression due to nonopioid drugs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F199430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F199432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F199446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Naloxone crosses the placenta. Consider the benefit to the mother and the risk to the fetus before administering to a pregnant woman who is known or suspected to be opioid dependent; may precipitate withdrawal in both the mother and fetus. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003). Use caution in pregnant women with mild-to-moderate hypertension during labor; severe hypertension may occur.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory rate, heart rate, blood pressure, temperature, level of consciousness, ABGs, or pulse oximetry",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pure opioid antagonist that competes and displaces narcotics at opioid receptor sites",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E.T., I.M., SubQ: Within 2-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalation via nebulization: ~5 minutes (Mycyk, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intranasal: ~8-13 minutes (Kelley, 2005; Robertson, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Within 2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: (20-60 minutes) is shorter than that of most opioids; therefore, repeated doses are usually needed",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily by glucuronidation in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 1.2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.5-1.5 hours (mean: &sim;1 hour)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine as metabolites",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For administration to neonates, it is no longer recommended to use a more dilute concentration (0.02 mg/mL) and product has been discontinued. Use of this concentration results in unacceptably high fluid volumes, especially in small neonates. The 0.4 mg/mL preservative-free preparation should be used and can be accurately dosed with appropriately sized syringes (1 mL).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     To prevent overdose deaths, there are initiatives to dispense naloxone for self- or buddy-administration to patients at risk of opioid overdose (eg, recipients of high-dose opioids, suspected or confirmed history of illicit opioid use) and individuals likely to be present in an overdose situation (eg, family members of illicit drug users) (Albert, 2011; Bennett, 2011). Needleless administration via nebulization and the intranasal route by first responders and bystanders has also been described (Doe-Simkins, 2009; Weber, 2012). Needleless administration provides an alternative route of administration in patients with venous scarring due to illicit drug use (eg, heroin). There is a low incidence of death following naloxone reversal of opioid toxicity in patients who refuse transport to a healthcare facility (Wampler, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some products contain methyl and propylparabens. Naloxone has been used to increase blood pressure in patients with septic shock; increases in blood pressure may last several hours; however, an increase in patient survival has not been demonstrated and in some studies serious adverse effects (eg, agitation, pulmonary edema, hypotension, cardiac arrhythmias, seizures) have been reported; naloxone is generally not used for septic shock, especially in patients with underlying pain or opioid tolerance; optimal dosage for this indication has not been established; one neonatal study (n=2) reported a positive blood pressure response, but one neonate developed intractable seizures and died.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Albert S, Brason FW 2nd, Sanford CK, et al, \"Project Lazarus: Community-Based Overdose Prevention in Rural North Carolina,\"",
"      <i>",
"       Pain Med",
"      </i>",
"      , 2011, (12 Suppl 2):S77-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/21668761/pubmed\" id=\"21668761\" target=\"_blank\">",
"        21668761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Naloxone Dosage and Route of Administration for Infants and Children: Addendum to Emergency Drug Doses for Infants and Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(3):484-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/2388800/pubmed\" id=\"2388800\" target=\"_blank\">",
"        2388800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Pain Society (APS),",
"      <i>",
"       Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain",
"      </i>",
"      , 6th ed, Glenview, IL: 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bennett AS, Bell A, Tomedi L, et al, \"Characteristics of an Overdose Prevention, Response, and Naloxone Distribution Program in Pittsburgh and Allegheny County, Pennsylvania,\"",
"      <i>",
"       J Urban Health",
"      </i>",
"      , 2011, 88(6):1020-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/21773877/pubmed\" id=\"21773877\" target=\"_blank\">",
"        21773877",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW, \"Management of Opioid Analgesic Overdose,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(2):146-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/22784117/pubmed\" id=\"22784117\" target=\"_blank\">",
"        22784117",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chamberlain JM and Klein BL, &ldquo;A Comprehensive Review of Naloxone for the Emergency Physician,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1994, 12(6):650-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/7945608 /pubmed\" id=\"7945608 \" target=\"_blank\">",
"        7945608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doe-Simkins M, Walley AY, Epstein A, et al, \"Saved by the Nose: Bystander-Administered Intranasal Naloxone Hydrochloride for Opioid Overdose,\"",
"      <i>",
"       Am J Public Health",
"      </i>",
"      , 2009, 99(5):788-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/19363214/pubmed\" id=\"19363214\" target=\"_blank\">",
"        19363214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, \"Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fischer CG and Cook DR, \"The Respiratory and Narcotic Antagonistic Effects of Naloxone in Infants,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1974, 53(6):849-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/4473926/pubmed\" id=\"4473926\" target=\"_blank\">",
"        4473926",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldfrank L, Weisman RS, Errick JK, et al, \"A Dosing Nomogram for Continuous Infusion Intravenous Naloxone,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1986, 15(5):566-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/3963538/pubmed\" id=\"3963538\" target=\"_blank\">",
"        3963538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gourlay GK and Coulthard K, \"The Role of Naloxone Infusions in the Treatment of Overdoses of Long Half-Life Narcotic Agonists: Application to Nor-methadone,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1983, 15(2):269-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/6849762/pubmed\" id=\"6849762\" target=\"_blank\">",
"        6849762",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, \"Preparing for Pediatric Emergencies: Drugs to Consider,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kattwinkel J, Perlman JM, Aziz K, et al, \"Part 15: Neonatal Resuscitation: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):909-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/20956231/pubmed\" id=\"20956231\" target=\"_blank\">",
"        20956231",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly AM, Kerr D, Dietze P, et al, \"Randomised Trial of Intranasal Versus Intramuscular Naloxone in Prehospital Treatment for Suspected Opioid Overdose,\"",
"      <i>",
"       Med J Aust",
"      </i>",
"      , 2005, 182(1):24-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/15651944/pubmed\" id=\"15651944\" target=\"_blank\">",
"        15651944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kjellberg F and Tramer MR, \"Pharmacological Control of Opioid-Induced Pruritus: A Quantitative Systematic Review of Randomized Trials,\"",
"      <i>",
"       Eur J Anaesthesiol",
"      </i>",
"      , 2001, 18(6):346-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/11412287/pubmed\" id=\"11412287\" target=\"_blank\">",
"        11412287",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, \"Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/20956230 /pubmed\" id=\"20956230 \" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lewis JM, Klein-Schwartz W, Benson BE, et al, \"Continuous Naloxone Infusion in Pediatric Narcotic Overdose,\"",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1984, 138(10):944-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/6475855/pubmed\" id=\"6475855\" target=\"_blank\">",
"        6475855",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maxwell LG, Kaufmann SC, and Bitzer S, \"The Effects of a Small-Dose Naloxone Infusion on Opioid-Induced Side Effects and Analgesia in Children and Adolescents Treated With Intravenous Patient-controlled Analgesia: A Double-Blind, Prospective, Randomized, Controlled Study,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2005, 100(4):953-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/15781505/pubmed\" id=\"15781505\" target=\"_blank\">",
"        15781505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mycyk MB, Szyszko AL, and Aks SE, \"Nebulized Naloxone Gently and Effectively Reverses Methadone Intoxication,\"",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 2003, 24(2):185-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/12609650/pubmed\" id=\"12609650\" target=\"_blank\">",
"        12609650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, \"Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/20956224/pubmed\" id=\"20956224\" target=\"_blank\">",
"        20956224",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry HE and Shannon MW, \"Diagnosis and Management of Opioid- and Benzodiazepine-Induced Comatose Overdose in Children,\"",
"      <i>",
"       Curr Opin Pediatr",
"      </i>",
"      , 1996, 8(3):243-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/8814402/pubmed\" id=\"8814402\" target=\"_blank\">",
"        8814402",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robertson TM, Hendey GW, Stroh G, et al, \"Intranasal Naloxone Is a Viable Alternative to Intravenous Naloxone for Prehospital Narcotic Overdose,\"",
"      <i>",
"       Prehosp Emerg Care",
"      </i>",
"      , 2009, 13(4):512-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/19731165/pubmed\" id=\"19731165\" target=\"_blank\">",
"        19731165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith K, Hopp M, Mundin G, et al, \"Low Absolute Bioavailability of Oral Naloxone in Healthy Subjects,\"",
"      <i>",
"       Int J Clin Pharmacol Ther",
"      </i>",
"      , 2012, 50(5):360-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/22541841/pubmed\" id=\"22541841\" target=\"_blank\">",
"        22541841",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tenenbein M, \"Continuous Naloxone Infusion for Opiate Poisoning in Infancy,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1984, 105(4):645-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/6481543/pubmed\" id=\"6481543\" target=\"_blank\">",
"        6481543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vanden Hoek TL, Morrison LJ, Shuster M, et al, \"Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):829-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/20956228 /pubmed\" id=\"20956228 \" target=\"_blank\">",
"        20956228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vonderen JJ, Siew ML, Hooper SB, et al, \"Effects of Naloxone on the Breathing Pattern of a Newborn Exposed to Maternal Opiates,\"",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      , 2012, 101(7):e309-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/22372574/pubmed\" id=\"22372574\" target=\"_blank\">",
"        22372574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vrchoticky T, &ldquo;Naloxone for the Treatment of Narcotic Indiced Pruritus,&rdquo;",
"      <i>",
"       Journal of Pediatric Pharmacy Practice",
"      </i>",
"      , 2000, 5(2):92-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wampler DA, Molina DK, McManus J, et al, \"No Deaths Associated With Patient Refusal of Transport After Naloxone-Reversed Opioid Overdose,\"",
"      <i>",
"       Prehosp Emerg Care",
"      </i>",
"      , 2011, 15(3):320-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/21612385/pubmed\" id=\"21612385\" target=\"_blank\">",
"        21612385",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weber JM, Tataris KL, Hoffman JD, et al, \"Can Nebulized Naloxone Be Used Safely and Effectively by Emergency Medical Services for Suspected Opioid Overdose,\"",
"      <i>",
"       Prehosp Emerg Care",
"      </i>",
"      , 2012, 16(2):289-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/4/20551/abstract-text/22191727/pubmed\" id=\"22191727\" target=\"_blank\">",
"        22191727",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12628 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-17702BD6A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_4_20551=[""].join("\n");
var outline_f20_4_20551=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2980444\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054265\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443895\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054259\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199436\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199421\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054269\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199505\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054261\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054268\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199507\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199504\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054273\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054258\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054257\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299739\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199430\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199432\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199446\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054264\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054256\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054271\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054272\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054274\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12628\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12628|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=related_link\">",
"      Naloxone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/10/31907?source=related_link\">",
"      Naloxone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_4_20552="Treatment of early (stage I and II) head and neck cancer: The larynx";
var content_f20_4_20552=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of early (stage I and II) head and neck cancer: The larynx",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/4/20552/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/4/20552/contributors\">",
"     Wayne M Koch, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/4/20552/contributors\">",
"     Mitchell Machtay, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/4/20552/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/4/20552/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/4/20552/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/4/20552/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/4/20552/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/4/20552/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/4/20552/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of early laryngeal cancer is presented here. The treatment of locoregionally advanced laryngeal cancer is discussed separately, as is the management of metastatic disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=see_link\">",
"       \"Treatment of metastatic and recurrent head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636378107\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide, there are an estimated 130,000 new laryngeal cancer cases and 82,000 deaths annually [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States, laryngeal cancer accounts for about one-fourth of the 53,000 cases of head and neck cancer diagnosed annually [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laryngeal cancer is diagnosed predominantly in men, which at least in part reflects in the effects of tobacco and alcohol use. Laryngeal cancer may also be due to infection with high-risk HPV infection in some cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and risk factors for head and neck cancer\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link&amp;anchor=H1587553040#H1587553040\">",
"     \"Human papillomavirus associated head and neck cancer\", section on 'HPV associated cancers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STAGING AND ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumor node metastases (TNM) staging system of the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) is used to classify cancers of the larynx (",
"    <a class=\"graphic graphic_table graphicRef66619 \" href=\"UTD.htm?22/14/22766\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The larynx is divided into three anatomic regions: the supraglottis, glottis, and subglottis (",
"    <a class=\"graphic graphic_figure graphicRef58555 graphicRef72411 \" href=\"UTD.htm?22/62/23530\">",
"     figure 1A-B",
"    </a>",
"    ). Glottic, supraglottic, and subglottic cancers represent approximately two-thirds, one-third, and two percent of laryngeal cancers, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/4\">",
"     4",
"    </a>",
"    ]. This division is incorporated into staging the primary tumor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Supraglottis",
"      </strong>",
"      - suprahyoid epiglottis, infrahyoid epiglottis, aryepiglottic folds (laryngeal aspect), arytenoids, and ventricular bands (false cords)",
"     </li>",
"     <li>",
"      <strong>",
"       Glottis",
"      </strong>",
"      - true vocal cords, including anterior and posterior commissures",
"     </li>",
"     <li>",
"      <strong>",
"       Subglottis",
"      </strong>",
"      - subglottis, extending from lower boundary of the glottis to the lower margin of the cricoid cartilage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By definition, patients with early laryngeal cancer have stage I or II tumors, with no evidence of thyroid cartilage invasion or lymph node involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\", section on 'Diagnosis and staging evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRIMARY TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with early laryngeal cancer should be treated initially with the intent to preserve the larynx [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The larynx performs three vital functions: maintenance of airway patency, occlusion of the airway during the pharyngeal phase of swallowing, and voice production. Optimal treatment maximizes these functional outcomes (ie, voice quality, swallowing ability) and survival.",
"   </p>",
"   <p>",
"    Both radiation therapy (RT) and laryngeal preservation surgery can cure a high proportion of patients with early stage disease, but these approaches have not been compared in a randomized trial. Five-year disease-specific survival rates with both approaches are above 90 percent for stage I disease and around 80 percent for stage II tumors based upon observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RT is often preferred because functional outcomes, particularly voice quality, are perceived to be better. However, transoral endoscopic surgery may offer equivalent voice quality for appropriately selected patients. Chemotherapy alone does not have a role in the management of early stage laryngeal cancer outside of a clinical trial setting. Only uncommon and highly selected patients with T2 cancers, eg, bulky, invasive T2 cancers with impaired cord mobility, would receive concurrent chemoradiation. Total laryngectomy is only rarely indicated for stage I and stage II laryngeal cancer and should be reserved for salvage when no other meaningful option exists.",
"   </p>",
"   <p>",
"    Although total laryngectomy is a straightforward surgical procedure that can eradicate tumor confined to the cartilaginous boundaries of the larynx, loss of the natural voice and the stigma and life style and voice restrictions of a permanent stoma make it a procedure that patients fear. Although different options for voice rehabilitation exist, many patients express dissatisfaction with the results; social isolation, job loss, and depression are common sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3466?source=see_link\">",
"     \"Quality of life in head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16231?source=see_link\">",
"     \"Alaryngeal speech rehabilitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The size, extent, and location of the tumor, the patient's pulmonary and swallowing function, health and preferences, the clinician&rsquo;s expertise and experience, and available rehabilitation resources must all be considered in selecting surgical versus nonsurgical initial treatment. Logistical issues and cost may also be factors in deciding between surgery and RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16909989\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary radiation therapy (RT) may offer improved functional outcomes and a high chance for preservation of voice quality, while avoiding general anesthesia and other immediate risks associated with surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/10\">",
"     10",
"    </a>",
"    ]. Most patients with T1-2 cancers are treated with single modality RT.",
"   </p>",
"   <p>",
"    However, local recurrence following RT may require surgical salvage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/11\">",
"     11",
"    </a>",
"    ]. Although some patients can be salvaged with larynx-preserving procedures, total laryngectomy is necessary in more than one-half of cases. In addition, surgical resection following RT has a higher risk of wound complications than similar surgery in the unirradiated neck. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9559?source=see_link\">",
"     \"Treatment of locally recurrent head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation dermatitis, hoarseness, and painful or difficulty swallowing (odynophagia, dysphagia) commonly develop during the course of RT, but these acute toxicities typically resolve in two to eight weeks and are generally mild (grade 1 and 2). Patients with early stage laryngeal cancer are less likely to have prolonged acute, subacute, and permanent toxicity than patients with advanced laryngeal cancer who require larger RT fields and concurrent chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/12\">",
"     12",
"    </a>",
"    ]. However, prolonged edema of the larynx, soft tissue necrosis leading to chondritis, laryngeal stenosis, and pharyngeal stenosis can occasionally occur even in patients with early stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation therapy techniques, including dose and schedule, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both partial open laryngectomy and transoral laser microsurgery (TOLM) can be used to treat patients with early laryngeal cancer. Larynx-preserving surgery should be undertaken only when the surgeon is confident that tumor-free margins can be obtained, because postoperative RT may compromise functional outcomes, particularly after open surgical procedures. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Adjuvant therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Transoral laser surgery is a minimally invasive technique, which combines suspension laryngoscopy with an operating microscope, microsurgical instruments, and a carbon dioxide laser (which is used because its frequency of light is absorbed by water, thus minimizing tissue damage). The tumor is transected, revealing the depth of invasion and allowing visualization of tumor margins, and removed piecemeal through the laryngoscope. At least one mobile arytenoid complex must be preserved so that function of the larynx is maintained.",
"   </p>",
"   <p>",
"    If complete resection can be achieved, transoral laser surgery is often preferred over open partial laryngectomy in the treatment of early stage laryngeal cancer, given the accumulating evidence of comparable efficacy with decreased morbidity and improved preservation of laryngeal function [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications that can occur with open partial laryngectomy include infection, bleeding, laryngocutaneous fistula, airway obstruction requiring tracheostomy, aspiration pneumonia, and swallowing difficulty [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/18\">",
"     18",
"    </a>",
"    ]. Transoral laser surgery has been associated with decreased morbidity, including the need for tracheostomy and nasogastric feeding, as well as lower costs and shorter hospital stays, compared to partial laryngectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636379383\">",
"    <span class=\"h2\">",
"     Glottis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glottic (true vocal cord) cancer accounts for approximately two-thirds of all laryngeal cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/4,19\">",
"     4,19",
"    </a>",
"    ]. Most true vocal cord cancers occur on the anterior two-thirds of the cords with a small percentage developing on the anterior commissure.",
"   </p>",
"   <p>",
"    Persistent hoarseness, which is frequently the presenting complaint, tends to occur relatively early in the course of disease and causes glottic cancers to be discovered at an earlier stage than other head and neck cancers. If disease is more advanced, symptoms may include dysphagia, referred otalgia, sore throat, chronic cough, hemoptysis, and stridor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636381641\">",
"    <span class=\"h3\">",
"     Primary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with early stage glottic cancer should be treated with a larynx-preserving approach, generally either RT or transoral laser surgery. Those with higher risk lesions (bilateral disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extensive involvement of the anterior or posterior commissures) generally are treated with RT, because of the risk of positive margins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suboptimal voice quality after transoral laser surgery or open vertical hemilaryngectomy and risk for web formation.",
"   </p>",
"   <p>",
"    The five-year cause-specific and overall survival rates are approximately 95 and 80 percent for patients with early glottic cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/20\">",
"     20",
"    </a>",
"    ]. Local control, laryngeal preservation, and survival rates are similar with RT, transoral laser surgery, and open partial laryngectomy (open vertical hemilaryngectomy).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients managed with RT, treatment interruptions and a prolonged overall treatment time are associated with a worse outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/21\">",
"       21",
"      </a>",
"      ]. Other prognostic factors associated with worse local control include T2 lesions with subglottic extension or impaired vocal cord mobility, and the presence of visible rather than subclinical disease [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/22-24\">",
"       22-24",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Involvement of the anterior commissure provides a portal for partial cartilage invasion (T3) or extralaryngeal (T4) disease progression, which results in upstaging with an increased risk of local recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/5,25,26\">",
"       5,25,26",
"      </a>",
"      ]. For those patients, accurate imaging evaluation of the anterior commissure is critical to ensure proper staging. For patients with adequately staged early disease involving the anterior commissure, RT is appropriate treatment, and the details of radiation planning and delivery can be customized to assure an adequately high radiation dose to the region of interest. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link\">",
"       \"General principles of radiation therapy for head and neck cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link\">",
"       \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients managed with surgery, transoral laser surgery is associated with better functional outcomes, particularly voice quality and decreased morbidity compared with open partial laryngectomy. In addition, tracheostomy and nasogastric feeding are required less frequently [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/27-29\">",
"       27-29",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Voice quality with surgical excision is related to extent of vocal cord resection required [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. RT has been the preferred treatment approach for early glottic cancers because it tends to result in better voice quality. However, voice quality after laser excision of selected early lesions involving only the membranous true cord is usually excellent and comparable with that achieved by RT [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/32-34\">",
"       32-34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636381648\">",
"    <span class=\"h3\">",
"     Regional lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true vocal cords (glottic larynx) possess minimal lymphatic drainage, and early stage disease has a low incidence of occult lymph node disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/5\">",
"     5",
"    </a>",
"    ]. Therefore, expectant management with observation of the neck rather than elective neck treatment for early stage glottic cancers is generally recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Supraglottis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supraglottic cancers, which constitute about one-third of laryngeal cancers, are more aggressive than glottic cancers. Patients with supraglottic laryngeal cancer typically present with advanced disease, which is manifested by signs of airway obstruction (stridor or dyspnea on exertion) and pain, as well as palpable lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=see_link\">",
"     \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636383992\">",
"    <span class=\"h3\">",
"     Primary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;In those cases when supraglottic cancers are diagnosed at an early stage, either RT or surgery as initial therapy is effective in achieving local control in most patients (about 90 percent for stage I and 80 percent for stage II). However, unlike glottic cancer, recurrences can be more difficult to salvage due to concomitant tumor progression within the neck. The five-year overall survival rate for patients with early stage supraglottic cancers ranges from 55 to 75 percent in observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/13,35\">",
"     13,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We generally suggest RT for T1 lesions T2 lesions with normal vocal cord mobility. Transoral laser surgery may be an alternative for appropriately selected patients if complete resection can be achieved. Larger T2 lesions with impaired vocal cord mobility can be treated with transoral laser surgery, open supraglottic laryngectomy, or intensified RT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients managed with RT, the initial treatment volume includes the larynx and subdigastric, midjugular, and low jugular nodes. RT techniques, including optimal dose and schedule of RT, and complications are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link\">",
"       \"General principles of radiation therapy for head and neck cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link\">",
"       \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"       \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients managed surgically, transoral laser surgery yields similar local control and survival but superior functional results compared with open supraglottic laryngectomy for tumors amenable to complete endoscopic resection [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/36-38\">",
"       36-38",
"      </a>",
"      ]. Transoral laser surgery may be combined with postoperative RT and neck irradiation with high rates of locoregional control and survival (88 percent at three years) and good functional outcome (in 90 percent of patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/38\">",
"       38",
"      </a>",
"      ]. Transoral laser surgery is appropriate for tumors involving the epiglottis and false cords, and potentially for tumors involving the aryepiglottic fold and pyriform sinus. Patients who do not get postoperative radiation therapy require staging neck dissections.",
"      <br/>",
"      <br/>",
"      Transoral laser surgery has been associated with decreased morbidity compared with open supraglottic laryngectomy. Benefits include decreased aspiration, length of hospitalization, feeding tube duration, and tracheostomy duration, and superior functional outcomes, in particular, improved swallowing [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/17,36,37\">",
"       17,36,37",
"      </a>",
"      ]. Furthermore, transoral laser surgery obviates the needs for emergency tracheostomy in patients who present with obstructing lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/15\">",
"       15",
"      </a>",
"      ]. Further developments in microsurgery, including the transoral robotic surgical system, appear promising, particularly with respect to surgical exposure and precision [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Regardless of the surgical approach, negative resection margins are important [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636383999\">",
"    <span class=\"h3\">",
"     Regional lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The supraglottis is a midline structure with rich bilateral lymphatic drainage; as a result, occult bilateral cervical lymph node metastasis are frequent among patients with a clinically negative neck [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/3,42-45\">",
"     3,42-45",
"    </a>",
"    ]. Accordingly, bilateral elective neck treatment (at minimum levels II through IV (",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    )) is indicated for early stage supraglottic cancer both for patients treated with primary RT or primary surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Subglottis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary subglottic tumors are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/46\">",
"     46",
"    </a>",
"    ]. Subglottic tumors are commonly asymptomatic until locally advanced, but small tumors can sometimes present with hoarseness, dyspnea, or stridor. Direct extralaryngeal extension is common [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/47\">",
"     47",
"    </a>",
"    ]. For these reasons, survival is lower than that observed for tumors at other laryngeal subsites, with five-year disease-free and overall survival of 71 and 86 percent for stage I disease and 42 and 50 percent for stage II disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since subglottic cancers have high rates of local recurrence and poor survival when compared to lesions involving the supraglottic and glottic larynx, treatment of these cancers is aggressive [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20552/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Initial surgical treatment consists of either total laryngectomy or for selected cases, partial laryngectomy. In addition, thyroidectomy and bilateral paratracheal node dissection are performed. An alternative is RT, with the low neck and upper mediastinum included in the treatment fields.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ADJUVANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional early stage laryngeal cancers will be resected but found to have compromised resection margins, lymphovascular or perineural invasion, or be upstaged to stage",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    (positive nodes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    large or deeply invasive primary tumor). In these settings, postoperative RT is indicated. In some settings (eg, nodal extracapsular extension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frankly positive margins), adjuvant therapy consisting of chemoradiotherapy should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=see_link\">",
"     \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25719?source=see_link\">",
"     \"Postoperative radiation therapy in the management of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular posttreatment follow-up is an essential part of the care of patients after potentially curative treatment of laryngeal cancer. Patients should be educated about possible signs and symptoms of tumor recurrence, including hoarseness, pain, dysphagia, bleeding,",
"    <span class=\"nowrap\">",
"     dyspnea/stridor,",
"    </span>",
"    and enlarged lymph nodes.",
"   </p>",
"   <p>",
"    In general, the intensity of follow-up is greatest in the first two to four years, since approximately 80 to 90 percent of all recurrences after curative intent treatment will occur during this period. Continued follow-up beyond five years is generally suggested because of the risk of late recurrence and for second primary malignancies. Because of the increased risk of recurrence and second primary malignancy in those who continue tobacco use, more frequent surveillance visits and continue for longer duration of follow-up is indicated for patients who continue tobacco use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/38/6755?source=see_link\">",
"       \"Patient information: Laryngeal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The larynx is divided into three anatomic regions: the supraglottic larynx, glottic larynx (where most laryngeal cancers occur), and the subglottic larynx. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Staging and anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For early (stage I and stage II (",
"      <a class=\"graphic graphic_table graphicRef66619 \" href=\"UTD.htm?22/14/22766\">",
"       table 1",
"      </a>",
"      )) laryngeal cancer, both definitive radiation therapy (RT) and larynx-sparing surgery (transoral laser surgery and open partial laryngectomy) generally offer equivalent local tumor control and survival. The optimal treatment maximizes both survival outcomes and functional consequences, given the importance of maintaining laryngeal function (voice production, swallowing, and airway protection and patency). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For many patients with early stage cancers of the supraglottic and glottis larynx we suggest RT rather than surgery because of better functional outcomes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, transoral laser (or robotic) surgery is a good option for patients with low-volume tumors not involving the anterior or posterior commissures. Larger tumors are often treated with RT (commonly intensified RT), as voice quality may be compromised with transoral laser surgery or open partial laryngectomy. (See",
"      <a class=\"local\" href=\"#H636379383\">",
"       'Glottis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Supraglottis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For a patient with an early stage cancer of the subglottic larynx, we suggest total laryngectomy or for selected cases, partial laryngectomy, both also in conjunction with thyroidectomy and bilateral paratracheal node dissection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An alternative is intensified RT, with the low neck and upper mediastinum included in the treatment fields. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Subglottis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend bilateral elective neck treatment, at minimum levels II through IV (",
"      <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"       figure 2",
"      </a>",
"      ) , for early stage supraglottic cancer (with a clinically negative neck) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Choice of elective bilateral neck dissection versus comprehensive neck RT depends on treatment approach for the primary tumor. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Supraglottis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with early stage glottic cancers with a clinically negative neck be managed with observation rather than elective neck treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H636379383\">",
"       'Glottis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients treated with primary surgery, we recommend postoperative RT for those with positive resection margins, lymphovascular or perineural invasion, or pathologically positive lymph nodes identified after neck dissection. (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Postoperative concurrent chemoradiation may be preferable for positive margins or if a positive lymph node contains extracapsular extension. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Adjuvant therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Globocan file://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 (Accessed on October 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/4\">",
"      Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006; 116:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/5\">",
"      American Society of Clinical Oncology, Pfister DG, Laurie SA, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006; 24:3693.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN guidelines file://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/7\">",
"      Tamura Y, Tanaka S, Asato R, et al. Therapeutic outcomes of laryngeal cancer at Kyoto University Hospital for 10 years. Acta Otolaryngol Suppl 2007; :62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/8\">",
"      Breitbart W, Holland J. Psychosocial aspects of head and neck cancer. Semin Oncol 1988; 15:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/9\">",
"      de Boer MF, Pruyn JF, van den Borne B, et al. Rehabilitation outcomes of long-term survivors treated for head and neck cancer. Head Neck 1995; 17:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/10\">",
"      Chera BS, Amdur RJ, Morris CG, et al. T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2010; 78:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/11\">",
"      Carl J, Andersen LJ, Pedersen M, Greisen O. Prognostic factors of local control after radiotherapy in T1 glottic and supraglottic carcinoma of the larynx. Radiother Oncol 1996; 39:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/12\">",
"      Sakata K, Oouchi A, Nagakura H, et al. Accelerated radiotherapy for T1, 2 glottic carcinoma: analysis of results with KI-67 index. Int J Radiat Oncol Biol Phys 2000; 47:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/13\">",
"      Hinerman RW, Mendenhall WM, Amdur RJ, et al. Carcinoma of the supraglottic larynx: treatment results with radiotherapy alone or with planned neck dissection. Head Neck 2002; 24:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/14\">",
"      Mendenhall WM, Amdur RJ, Morris CG, Hinerman RW. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 2001; 19:4029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/15\">",
"      Silver CE, Beitler JJ, Shaha AR, et al. Current trends in initial management of laryngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol 2009; 266:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/16\">",
"      Steiner W. Results of curative laser microsurgery of laryngeal carcinomas. Am J Otolaryngol 1993; 14:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/17\">",
"      Ambrosch P. The role of laser microsurgery in the treatment of laryngeal cancer. Curr Opin Otolaryngol Head Neck Surg 2007; 15:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/18\">",
"      Ganly I, Patel SG, Matsuo J, et al. Analysis of postoperative complications of open partial laryngectomy. Head Neck 2009; 31:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/19\">",
"      Raitiola H, Pukander J, Laippala P. Glottic and supraglottic laryngeal carcinoma: differences in epidemiology, clinical characteristics and prognosis. Acta Otolaryngol 1999; 119:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/20\">",
"      Mendenhall WM, Werning JW, Hinerman RW, et al. Management of T1-T2 glottic carcinomas. Cancer 2004; 100:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/21\">",
"      Groome PA, O'Sullivan B, Mackillop WJ, et al. Compromised local control due to treatment interruptions and late treatment breaks in early glottic cancer: Population-based outcomes study supporting need for intensified treatment schedules. Int J Radiat Oncol Biol Phys 2006; 64:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/22\">",
"      McCoul ED, Har-El G. Meta-analysis of impaired vocal cord mobility as a prognostic factor in T2 glottic carcinoma. Arch Otolaryngol Head Neck Surg 2009; 135:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/23\">",
"      Marshak G, Brenner B, Shvero J, et al. Prognostic factors for local control of early glottic cancer: the Rabin Medical Center retrospective study on 207 patients. Int J Radiat Oncol Biol Phys 1999; 43:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/24\">",
"      Reddy SP, Mohideen N, Marra S, Marks JE. Effect of tumor bulk on local control and survival of patients with T1 glottic cancer. Radiother Oncol 1998; 47:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/25\">",
"      Nonoshita T, Shioyama Y, Kunitake N, et al. Retrospective analysis: concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma. Fukuoka Igaku Zasshi 2009; 100:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/26\">",
"      Sachse F, Stoll W, Rudack C. Evaluation of treatment results with regard to initial anterior commissure involvement in early glottic carcinoma treated by external partial surgery or transoral laser microresection. Head Neck 2009; 31:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/27\">",
"      Dey P, Arnold D, Wight R, et al. Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer. Cochrane Database Syst Rev 2002; :CD002027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/28\">",
"      Cellai E, Frata P, Magrini SM, et al. Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1N0 disease. Int J Radiat Oncol Biol Phys 2005; 63:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/29\">",
"      Schrijvers ML, van Riel EL, Langendijk JA, et al. Higher laryngeal preservation rate after CO2 laser surgery compared with radiotherapy in T1a glottic laryngeal carcinoma. Head Neck 2009; 31:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/30\">",
"      Remacle M, Eckel HE, Antonelli A, et al. Endoscopic cordectomy. A proposal for a classification by the Working Committee, European Laryngological Society. Eur Arch Otorhinolaryngol 2000; 257:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/31\">",
"      Remacle M, Van Haverbeke C, Eckel H, et al. Proposal for revision of the European Laryngological Society classification of endoscopic cordectomies. Eur Arch Otorhinolaryngol 2007; 264:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/32\">",
"      Gallo A, de Vincentiis M, Manciocco V, et al. CO2 laser cordectomy for early-stage glottic carcinoma: a long-term follow-up of 156 cases. Laryngoscope 2002; 112:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/33\">",
"      Delsupehe KG, Zink I, Lejaegere M, Bastian RW. Voice quality after narrow-margin laser cordectomy compared with laryngeal irradiation. Otolaryngol Head Neck Surg 1999; 121:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/34\">",
"      Vilaseca I, Huerta P, Blanch JL, et al. Voice quality after CO2 laser cordectomy--what can we really expect? Head Neck 2008; 30:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/35\">",
"      Groome PA, O'Sullivan B, Irish JC, et al. Management and outcome differences in supraglottic cancer between Ontario, Canada, and the Surveillance, Epidemiology, and End Results areas of the United States. J Clin Oncol 2003; 21:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/36\">",
"      Cabanillas R, Rodrigo JP, Llorente JL, Su&aacute;rez C. Oncologic outcomes of transoral laser surgery of supraglottic carcinoma compared with a transcervical approach. Head Neck 2008; 30:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/37\">",
"      Peretti G, Piazza C, Cattaneo A, et al. Comparison of functional outcomes after endoscopic versus open-neck supraglottic laryngectomies. Ann Otol Rhinol Laryngol 2006; 115:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/38\">",
"      Agrawal A, Moon J, Davis RK, et al. Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: report of Southwest Oncology Group Phase 2 Trial S9709. Arch Otolaryngol Head Neck Surg 2007; 133:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/39\">",
"      Weinstein GS, O'Malley BW Jr, Snyder W, Hockstein NG. Transoral robotic surgery: supraglottic partial laryngectomy. Ann Otol Rhinol Laryngol 2007; 116:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/40\">",
"      Desai SC, Sung CK, Jang DW, Genden EM. Transoral robotic surgery using a carbon dioxide flexible laser for tumors of the upper aerodigestive tract. Laryngoscope 2008; 118:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/41\">",
"      Sessions DG, Lenox J, Spector GJ. Supraglottic laryngeal cancer: analysis of treatment results. Laryngoscope 2005; 115:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/42\">",
"      Levendag P, Vikram B. The problem of neck relapse in early stage supraglottic cancer--results of different treatment modalities for the clinically negative neck. Int J Radiat Oncol Biol Phys 1987; 13:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/43\">",
"      Lutz CK, Johnson JT, Wagner RL, Myers EN. Supraglottic carcinoma: patterns of recurrence. Ann Otol Rhinol Laryngol 1990; 99:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/44\">",
"      Hicks WL Jr, Kollmorgen DR, Kuriakose MA, et al. Patterns of nodal metastasis and surgical management of the neck in supraglottic laryngeal carcinoma. Otolaryngol Head Neck Surg 1999; 121:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/45\">",
"      Chiu RJ, Myers EN, Johnson JT. Efficacy of routine bilateral neck dissection in the management of supraglottic cancer. Otolaryngol Head Neck Surg 2004; 131:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/46\">",
"      Dahm JD, Sessions DG, Paniello RC, Harvey J. Primary subglottic cancer. Laryngoscope 1998; 108:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/47\">",
"      Strome SE, Robey TC, Devaney KO, et al. Subglottic carcinoma: review of a series and characterization of its patterns of spread. Ear Nose Throat J 1999; 78:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/48\">",
"      Garas J, McGuirt WF Sr. Squamous cell carcinoma of the subglottis. Am J Otolaryngol 2006; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20552/abstract/49\">",
"      Paisley S, Warde PR, O'Sullivan B, et al. Results of radiotherapy for primary subglottic squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2002; 52:1245.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3388 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_4_20552=[""].join("\n");
var outline_f20_4_20552=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H636378107\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STAGING AND ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRIMARY TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16909989\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H636379383\">",
"      Glottis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H636381641\">",
"      - Primary tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H636381648\">",
"      - Regional lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Supraglottis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H636383992\">",
"      - Primary tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H636383999\">",
"      - Regional lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Subglottis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ADJUVANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3388\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3388|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/27/22967\" title=\"figure 1A\">",
"      Laryngeal anatomy coronal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/61/29654\" title=\"figure 1B\">",
"      Laryngeal anatomy sagittal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/3/8244\" title=\"figure 2\">",
"      Lymph node levels of the neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3388|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/14/22766\" title=\"table 1\">",
"      TNM stage larynx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16231?source=related_link\">",
"      Alaryngeal speech rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=related_link\">",
"      Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/38/6755?source=related_link\">",
"      Patient information: Laryngeal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25719?source=related_link\">",
"      Postoperative radiation therapy in the management of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3466?source=related_link\">",
"      Quality of life in head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9559?source=related_link\">",
"      Treatment of locally recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=related_link\">",
"      Treatment of metastatic and recurrent head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_4_20553="Neuroleptic malignant syndrome";
var content_f20_4_20553=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neuroleptic malignant syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/4/20553/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/4/20553/contributors\">",
"     Eelco FM Wijdicks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/4/20553/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/4/20553/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/4/20553/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/4/20553/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/4/20553/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroleptic malignant syndrome (NMS) is a life threatening neurologic emergency associated with the use of neuroleptic agents and characterized by a distinctive clinical syndrome of mental status change, rigidity, fever, and dysautonomia.",
"   </p>",
"   <p>",
"    Mortality results directly from the dysautonomic manifestations of the disease and from systemic complications. Mortality has declined from the earliest reports in the 1960s of 76 percent and is more recently estimated between 10 and 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/1\">",
"     1",
"    </a>",
"    ]. This probably reflects greater awareness of the disease, earlier diagnosis, and more aggressive intervention. Requiring a high clinical suspicion for diagnosis and treatment, NMS is appropriately a syndrome more often considered than truly diagnosed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incidence rates for neuroleptic malignant syndrome (NMS) range from 0.02 to 3 percent among patients taking neuroleptic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This wide range probably reflects differences in the populations sampled, for example, inpatient versus outpatient psychiatric populations, as well as differences in the surveillance methods and definitions of disease used.",
"   </p>",
"   <p>",
"    While most patients with NMS are young adults, the syndrome has been described in all age groups from 0.9 to 78 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ]. Age is not a risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/7\">",
"     7",
"    </a>",
"    ]. In most studies, men outnumber women twofold. Both age and gender distributions correspond with the distribution of the exposure to neuroleptic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASSOCIATED MEDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neuroleptic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;NMS is most often seen with the \"typical\" high potency neuroleptic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. However, every class of neuroleptic drug has been implicated, including the low potency (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ) and the newer \"atypical\" antipsychotic drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ) as well as antiemetic drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]. Associated medications are listed in the Table (",
"    <a class=\"graphic graphic_table graphicRef75621 \" href=\"UTD.htm?32/59/33723\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    While symptoms usually develop during the first two weeks of neuroleptic therapy, the association of the syndrome with drug use is idiosyncratic. NMS can occur after a single dose or after treatment with the same agent at the same dose for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/12\">",
"     12",
"    </a>",
"    ]. It is not a dose-dependent phenomenon, but higher doses are a risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/4\">",
"     4",
"    </a>",
"    ]. Case-control studies implicate recent or rapid dose escalation, a switch from one agent to another, and parenteral administration as risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/1,7,13,14\">",
"     1,7,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Associated risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case series and case-control studies also suggest that certain psychiatric conditions, acute catatonia, and extreme agitation are over represented in patients who develop NMS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/3,13-15\">",
"     3,13-15",
"    </a>",
"    ]. It is possible that these represent conditions of higher risk simply because of the increased use of higher doses, rapid escalation, and parenteral therapy. Other commonly listed risk factors, concomitant use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or other psychotropic drugs, higher potency agents, depot formulations, comorbid substance abuse or neurologic disease, and acute medical illness (including trauma, surgery, and infection) have not been substantiated in case-control studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/2,4,8,16-18\">",
"     2,4,8,16-18",
"    </a>",
"    ]. It is also unclear whether dehydration, present in 92 percent of patients, is a risk factor for, as well as an early complication of, NMS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/4,19\">",
"     4,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antiparkinson medication withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;NMS is also seen in patients treated for parkinsonism in the setting of withdrawal of L-Dopa or dopamine agonist therapy, as well as with dose reductions and a switch from one agent to another [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/1,3,20\">",
"     1,3,20",
"    </a>",
"    ]. Infection and surgery are possible precipitants as well [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/21\">",
"     21",
"    </a>",
"    ]. This may be considered a distinctive disorder from NMS and is sometimes called neuroleptic malignant-like syndrome or parkinsonism hyperpyrexia syndrome as well as acute akinesia or the malignant syndrome in Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. While some report that the clinical syndrome and laboratory findings are milder and the prognosis is better in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/23\">",
"     23",
"    </a>",
"    ], more severe cases and even fatalities have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/21,24,25\">",
"     21,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of NMS is unknown. Current theories are limited in their ability to explain all clinical manifestations and in supporting data. An animal model for NMS has been developed, but it does not fully correspond with the human syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the class of agents with which NMS is associated, dopamine receptor blockade is central to most theories of its pathogenesis. Central dopamine receptor blockade in the hypothalamus may cause hyperthermia and other signs of dysautonomia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Interference with nigrostriatal dopamine pathways may lead to Parkinsonian type symptoms such as rigidity and tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/16,29\">",
"     16,29",
"    </a>",
"    ]. Other neurotransmitter systems (gamma aminobutyric acid, epinephrine, serotonin, and acetylcholine) also appear to be involved, either directly or indirectly [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/26,30\">",
"     26,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative theory is that rigidity and muscle damage represent a primary effect on the peripheral muscle system, perhaps from direct changes in muscle mitochondrial function [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/16,31\">",
"     16,31",
"    </a>",
"    ]. This in itself may represent a primary skeletal muscle defect or a direct toxic effect by neuroleptics on skeletal muscle.",
"   </p>",
"   <p>",
"    A primary role has also been proposed for a disrupted modulation of the sympathetic nervous system, manifesting in increased muscle tone and metabolism and unregulated sudomotor and vasomotor activity leading to ineffective heat dissipation, labile blood pressure and heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/31\">",
"     31",
"    </a>",
"    ]. In this model, dopamine antagonists precipitate symptoms by destabilizing normal dopamine regulation of efferent sympathetic activity.",
"   </p>",
"   <p>",
"    Familial clusters of NMS suggest a genetic predisposition to the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/32\">",
"     32",
"    </a>",
"    ]. Genetic studies have shown that the presence of a specific allele of the dopamine D2 receptor gene is over represented in NMS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/33\">",
"     33",
"    </a>",
"    ]. This allele is associated with reduced density and function of dopamine receptors as well as decreased dopaminergic activity and metabolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NMS is defined by its association with a class of medications that block dopamine transmission and a tetrad of distinctive clinical features: fever, rigidity, mental status changes, and autonomic instability [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/3,34\">",
"     3,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Typical symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tetrad of NMS symptoms typically evolves over one to three days. Each feature is present in 97 to 100 percent of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mental status change is the initial symptom in 82 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/35\">",
"       35",
"      </a>",
"      ]. It is not surprising, given the usual psychiatric comorbidity of the typical patient, that its significance is often underappreciated. This often takes the form of an agitated delirium with confusion rather than psychosis. Catatonic signs and mutism can be prominent. Evolution to profound encephalopathy with stupor and eventual coma is typical [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Muscular rigidity is generalized and is often extreme. The increased tone can be demonstrated by moving the extremities and is characterized by \"lead pipe rigidity\" or stable resistance through all ranges of movement. Superimposed tremor may lead to a ratcheting quality or a cogwheel phenomenon. Other motor abnormalities include tremor (seen in 45 to 92 percent), and less commonly, dystonia, opisthotonus, trismus, chorea, and other dyskinesias [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/2,4\">",
"       2,4",
"      </a>",
"      ]. Patients can also have prominent sialorrhea, dysarthria, and dysphagia.",
"     </li>",
"     <li>",
"      Hyperthermia is a defining symptom according to many diagnostic criteria. Temperatures of more than 38&ordm;C are typical (87 percent), but even higher temperatures, greater than 40&ordm;C, are common (40 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autonomic instability typically takes the form of tachycardia (in 88 percent), labile or high blood pressure (in 61 to 77 percent), and tachypnea (in 73 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/2,19\">",
"       2,19",
"      </a>",
"      ]. Dysrhythmias may occur. Diaphoresis is often profuse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an analysis of 340 cases, 70 percent of patients followed a typical course of mental status changes appearing first, followed by rigidity, then hyperthermia, and autonomic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/35\">",
"     35",
"    </a>",
"    ]. Some case reports document delay in the appearance of fever of more than 24 hours, leading to initial diagnostic confusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/2\">",
"     2",
"    </a>",
"    ]. There is substantial variability in the presentation of NMS, and other reports do not necessarily substantiate a typical course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133036425\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133036433\">",
"    <span class=\"h3\">",
"     Elevated serum CK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory findings often reflect the clinical manifestations of NMS with more severe rigidity leading to more profound creatine kinase (CK) elevation. In NMS, CK is typically more than 1000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    and can be as high as 100,000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/2,3,16,19,36,37\">",
"     2,3,16,19,36,37",
"    </a>",
"    ]. Normal CK can be seen if rigidity is not clearly well developed, particularly early in the onset of the syndrome. Elevated CK, particularly in the mild to moderate range, is not specific for NMS and is often seen in patients with acute and chronic psychosis due to intramuscular injections and physical restraints, and sometimes without specific explanation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/31,36\">",
"     31,36",
"    </a>",
"    ]. CK levels greater than 1000",
"    <span class=\"nowrap\">",
"     IU/L,",
"    </span>",
"    however, are probably more specific for NMS, and the degree of CK elevation correlates with disease severity and prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/2\">",
"     2",
"    </a>",
"    ]. A case-control study demonstrated that patients with NMS were more likely to have had elevated CK levels during previous non-NMS admissions than did controls (76 versus 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/37\">",
"     37",
"    </a>",
"    ]. CK levels do usually normalize after an NMS episode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133036440\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other laboratory abnormalities are common but nonspecific.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A consistent laboratory finding is leukocytosis, with a white blood cell count typically 10,000 to",
"      <span class=\"nowrap\">",
"       40,000/mm3",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/2,4,19\">",
"       2,4,19",
"      </a>",
"      ]. A left shift may be present.",
"     </li>",
"     <li>",
"      Mild elevations of lactate dehydrogenase, alkaline phosphatase, and liver transaminases are common.",
"     </li>",
"     <li>",
"      Electrolyte abnormalities - hypocalcemia, hypomagnesemia, hypo and hypernatremia, hyperkalemia, and metabolic acidosis are frequently observed.",
"     </li>",
"     <li>",
"      Myoglobinuric acute renal failure can result from rhabdomyolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/2,38\">",
"       2,38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A low serum iron concentration (mean 5.71",
"      <span class=\"nowrap\">",
"       &micro;mol/L;",
"      </span>",
"      normal 11 to 32",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      is commonly seen in NMS patients and is a sensitive (92 to 100 percent) but not specific marker for NMS among acutely ill psychiatric patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/19,39\">",
"       19,39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Atypical cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is debate in the literature about milder or atypical cases of NMS. A \"forme fruste\" of the syndrome has been suggested to occur in milder cases, those associated with lower potency agents, or those diagnosed early on. In particular, rigidity may be milder and perhaps even absent in these situations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/40\">",
"     40",
"    </a>",
"    ]. While many consider fever to be an essential feature of the diagnosis, cases are reported where it is absent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/4\">",
"     4",
"    </a>",
"    ]. Complicating this issue is the fact that the isolated appearance of dysautonomia, hyperthermia, Parkinsonian rigidity, and creatine kinase (CK) elevations all occur with antipsychotic therapy. Individually they do not necessarily appear to be a harbinger of NMS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/16,41\">",
"     16,41",
"    </a>",
"    ]. From a practical clinical point of view, it seems reasonable to consider the diagnosis when any two of the tetrad of symptoms are present in the setting of an offending agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of NMS can be broadly defined in two categories &ndash; those conditions that are related to NMS and those unrelated to NMS but commonly considered in the differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Related disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;NMS is one of a group of acute dysautonomias that share common features: rigidity, hyperpyrexia, and dysautonomia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/4,6,40,42\">",
"     4,6,40,42",
"    </a>",
"    ]. These entities are usually distinguishable if only by the implicated drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Serotonin syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly diagnosed related disorder is serotonin syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/40,43,44\">",
"     40,43,44",
"    </a>",
"    ]. This is usually caused by use of selective serotonin reuptake inhibitors and has a similar presentation that is difficult to distinguish from NMS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/17\">",
"     17",
"    </a>",
"    ]. Typical features in these patients that are not often seen in NMS patients are shivering, hyperreflexia, myoclonus, and ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Nausea, vomiting, and diarrhea are also a common part of the prodrome in serotonin syndrome and are rarely described in NMS. Rigidity and hyperthermia, when present, are less severe than in patients with NMS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Malignant hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rare genetic disorder, malignant hyperthermia is distinguished from NMS by its clinical setting - occurring with use of potent halogenated inhalational anesthetic agents and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    . Its clinical appearance with hyperthermia, muscle rigidity, and dysautonomia is quite similar to NMS although often more fulminant. Studies using muscle contracture testing to evaluate malignant hyperthermia susceptibility among NMS patients have yielded conflicting results, with some finding a high and others a low prevalence of susceptibility. The test may be unreliable in the setting of acute or recent NMS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/16,31,42\">",
"     16,31,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=see_link\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Malignant catatonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most problematic in the differential diagnosis of NMS, malignant catatonia shares clinical features of hyperthermia and rigidity with NMS. However, in this syndrome, there is usually a behavioral prodrome of some weeks that is characterized by psychosis, agitation, and catatonic excitement. The motor symptoms are also characterized by more positive phenomena (dystonic posturing, waxy flexibility, and stereotyped repetitive movements) than are described in NMS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Laboratory values are more typically normal. The two disorders can be difficult to distinguish clinically, and historical details, particularly in the typical patient population, can be hard to elicit and interpret. The two syndromes may overlap; many case descriptions exist of NMS arising in patients with malignant catatonia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/3,15\">",
"     3,15",
"    </a>",
"    ]. One reviewer found it impossible to distinguish between the two disorders in 22 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5017?source=see_link&amp;anchor=H14470950#H14470950\">",
"     \"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis\", section on 'Malignant catatonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other drug-related syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Withdrawal of intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    therapy has been associated with an NMS-like syndrome in several case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/49\">",
"     49",
"    </a>",
"    ]. In these instances, the increased muscle tone is often described as rebound spasticity rather than rigidity. Otherwise, the spectrum of symptoms appears similar to NMS with dysautonomia, altered sensorium, fever, and elevated creatine kinase (CK) levels. Reduced gamma aminobutyric acid activity is believed to be the pathophysiologic cause. The symptoms reverse with reinstitution of therapy, and benzodiazepines may be helpful.",
"   </p>",
"   <p>",
"    A central anticholinergic syndrome most often associated with intended or inadvertent drug overdose is better known. Patients present with encephalopathy and elevated body temperatures that are usually not as severe as NMS. Other features seen in NMS (diaphoresis, rigidity, and elevated CK levels) are absent here, while atypical features of NMS (flushing, mydriasis, bladder distension) are common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=see_link&amp;anchor=H5#H5\">",
"     \"Anticholinergic poisoning\", section on 'Clinical features of overdose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute intoxication with certain recreational drugs, especially cocaine and ecstasy (3,4-methylenedioxymethamphetamine, MDMA), can be confused with NMS. Both potent stimulants of the central nervous system, these agents are attractive to abusers because they produce heightened vigilance, energy, and euphoria; however, these same effects can also manifest as psychomotor agitation, delirium, and even psychosis. Hyperthermia and rhabdomyolysis can develop, usually in association with increased physical exertion and ambient temperature. Rigidity is not common in these cases. MDMA use can also cause a serotonin syndrome. These syndromes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=see_link\">",
"     \"MDMA (ecstasy) intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=see_link\">",
"     \"Methamphetamine intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Unrelated disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative neurologic and medical disorders should be considered in the patient with NMS. Clinical symptoms of these disorders can overlap with NMS, particularly in patients who have extrapyramidal side effects of concomitant neuroleptic use. These diagnoses have serious prognostic and treatment implications and should not be overlooked [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/9,40\">",
"     9,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Central nervous system infection (eg, meningitis, encephalitis)",
"     </li>",
"     <li>",
"      Systemic infections (eg, pneumonia, sepsis)",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Acute hydrocephalus",
"     </li>",
"     <li>",
"      Acute spinal cord injury",
"     </li>",
"     <li>",
"      Heat stroke (neuroleptics predispose to heat stroke by impairing thermoregulation)",
"     </li>",
"     <li>",
"      Acute dystonia",
"     </li>",
"     <li>",
"      Tetanus",
"     </li>",
"     <li>",
"      Central nervous system vasculitis",
"     </li>",
"     <li>",
"      Thyrotoxicosis",
"     </li>",
"     <li>",
"      Pheochromocytoma",
"     </li>",
"     <li>",
"      Drug intoxication, toxicity (eg, phencyclidine, ecstasy, cocaine, amphetamines,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Withdrawal states",
"     </li>",
"     <li>",
"      Acute porphyria",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is no diagnostic test for NMS, testing has a crucial role in the evaluation of patients with potential NMS. Typical laboratory abnormalities help to confirm the clinical diagnosis, some tests rule out other conditions, and others are used to monitor patients for complications of NMS.",
"   </p>",
"   <p>",
"    In patients with possible NMS, brain imaging studies and lumbar puncture are required to exclude structural brain disease and infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/40\">",
"     40",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) and computed tomography (CT) are typically normal. In isolated cases diffuse cerebral edema has been reported in the setting of severe metabolic derangements [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/50\">",
"     50",
"    </a>",
"    ], as well as signal abnormalities in the cerebellum and basal ganglia that are similar to those seen in malignant hyperthermia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/51\">",
"     51",
"    </a>",
"    ]. Cerebrospinal fluid is usually normal, but a nonspecific elevation in protein is reported in 37 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electroencephalography may be done to rule out nonconvulsive status epilepticus. In NMS patients, generalized slow wave activity is seen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/3,19\">",
"     3,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An international multispecialty consensus group published diagnostic criteria for NMS in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/52\">",
"     52",
"    </a>",
"    ]. These are based on positive clinical and laboratory findings as well as the exclusion of alternative causes, each item given a priority score for its relative importance in contributing to the diagnosis. This requires independent validation before its use can be recommended in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Stop causative agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of the causative agent is the single most important treatment in NMS. Other potential contributing psychotropic agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , anticholinergic therapy, serotonergic agents) should also be stopped if possible. When the precipitant is discontinuation of dopaminergic therapy, it should be reinstituted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for aggressive and supportive care in NMS is essential and uncontroversial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/53\">",
"     53",
"    </a>",
"    ]. Complications are common and severe, even fatal. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dehydration",
"     </li>",
"     <li>",
"      Electrolyte imbalance",
"     </li>",
"     <li>",
"      Acute renal failure associated with rhabdomyolysis",
"     </li>",
"     <li>",
"      Cardiac arrhythmias including torsades de pointes and cardiac arrest",
"     </li>",
"     <li>",
"      Myocardial infarction",
"     </li>",
"     <li>",
"      Cardiomyopathy",
"     </li>",
"     <li>",
"      Respiratory failure from chest wall rigidity, aspiration pneumonia, pulmonary embolism",
"     </li>",
"     <li>",
"      Deep venous thrombophlebitis",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation",
"     </li>",
"     <li>",
"      Deep venous thrombosis",
"     </li>",
"     <li>",
"      Seizures from hyperthermia and metabolic derangements",
"     </li>",
"     <li>",
"      Hepatic failure",
"     </li>",
"     <li>",
"      Sepsis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The intensive nature of the required monitoring and supportive treatment are such that admission to the intensive care unit is required. The following supportive treatment should be provided:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discontinue any neuroleptic agent or precipitating drug.",
"     </li>",
"     <li>",
"      Maintain cardiorespiratory stability. Mechanical ventilation, antiarrhythmic agents, or pacemakers may be required [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Maintain euvolemic state using intravenous fluids. Insensible fluid loss from fever and from diaphoresis should also be considered [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/55\">",
"       55",
"      </a>",
"      ]. If CK is very elevated, high volume intravenous fluids with urine alkalinization may help prevent or mitigate renal failure from rhabdomyolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/56\">",
"       56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lower fever using cooling blankets. More aggressive physical measures may be required: ice water gastric lavage and ice packs in the axilla. The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      may have a role in reducing temperature in NMS, but it is not established. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"       \"Severe hyperthermia (heat stroke) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lower blood pressure if markedly elevated. The use of any specific agent over another is not supported by clinical data.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       Clonidine",
"      </a>",
"      is effective in this setting [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/57\">",
"       57",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       Nitroprusside",
"      </a>",
"      may have advantages by also facilitating cooling through cutaneous vasodilation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/58\">",
"       58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18853?source=see_link\">",
"       \"Drug treatment of hypertensive emergencies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prescribe",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or low molecular weight heparin for prevention of deep venous thrombosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use benzodiazepines (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      0.5 to 1.0 mg) to control agitation, if necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Specific treatments",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for specific medical treatments in NMS are based upon case reports and clinical experience, not upon data from clinical trials. Their efficacy is unclear and disputed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/59\">",
"     59",
"    </a>",
"    ]. Commonly used agents are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"     dantrolene",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"       Dantrolene",
"      </a>",
"      is a direct-acting skeletal muscle relaxant and is effective in treating malignant hyperthermia. Doses of 1 to 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV is typically used in adults and can be repeated to a maximum dose of 10",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. Efficacy includes reduction of heat production as well as rigidity, and effects are reported within minutes of administration. There is associated risk of hepatotoxicity, and dantrolene should probably be avoided if liver function tests are very abnormal. While some recommend discontinuing it after a few days, others suggest continuing for 10 days followed by a slow taper to minimize relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"       Bromocriptine",
"      </a>",
"      , a dopamine agonist, is prescribed to restore lost dopaminergic tone. It is well tolerated in psychotic patients. Doses of 2.5 mg (through nasogastric tube) every six to eight hours are titrated up to a maximum dose of 40",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      It is recommended that this be continued for 10 days after NMS is controlled and then tapered slowly.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       Amantadine",
"      </a>",
"      has dopaminergic and anticholinergic effects and is used as an alternative to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      . An initial dose is 100 mg orally or via gastric tube and is titrated upward as needed to a maximum dose of 200 mg every 12 hours.",
"     </li>",
"     <li>",
"      Other medications used with anecdotal success include levodopa [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/29\">",
"       29",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/14/21734?source=see_link\">",
"       apomorphine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/63\">",
"       63",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/64\">",
"       64",
"      </a>",
"      ], and benzodiazepines (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/16,40,65\">",
"       16,40,65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of any of these medications is controversial and largely unsupported. In an animal model of NMS,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"     dantrolene",
"    </a>",
"    reduced body temperature, CK levels, and an EMG activation measure of rigidity compared with control [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/26\">",
"     26",
"    </a>",
"    ]. A retrospective analysis of published cases indicates that the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dantrolene appeared to hasten clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/66\">",
"     66",
"    </a>",
"    ]. Time to complete recovery was reduced from a mean of 15 days (with supportive care alone) to nine days (with dantrolene) and 10 days (with bromocriptine). Another analysis found reduced mortality: 8.6 percent in patients treated with dantrolene, 7.8 percent in patients treated with bromocriptine, and 5.9 percent in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    compared with 21 percent in those receiving supportive care alone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These and similar analyses are of questionable validity because of publication and other biases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/1,67\">",
"     1,67",
"    </a>",
"    ]. In contrast, a small prospective study in 20 patients showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"     dantrolene",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    use was associated with a more prolonged course (9.9 versus 6.8 days) and a higher incidence of sequelae compared with those receiving supportive care alone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/68\">",
"     68",
"    </a>",
"    ]. However, the findings in this nonrandomized study could be explained by the fact that patients in the treated group were sicker than those not treated.",
"   </p>",
"   <p>",
"    While evidence supporting the use of these agents is limited, they are frequently used because of anecdotal evidence of efficacy, lack of other proven treatments, and high morbidity and mortality of the disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Electroconvulsive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for the use of electroconvulsive therapy (ECT) in NMS includes its efficacy in treating malignant catatonia and reports of Parkinsonism improving with ECT. A further impetus for ECT comes from the frequent need for psychotropic therapy in a setting in which neuroleptics cannot be used.",
"   </p>",
"   <p>",
"    ECT is a reasonable treatment option in NMS; however, there are no prospective, randomized, controlled data supporting its efficacy. A review of published cases found a lower mortality rate in ECT treated patients compared with those receiving supportive care alone (10.3 versus 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/69\">",
"     69",
"    </a>",
"    ]. In another comprehensive literature review, clinical response occurred after an average of 4.1 treatments. However, interpretation of this is complicated by the variable timing of ECT in relation to symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/70\">",
"     70",
"    </a>",
"    ]. While these results are interpreted as supporting ECT use in NMS, methodological issues, including publication bias and lack of randomization preclude conclusions about the efficacy of ECT in NMS.",
"   </p>",
"   <p>",
"    There are safety concerns for ECT in NMS. Cardiovascular complications occurred in 4 of 55 patients including two patients with ventricular fibrillation and cardiac arrest with permanent anoxic brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/70\">",
"     70",
"    </a>",
"    ]. Another patient had status epilepticus. Other authors also report uncontrolled spontaneous seizures and aspiration pneumonia complicating ECT treatment for NMS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of ECT in this setting is further challenged by the requirement for anesthesia. Because of concerns for associated malignant hyperthermia, some authors suggest the use of nondepolarizing agents. However, in over 16 reported cases of NMS patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    , there was no malignant hyperthermia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/16,70\">",
"     16,70",
"    </a>",
"    ]. Succinylcholine may also cause hyperkalemia and cardiac arrhythmias in patients with rhabdomyolysis and autonomic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ECT is generally reserved for patients not responding to other treatments or in whom nonpharmacologic psychotropic treatment is needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=see_link\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most episodes resolve within two weeks. Reported mean recovery times are 7 to 11 days [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/4,19\">",
"     4,19",
"    </a>",
"    ]. Cases persisting for six months with residual catatonia and motor signs are reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/5\">",
"     5",
"    </a>",
"    ]. Risk factors for a prolonged course are depot antipsychotic use and concomitant structural brain disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/71\">",
"     71",
"    </a>",
"    ]. Most patients recover without neurologic sequelae except where there is severe hypoxia or grossly elevated temperatures for a long duration.",
"   </p>",
"   <p>",
"    Reported mortality rates for NMS are 5 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/1,5,65,72\">",
"     1,5,65,72",
"    </a>",
"    ]. Disease severity and the occurrence of medical complications are the strongest predictors of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/40\">",
"     40",
"    </a>",
"    ]. A systematic review of published cases before 1989 revealed increased mortality in patients with myoglobinuria and renal failure compared with controls (50 versus 18.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with organic brain disease including alcohol and drug addiction had a mortality of 38.5 percent. Others have documented lower mortalities associated with higher potency versus lower potency agents [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/5\">",
"     5",
"    </a>",
"    ] and with atypical compared with typical antipsychotic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     RESTARTING NEUROLEPTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients restarted on neuroleptic agents may or may not have a recurrent NMS episode. It is difficult to quantify this risk from the available data. Different case series with variable duration of follow-up and various use of precautionary measures report relapse rates between 10 and 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/1,4,12,73\">",
"     1,4,12,73",
"    </a>",
"    ]. Early resumption of neuroleptic therapy, use of high potency, parenteral neuroleptics, and concomitant use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    appear to be risk factors for recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/4,73\">",
"     4,73",
"    </a>",
"    ]. Recurrent NMS is also idiosyncratic, with reports of patients with no sequelae after early resumption of a high potency neuroleptic, and relapses of NMS occurring on low potency agents up to two years later [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/12,73\">",
"     12,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If neuroleptic medication is required, the following guidelines may minimize risk of NMS recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/3,19,73\">",
"     3,19,73",
"    </a>",
"    ]; none of these guarantee either success or failure.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wait at least two weeks before resuming therapy, longer if any clinical residua exist.",
"     </li>",
"     <li>",
"      Use lower rather than higher potency agents.",
"     </li>",
"     <li>",
"      Start with low doses and titrate upward slowly.",
"     </li>",
"     <li>",
"      Avoid concomitant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Avoid dehydration.",
"     </li>",
"     <li>",
"      Carefully monitor for symptoms of NMS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroleptic malignant syndrome (NMS) is a life threatening neurologic emergency associated with the use of neuroleptic agents and characterized by a distinctive clinical syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis should be suspected when any two of the four cardinal clinical features, mental status change, rigidity, fever, or dysautonomia, appear in the setting of neuroleptic use or dopamine withdrawal. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important considerations in the differential diagnosis include meningitis, encephalitis, systemic infections, heat stroke, and other drug-induced dysautonomias. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic testing includes tests to rule out these conditions and laboratory evaluation of common metabolic sequelae of NMS, especially elevated CK. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with NMS should be based upon a hierarchy of clinical severity and diagnostic certainty [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20553/abstract/3,27\">",
"     3,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When there is any suspicion of NMS, neuroleptic agents should be withheld. Patients should have close inpatient monitoring of clinical signs and laboratory values. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with significant hyperthermia and rigidity should be admitted to an intensive care unit setting and undergo aggressive supportive care as outlined above, as well as monitoring for potential dysautonomia and other complications. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with CK elevations or hyperthermia on presentation, or who do not respond to withdrawal of medication and supportive care within the first day or two, the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"       dantrolene",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      should be considered. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Specific treatments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ECT should be considered in patients not responding to medical therapy in the first week, those in whom residual catatonia persists after other symptoms have resolved, and those in whom lethal catatonia is suspected as an alternative or concomitant disorder. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Electroconvulsive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients restarted on neuroleptic agents may or may not have a recurrent NMS episode. If neuroleptic medication is required, risk may be minimized by following some general guidelines. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Restarting neuroleptics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/1\">",
"      Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989; 50:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/2\">",
"      Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/3\">",
"      Velamoor VR. Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Saf 1998; 19:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/4\">",
"      Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/5\">",
"      Silva RR, Munoz DM, Alpert M, et al. Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999; 38:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/6\">",
"      Margeti B, Aukst-Margeti B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf 2010; 19:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/7\">",
"      Keck PE Jr, Pope HG Jr, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry 1989; 46:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/8\">",
"      Chandran GJ, Mikler JR, Keegan DL. Neuroleptic malignant syndrome: case report and discussion. CMAJ 2003; 169:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/9\">",
"      Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/10\">",
"      Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. Psychosomatics 2009; 50:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/11\">",
"      Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome--a case review. Hum Psychopharmacol 2003; 18:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/12\">",
"      Pope HG Jr, Aizley HG, Keck PE Jr, McElroy SL. Neuroleptic malignant syndrome: long-term follow-up of 20 cases. J Clin Psychiatry 1991; 52:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/13\">",
"      Hermesh H, Aizenberg D, Weizman A, et al. Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients. Br J Psychiatry 1992; 161:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/14\">",
"      Berardi D, Amore M, Keck PE Jr, et al. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry 1998; 44:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/15\">",
"      Koch M, Chandragiri S, Rizvi S, et al. Catatonic signs in neuroleptic malignant syndrome. Compr Psychiatry 2000; 41:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/16\">",
"      Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000; 85:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/17\">",
"      Haddow AM, Harris D, Wilson M, Logie H. Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin. BMJ 2004; 329:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/18\">",
"      Nimmagadda SR, Ryan DH, Atkin SL. Neuroleptic malignant syndrome after venlafaxine. Lancet 2000; 355:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/19\">",
"      Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989; 146:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/20\">",
"      Wu YF, Kan YS, Yang CH. Neuroleptic malignant syndrome associated with bromocriptine withdrawal in Parkinson's disease--a case report. Gen Hosp Psychiatry 2011; 33:301.e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/21\">",
"      Onofrj M, Thomas A. Acute akinesia in Parkinson disease. Neurology 2005; 64:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/22\">",
"      Mizuno Y, Takubo H, Mizuta E, Kuno S. Malignant syndrome in Parkinson's disease: concept and review of the literature. Parkinsonism Relat Disord 2003; 9 Suppl 1:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/23\">",
"      Serrano-Due&ntilde;as M. Neuroleptic malignant syndrome-like, or--dopaminergic malignant syndrome--due to levodopa therapy withdrawal. Clinical features in 11 patients. Parkinsonism Relat Disord 2003; 9:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/24\">",
"      Sechi GP, Tanda F, Mutani R. Fatal hyperpyrexia after withdrawal of levodopa. Neurology 1984; 34:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/25\">",
"      Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care 2009; 10:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/26\">",
"      Tanii H, Taniguchi N, Niigawa H, et al. Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level. Brain Res 1996; 743:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/27\">",
"      Caroff SN, Mann SC, Keck PE Jr. Specific treatment of the neuroleptic malignant syndrome. Biol Psychiatry 1998; 44:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/28\">",
"      Boulant JA. Role of the preoptic-anterior hypothalamus in thermoregulation and fever. Clin Infect Dis 2000; 31 Suppl 5:S157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/29\">",
"      Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology 1981; 31:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/30\">",
"      Spivak B, Maline DI, Vered Y, et al. Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignant syndrome. Acta Psychiatr Scand 2000; 102:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/31\">",
"      Gurrera RJ. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin Neuropharmacol 2002; 25:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/32\">",
"      Otani K, Horiuchi M, Kondo T, et al. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry 1991; 158:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/33\">",
"      Mihara K, Kondo T, Suzuki A, et al. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet B Neuropsychiatr Genet 2003; 117B:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/34\">",
"      Waldorf S. AANA journal course. Update for nurse anesthetists. Neuroleptic malignant syndrome. AANA J 2003; 71:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/35\">",
"      Velamoor VR, Norman RM, Caroff SN, et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis 1994; 182:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/36\">",
"      . The myth of elevated serum creatine phosphokinase level and neuroleptic malignant syndrome. Br J Psychiatry 1991; 158:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/37\">",
"      Hermesh H, Manor I, Shiloh R, et al. High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. J Clin Psychopharmacol 2002; 22:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/38\">",
"      Eiser AR, Neff MS, Slifkin RF. Acute myoglobinuric renal failure. A consequence of the neuroleptic malignant syndrome. Arch Intern Med 1982; 142:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/39\">",
"      Lee JW. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry 1998; 44:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/40\">",
"      Carbone JR. The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am 2000; 18:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/41\">",
"      Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998; 155:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/42\">",
"      Caroff SN, Rosenberg H, Fletcher JE, et al. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology 1987; 67:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/43\">",
"      Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology 1995; 45:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/44\">",
"      Ener RA, Meglathery SB, Van Decker WA, Gallagher RM. Serotonin syndrome and other serotonergic disorders. Pain Med 2003; 4:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/45\">",
"      Lejoyeux M, Fineyre F, Ad&egrave;s J. The serotonin syndrome. Am J Psychiatry 1992; 149:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/46\">",
"      Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/47\">",
"      Fleischhacker WW, Unterweger B, Kane JM, Hinterhuber H. The neuroleptic malignant syndrome and its differentiation from lethal catatonia. Acta Psychiatr Scand 1990; 81:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/48\">",
"      Castillo E, Rubin RT, Holsboer-Trachsler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry 1989; 146:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/49\">",
"      Coffey RJ, Edgar TS, Francisco GE, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil 2002; 83:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/50\">",
"      Blasi C, D'Amore F, Levati M, Bandinelli MC. [Neuroleptic malignant syndrome: a neurologic pathology of great interest for the internist]. Ann Ital Med Int 1998; 13:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/51\">",
"      Lyons JL, Cohen AB. Selective Cerebellar and Basal Ganglia Injury in Neuroleptic Malignant Syndrome. J Neuroimaging 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/52\">",
"      Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 2011; 72:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/53\">",
"      Prevention and treatment of heat injury. Med Lett Drugs Ther 2003; 45:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/54\">",
"      Parry AK, Ormerod LP, Hamlin GW, Saleem PT. Recurrent sinus arrest in association with neuroleptic malignant syndrome. Br J Psychiatry 1994; 164:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/55\">",
"      Guz&eacute; BH, Baxter LR Jr. Current concepts. Neuroleptic malignant syndrome. N Engl J Med 1985; 313:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/56\">",
"      Lappa A, Podest&agrave; M, Capelli O, et al. Successful treatment of a complicated case of neuroleptic malignant syndrome. Intensive Care Med 2002; 28:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/57\">",
"      Gregorakos L, Thomaides T, Stratouli S, Sakayanni E. The use of clonidine in the management of autonomic overactivity in neuroleptic malignant syndrome. Clin Auton Res 2000; 10:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/58\">",
"      Blue MG, Schneider SM, Noro S, Fraley DS. Successful treatment of neuroleptic malignant syndrome with sodium nitroprusside. Ann Intern Med 1986; 104:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/59\">",
"      Reulbach U, D&uuml;tsch C, Biermann T, et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 2007; 11:R4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/60\">",
"      Bond WS. Detection and management of the neuroleptic malignant syndrome. Clin Pharm 1984; 3:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/61\">",
"      Tsutsumi Y, Yamamoto K, Matsuura S, et al. The treatment of neuroleptic malignant syndrome using dantrolene sodium. Psychiatry Clin Neurosci 1998; 52:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/62\">",
"      Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin 2004; 22:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/63\">",
"      Wang HC, Hsieh Y. Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy. Mov Disord 2001; 16:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/64\">",
"      Thomas P, Maron M, Rascle C, et al. Carbamazepine in the treatment of neuroleptic malignant syndrome. Biol Psychiatry 1998; 43:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/65\">",
"      Tural U, Onder E. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry Clin Neurosci 2010; 64:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/66\">",
"      Rosenberg MR, Green M. Neuroleptic malignant syndrome. Review of response to therapy. Arch Intern Med 1989; 149:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/67\">",
"      Sakkas P, Davis JM, Janicak PG, Wang ZY. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull 1991; 27:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/68\">",
"      Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry 1991; 159:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/69\">",
"      Davis JM, Janicak PG, Sakkas P, et al. Electroconvulsive Therapy in the Treatment of the Neuroleptic Malignant Syndrome. Convuls Ther 1991; 7:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/70\">",
"      Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 1999; 33:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/71\">",
"      Caroff SN, Mann SC, Keck PE Jr, Francis A. Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol 2000; 20:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/72\">",
"      Nakamura M, Yasunaga H, Miyata H, et al. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry 2012; 73:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20553/abstract/73\">",
"      Susman VL, Addonizio G. Recurrence of neuroleptic malignant syndrome. J Nerv Ment Dis 1988; 176:234.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4829 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3AD7EB5AF7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_4_20553=[""].join("\n");
var outline_f20_4_20553=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASSOCIATED MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neuroleptic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Associated risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antiparkinson medication withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Typical symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133036425\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H133036433\">",
"      - Elevated serum CK",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H133036440\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Atypical cases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Related disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Malignant hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Malignant catatonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other drug-related syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Unrelated disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Stop causative agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Specific treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      RESTARTING NEUROLEPTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4829\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4829|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/59/33723\" title=\"table 1\">",
"      Drugs asso with NMS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=related_link\">",
"      Anticholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5017?source=related_link\">",
"      Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=related_link\">",
"      Cocaine: Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18853?source=related_link\">",
"      Drug treatment of hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=related_link\">",
"      MDMA (ecstasy) intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=related_link\">",
"      Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=related_link\">",
"      Methamphetamine intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=related_link\">",
"      Overview of electroconvulsive therapy (ECT) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_4_20554="Overview of herbal medicine and dietary supplements";
var content_f20_4_20554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of herbal medicine and dietary supplements",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/4/20554/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/4/20554/contributors\">",
"     Robert B Saper, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/4/20554/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/4/20554/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/4/20554/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/4/20554/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/4/20554/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plants have been used for medicinal purposes for thousands of years. All major cultures including Native American, European, South American, Asian, and African cultures have used botanicals for healing purposes. As an example, saw palmetto was used for urinary symptoms in men from Egypt in the 15th century BC [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/1\">",
"     1",
"    </a>",
"    ]. Hippocrates documented the use of St. John's wort for mood ailments in the 5th century BC [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/2\">",
"     2",
"    </a>",
"    ]. The Inner Classic of the Yellow Emperor around 100 BC describes complex traditional Chinese herbs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/3\">",
"     3",
"    </a>",
"    ]. Herbal medicines flourished in Europe in the 17th century, then showed a decline with the Scientific Revolution. European immigrants brought to North America their own herbal medicine traditions as well as acquiring many from Native Americans. Two-thirds of entries in the first edition of the United States Pharmacopoeia (USP) published in 1820 were botanical substances [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/2\">",
"     2",
"    </a>",
"    ]. After about 1920, standardized pharmaceutical drugs increasingly replaced herbal therapies in the US. Synthetic drugs were found to have larger pharmacologic effects and greater profitability [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over 120 conventionally used pharmaceuticals are derived from plant species (",
"    <a class=\"graphic graphic_table graphicRef54757 \" href=\"UTD.htm?19/24/19851\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States (US), in response to increased public interest and use of complementary and alternative medicines, Congress established the National Institutes of Health (NIH) Office of Alternative Medicine (OAM) in 1992. The NIH Office of Dietary Supplements was created in 1994 to conduct and coordinate research in herbs and supplements. In 1998, the NIH OAM was upgraded to the National Center for Complementary and Alternative Medicine (NCCAM). NCCAM has prioritized evaluating mechanisms, efficacy, and safety of botanical medicines through basic science studies, clinical research, and the establishment of dedicated botanical research centers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A list of commonly used herbs and supplements is provided below with links to more information about use, efficacy, and safety, elsewhere in UpToDate and from the US National Library of Medicine (NLM) and the European Medicines Agency (EMA) websites. General concerns about quality and safety are reviewed below. &nbsp; (See",
"    <a class=\"local\" href=\"#H1060381973\">",
"     'Commonly used herbs and supplements'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Quality and efficacy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H24\">",
"     'Safety'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several specific herbs and supplements are discussed in detail elsewhere. A partial list follows. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27784?source=see_link\">",
"     \"Clinical use of St. John's wort\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23542?source=see_link\">",
"     \"Clinical use of echinacea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/28/11720?source=see_link\">",
"     \"Clinical use of ginkgo biloba\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33061?source=see_link\">",
"     \"Clinical use of saw palmetto\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13034?source=see_link\">",
"     \"Physiology and clinical use of melatonin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link\">",
"     \"Fish oil and marine omega-3 fatty acids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link\">",
"     \"Probiotics for gastrointestinal diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/263?source=see_link\">",
"     \"Dehydroepiandrosterone and its sulfate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7513?source=see_link\">",
"     \"Complementary and alternative remedies in rheumatic disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=see_link\">",
"     \"Complementary and alternative therapies for cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6953?source=see_link\">",
"     \"Complementary and alternative therapies for allergic rhinitis and conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060381973\">",
"    <span class=\"h2\">",
"     Commonly used herbs and supplements",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acai (",
"      <em>",
"       Euterpe oleracea",
"      </em>",
"      ) &mdash;",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Acai&amp;id=1398\">",
"       NLM Dietary Supplements Database (NLM)",
"      </a>",
"     </li>",
"     <li>",
"      Arnica (",
"      <em>",
"       Arnica montana",
"      </em>",
"      )",
"      <em>",
"      </em>",
"      &mdash;",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Arnica+6X+(Arnica+montana)+(whole+plant,+homeopathically+prepared)&amp;id=4582\">",
"       NLM",
"      </a>",
"     </li>",
"     <li>",
"      Black cohosh (",
"      <em>",
"       Actaea racemosa, Cimicifuga racemosa",
"      </em>",
"      ) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"       \"Menopausal hot flashes\"",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Black+Cohosh&amp;id=1027\">",
"       NLM",
"      </a>",
"      and",
"      <a class=\"external\" href=\"file://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_Community_herbal_monograph/2011/01/WC500100981.pdf\">",
"       EMA Community Herbal Monograph (EMA)",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Chamomile (",
"      <em>",
"       Matricaria recutita",
"      </em>",
"      )",
"      <em>",
"       &mdash;",
"      </em>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/52/15177?source=see_link&amp;anchor=H18#H18\">",
"       \"Evaluation and management of colic\", section on 'Herbal remedies'",
"      </a>",
"      .)",
"      <em>",
"      </em>",
"      Also in",
"      <em>",
"      </em>",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Chamomile&amp;id=1057\">",
"       NLM",
"      </a>",
"      <em>",
"       .",
"      </em>",
"     </li>",
"     <li>",
"      Capsicum pepper, cayenne (",
"      <em>",
"       Capsicum frutescens, Capsicum annuum",
"      </em>",
"      ) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6953?source=see_link&amp;anchor=H1144540401#H1144540401\">",
"       \"Complementary and alternative therapies for allergic rhinitis and conjunctivitis\", section on 'Capsaicin (Capsicum annum)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link&amp;anchor=H16#H16\">",
"       \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Other local anesthetics'",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Cayenne+Pepper&amp;id=1053\">",
"       NLM",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Coenzyme Q10 (",
"      <em>",
"       Ubiquinol, Ubiquinone, Ubidecarenone",
"      </em>",
"      ) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link&amp;anchor=H17#H17\">",
"       \"Statin myopathy\", section on 'Coenzyme Q10'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39221?source=see_link&amp;anchor=H9#H9\">",
"       \"Unproven therapies for chronic systolic heart failure\", section on 'Coenzyme Q10'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2536?source=see_link&amp;anchor=H13#H13\">",
"       \"Mitochondrial myopathies: Treatment\", section on 'Coenzyme Q10 deficiency'",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Coenzyme+Q10&amp;id=1070\">",
"       NLM",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Cranberry (",
"      <em>",
"       Vaccinium macrocarpon, Vaccinium oxycoccos",
"      </em>",
"      ) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5514?source=see_link&amp;anchor=H2377565#H2377565\">",
"       \"Recurrent urinary tract infection in women\", section on 'Cranberry juice'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7606?source=see_link&amp;anchor=H9#H9\">",
"       \"Long-term management and prevention of urinary tract infections in children\", section on 'Cranberry juice'",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Cranberry&amp;id=1075\">",
"       NLM",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Creatine &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/19/9529?source=see_link&amp;anchor=H16909042#H16909042\">",
"       \"Non-hormonal performance enhancement\", section on 'Creatine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link&amp;anchor=H21630324#H21630324\">",
"       \"Initial treatment of depression in adults\", section on 'Creatine'",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Creatine&amp;id=1076\">",
"       NLM",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Evening primrose oil (",
"      <em>",
"       Oenothera biennis",
"      </em>",
"      ) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"       \"Menopausal hot flashes\"",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Evening+Primrose+Oil&amp;id=1093\">",
"       NLM",
"      </a>",
"      and",
"      <a class=\"external\" href=\"file://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_Community_herbal_monograph/2012/04/WC500124923.pdf\">",
"       EMA",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Feverfew (",
"      <em>",
"       Tanacetum parthenium",
"      </em>",
"      ) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link&amp;anchor=H17#H17\">",
"       \"Preventive treatment of migraine in adults\", section on 'Feverfew'",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Feverfew&amp;id=1096\">",
"       NLM",
"      </a>",
"      and",
"      <a class=\"external\" href=\"file://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_Community_herbal_monograph/2011/01/WC500100983.pdf\">",
"       EMA",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Flax, flaxseed oil, linseed (",
"      <em>",
"       Linum usitatissimum",
"      </em>",
"      ) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link&amp;anchor=H2#H2\">",
"       \"Lipid lowering with diet or dietary supplements\", section on 'Fish oil and omega-3 fatty acids'",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Flax%2FFlaxseed&amp;id=1099\">",
"       NLM",
"      </a>",
"      and",
"      <a class=\"external\" href=\"file://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_Community_herbal_monograph/2010/01/WC500059157.pdf\">",
"       EMA",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Garlic (",
"      <em>",
"       Allium sativum",
"      </em>",
"      ) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link&amp;anchor=H7#H7\">",
"       \"Lipid lowering with diet or dietary supplements\", section on 'Garlic'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30537?source=see_link&amp;anchor=H23#H23\">",
"       \"The common cold in adults: Treatment and prevention\", section on 'Herbal products'",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Garlic&amp;id=1103\">",
"       NLM",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Ginseng (",
"      <em>",
"       Panax quinquefolius, Panax ginseng, Eleutherococcus senticosus",
"      </em>",
"      ) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=see_link&amp;anchor=H37#H37\">",
"       \"Complementary and alternative therapies for cancer\", section on 'Ginseng and guarana for fatigue'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31496?source=see_link&amp;anchor=H11#H11\">",
"       \"Chinese herbal medicine for the treatment of allergic diseases\", section on 'Modified Mai Men Dong Tang (mMMDT) formula'",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/betaIngred.jsp?list=g\">",
"       NLM",
"      </a>",
"      and",
"      <a class=\"external\" href=\"file://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_Community_herbal_monograph/2009/12/WC500018320.pdf\">",
"       EMA",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Glucosamine and chondroitin &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=see_link&amp;anchor=H118398087#H118398087\">",
"       \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\", section on 'Glucosamine'",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Glucosamine&amp;id=1113\">",
"       NLM (glucosamine)",
"      </a>",
"      and",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Chondroitin+Sulfate&amp;id=1065\">",
"       NLM (chondroitin sulfate)",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Green tea (",
"      <em>",
"       Camellia sinensis",
"      </em>",
"      ) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=see_link&amp;anchor=H10#H10\">",
"       \"Complementary and alternative therapies for cancer\", section on 'Green tea'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17498?source=see_link&amp;anchor=H2#H2\">",
"       \"Benefits and risks of caffeine and caffeinated beverages\", section on 'Beverage consumption'",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Green+Tea&amp;id=1125\">",
"       NLM",
"      </a>",
"      . &nbsp;",
"     </li>",
"     <li>",
"      Hawthorn (",
"      <em>",
"       Crataegus monogyna",
"      </em>",
"      ) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18809?source=see_link&amp;anchor=H22#H22\">",
"       \"Possibly effective emerging therapies for heart failure\", section on 'Hawthorn extract'",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Hawthorn&amp;id=1129\">",
"       NLM",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Kava kava (",
"      <em>",
"       Piper methysticum",
"      </em>",
"      ) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25642?source=see_link&amp;anchor=H14#H14\">",
"       \"Hepatotoxicity due to herbal medications and dietary supplements\", section on 'Kava kava'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=see_link&amp;anchor=H425712691#H425712691\">",
"       \"Pharmacotherapy for generalized anxiety disorder\", section on 'Complementary and alternative treatments'",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Kava+Kava&amp;id=1359\">",
"       NLM",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Milk thistle (",
"      <em>",
"       Silymarin, Silybum marianum",
"      </em>",
"      )",
"      <em>",
"      </em>",
"      &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13242?source=see_link&amp;anchor=H21#H21\">",
"       \"Emerging therapies for hepatic fibrosis\", section on 'Silymarin'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=see_link&amp;anchor=H19#H19\">",
"       \"Investigational therapies for hepatitis C virus infection\", section on 'Silybum marianum (milk thistle)'",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Milk+Thistle&amp;id=1164\">",
"       NLM",
"      </a>",
"      . &nbsp;",
"     </li>",
"     <li>",
"      Soy isoflavones (",
"      <em>",
"       Glycine max",
"      </em>",
"      ) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link&amp;anchor=H3#H3\">",
"       \"Lipid lowering with diet or dietary supplements\", section on 'Soy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H28#H28\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Isoflavones'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link&amp;anchor=H8#H8\">",
"       \"Preparations for postmenopausal hormone therapy\", section on 'Phytoestrogens'",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Isoflavones&amp;id=1141\">",
"       NLM",
"      </a>",
"      . &nbsp;",
"     </li>",
"     <li>",
"      Valerian",
"      <em>",
"       (Valeriana officinalis",
"      </em>",
"      ) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of insomnia\", section on 'Over-the-counter'",
"      </a>",
"      .) Also in",
"      <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Valerian&amp;id=1278\">",
"       NLM",
"      </a>",
"      and",
"      <a class=\"external\" href=\"file://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_Community_herbal_monograph/2010/09/WC500096128.pdf\">",
"       EMA",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     UNITED STATES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Prevalence of use",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the US, use of herbal medicine declined in the early 1900s only to experience a resurgence beginning in the 1960's that was part of a larger movement towards using natural nonconventional approaches to healthcare [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/2\">",
"     2",
"    </a>",
"    ]. A 1990 national telephone survey of complementary and alternative medicine use by US adults demonstrated that 2.5 percent of respondents used herbal medicines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/6\">",
"     6",
"    </a>",
"    ]. A follow-up 1997 national survey showed almost a five-fold increase with 12.1 percent of US adults reporting herbal medicine use in the previous year [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One factor contributing to this dramatic increase was congressional passage of the Dietary Supplement Health and Education Act (DSHEA) in 1994. DSHEA allowed manufacturers to market their herbal products without prior demonstration of safety or efficacy. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Regulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Data from the 2007 National Health Interview Survey (NHIS) Alternative Medicine Supplement showed that 17.7 percent of US adults had used natural products in the previous year, including herbs and other naturally occurring non botanical supplements such as glucosamine sulfate (derived from crustacean shells) and fish oils [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/8\">",
"     8",
"    </a>",
"    ]. The following natural products were the most commonly used by US adults in the NHIS survey (percentages are the rate of use among Americans using natural products):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fish oil (37.4 percent)",
"     </li>",
"     <li>",
"      Echinacea (19.8 percent)",
"     </li>",
"     <li>",
"      Flax seed oil (15.9 percent)",
"     </li>",
"     <li>",
"      Ginseng (14.1 percent)",
"     </li>",
"     <li>",
"      Ginkgo biloba (11.3 percent)",
"     </li>",
"     <li>",
"      Garlic (11.0 percent)",
"     </li>",
"     <li>",
"      Coenzyme Q-10 (8.7 percent)",
"     </li>",
"     <li>",
"      Fiber or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=see_link\">",
"       psyllium",
"      </a>",
"      (6.6 percent)",
"     </li>",
"     <li>",
"      Green tea pills (6.3 percent)",
"     </li>",
"     <li>",
"      Cranberry (6.0 percent)",
"     </li>",
"     <li>",
"      Saw palmetto (5.1 percent)",
"     </li>",
"     <li>",
"      Soy supplements (5.0 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Market sales",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herbal sales have shown slow growth since 2004. Obtaining accurate market data that captures all of US herbal sales is difficult. This is due in part to the multiple channels available for purchasing supplements such as drug stores, supermarkets, warehouse buying clubs, natural food stores, multilevel marketing, health professionals, and the Internet. Nonetheless, using multiple survey methods, total sales of herbal and dietary supplements in the US were estimated to be $4.8 billion for 2008, a 10.6 percent increase from 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Reasons for use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Americans reported their top reasons for using herbs and supplements as enhancing health, and helping with common chronic symptoms or diseases such as memory loss, arthritis, and fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/10\">",
"     10",
"    </a>",
"    ]. In this way, herbs are similar to other complementary and alternative medicines in that they are frequently used for chronic conditions for which conventional medicine does not offer straightforward answers or cures.",
"   </p>",
"   <p>",
"    Herbs are also appealing to those who perceive nature as benevolent and healing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/11\">",
"     11",
"    </a>",
"    ]. Associated with this is the mistaken perception that a naturally-derived product is always safe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first half of the 20th century, medicinal herbs were included in the US National Formulary and the US Pharmacopoeia. In 1962, outrage over limb defects from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    prompted Congress to pass the Kefauver-Harris Drug Amendment. This required proof of safety and efficacy for all prescription and over-the-counter drugs, and reassigned herbal medicines to the category of food supplements which have a lower threshold of required evidence for safety [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the early 1990s the Food and Drug Administration (FDA) attempted to develop more strict regulations for herbal products. This was opposed in a campaign by consumers, supplement manufacturers, and political advocates. The result was a 1994 bill passed by Congress called the Dietary Supplement Health and Education Act (DSHEA). DSHEA defined dietary supplements as a product containing one or more of the following: a vitamin, mineral, amino acid, herb, other botanical, concentrate, metabolite, constituent, or extract [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/12\">",
"     12",
"    </a>",
"    ]. DSHEA placed dietary supplements in a distinct category from drugs. Labels of dietary supplements are required to state: \"this product in not intended to diagnose, treat, cure, or prevent any disease.\" However, product labels are allowed to make health claims, such as \"promotes prostate health\" or \"supports the circulatory system.\"",
"   </p>",
"   <p>",
"    Importantly, makers of dietary supplements are not required to prove efficacy, safety, or quality of a product prior to marketing. Supplement manufacturers are also not obligated to report postmarketing adverse events to the FDA. DSHEA therefore moved the burden of proving that a product is unsafe or ineffective to the FDA. For various reasons, the FDA has infrequently removed a dietary supplement product from marketing. Products containing ephedra, androstenedione, and PC-SPES are notable exceptions.",
"   </p>",
"   <p>",
"    Increasing research, case reports, and publicity of adverse effects and harmful drug-herb interactions have prompted many physicians, physician organizations such as the Institute of Medicine, and consumer groups such as the Center for Science in the Public Interest to call for reform of DSHEA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. National surveys found that 81 percent of Americans believed evidence of safety should be required before allowing the sale of a supplement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/16\">",
"     16",
"    </a>",
"    ]. However, more than half did not understand that current regulations do not require such evidence. Thus, the public appears to be sensitive to safety issues and supportive of greater regulation.",
"   </p>",
"   <p>",
"    In 2007, the US Food and Drug Administration (FDA) issued new rules requiring Good Manufacturing Practices (GMPs) for dietary supplements to be phased in from 2008 to 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/17\">",
"     17",
"    </a>",
"    ]. The new GMPs require dietary supplements be properly labeled, free of adulterants, and manufactured according to specified standards for personnel and equipment. Production controls and appropriate documentation are required. However, the new rules allow manufacturers, in particular smaller companies, significant flexibility to specify the quality criteria they will follow. As an example, there are no specified maximum acceptable concentrations or daily dose limits for heavy metals such as lead [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INTERNATIONAL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herbs are commonly used for medicinal purposes throughout the world. Data on this usage comes from convenience samples, national surveys, ethnographic studies, market data, and toxicity reports from Canada, Europe, Asia, Australia, the Caribbean, South and Central America, and Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/18-32\">",
"     18-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Europe",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Europe, herbal medicine is frequently referred to as phytotherapy and is commonly integrated with conventional medicine in many countries within the European Union (EU). Sales of over-the-counter herbal medicines in Europe in 2003 were over $5 billion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Herbal products are often used as a first line therapy for conditions such as benign prostatic hyperplasia (BPH) in Germany, Italy, and elsewhere.",
"   </p>",
"   <p>",
"    Other studies of use include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A nationally representative survey of the German general public found that 65 percent used herbal medicines [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/34\">",
"       34",
"      </a>",
"      ]. German physicians receive medical school training in medicinal herbs and must pass a test on herbal medicine to become licensed. Approximately 80 percent of German physicians regularly prescribe herbs.",
"     </li>",
"     <li>",
"      A survey of 21,923 adults in the Northwest region of England found 12.8 percent used one or more herbs [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Half of Danish preoperative patients reported taking herbal medicines, including ginkgo and echinacea&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Twenty-seven percent of outpatients in a Spanish gastroenterology clinic had used herbs in the previous year [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Asia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alongside acupuncture and massage, herbs play a significant role in traditional Chinese medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/35\">",
"     35",
"    </a>",
"    ]. Ayurveda, the most common traditional medicine practiced in India, uses over 6000 herbal combinations in its pharmacopoeia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/36\">",
"     36",
"    </a>",
"    ]. Vietnam, Malaysia, Korea, and other Southeast Asian countries have their own systems of traditional medicine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31496?source=see_link\">",
"     \"Chinese herbal medicine for the treatment of allergic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Developing world",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developing countries, herbal medicines are often less expensive and more accessible than conventional pharmaceuticals. As an example, 78 percent of households in a low income neighborhood of Managua, Nicaragua reported herbal use [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/25\">",
"     25",
"    </a>",
"    ]. Almost two-thirds of respondents from Brazilian urban primary care clinics reported use of herbal therapies, often due to inability to obtain conventional medicines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for herbal use are often given by family members, community elders, village health workers, midwives, or healers. Herbal formulations are often prepared individually for the patient from raw plant materials, instead of being commercially available.",
"   </p>",
"   <p>",
"    In many developing countries, the administering of traditional medicines is often part of an elaborate healing ritual with spiritual or supernatural components [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, regulation of the quality of herbal products is significantly greater in the EU than in the US. A 2004 EU directive requires manufacturers of all over-the-counter herbal products to register and license the product with the European Agency for the Evaluation of Medicinal Products. A premarket evaluation of quality and safety of the product is required. Companies need to carry out post-marketing surveillance and report serious adverse events. Indications for these OTC herbal products are for minor conditions not usually requiring a physician's care. Instead of requiring new rigorous efficacy studies to market a new product, documentation from the medical literature of safety for the relevant condition and reasonable plausibility of efficacy is needed. In countries such as Germany and France herbal medicines are partially or fully reimbursed.",
"   </p>",
"   <p>",
"    The World Health Organization (WHO) developed a Traditional Medicine Strategy \"to promote the integration of traditional medicine and CAM (complementary and alternative medicine) into national health care systems where appropriate\" [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/38\">",
"     38",
"    </a>",
"    ]. As part of this effort, the WHO distributed a survey about national policies and regulations for herbal medicines to help frame regulatory policies, enhance quality, safety and efficacy, ensure access, and support rational use of these remedies; 141 of 191 member states from all WHO regions responded [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/39\">",
"     39",
"    </a>",
"    ]. Thirty-seven percent of responding nations had herbal medicine regulations in place. Approximately half of the remaining nations were considering implementing regulations. Over two-thirds of countries sold herbal medicines without requiring a prescription. There are relatively few herbal medicines available by prescription only (eg, saw palmetto, ginkgo, St. John's wort).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     QUALITY AND EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the regulatory structure for herbal medicines, there is substantial variation in the quality of commercially available products in the United States and elsewhere. Variability in product quality can impact the product's efficacy, safety, and therefore clinical usefulness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Quality",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple determinants of the quality of an herbal product. These factors all impact the ability to insure consistency and standardization of herbal products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Plant species used",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several common herbal products are drawn from closely related species. As an example, studies of echinacea for the treatment and prevention of the common cold utilize Echinacea purpurea, E. pallida,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    E. angustifolia. The relative pharmacologic activity of these different species is unclear. Serious injury also has resulted from the misidentification of other plant species and subsequent mislabeling [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Plant parts used",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different plant parts from the same species may have different pharmacologic activity. As an example, echinacea products vary according to the proportion of root and aerial parts used. The relative activities of these different parts of the same plant are uncertain. Other inherent problems involve contamination by plant parts not normally utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Harvesting and storage conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strength of a plant's pharmacologic activity may also vary according to where it was raised, when it was harvested, and the length of time it was stored [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/42\">",
"     42",
"    </a>",
"    ]. Plant products and their active constituents can vary from year to year due to climatic changes involving rainfall, sunlight, and even genetic composition [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/41\">",
"     41",
"    </a>",
"    ]. Problems with prolonged storage may also lead to microbial contamination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herbs can be processed and formulated multiple ways. Whole herbs can be homogenized and extracted using solvents (eg, alcohol, glycerol, acetone, water). These extracts can be dried and encapsulated, or made into liquid tinctures. Whole herbs can also be eaten or consumed as teas. Topical applications can be made using poultices or creams. Different processing techniques can result in different chemical composition of the final product.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Accuracy of labeling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple reports of inaccurate herb labeling have been documented. As an example, a study of commercially available Asian ginseng products showed that among products with a labeled concentration of ginsenosides, the actual measured ginsenoside varied from zero to over 300 percent of labeled concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/43\">",
"     43",
"    </a>",
"    ]. Similarly, in a study of valerian products, 4 out of 17 products tested had no detectable levels of the expected valerenic acids, while another four had only one-half the expected amount [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, many brands of the same herb have labeling recommendations that vary greatly [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/45\">",
"     45",
"    </a>",
"    ]. Among 880 commercial products of the 10 most commonly purchased herbs, 43 percent were consistent with generally accepted benchmarks and 37 percent were either not consistent or were insufficiently labeled to determine whether or not it was consistent with generally accepted benchmarks. Cost per recommended daily dose was a significant predictor of consistency with the benchmark, but store type (ie, grocery, retail pharmacy, discount store, health food store) was not [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Standardization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herbs are complex substances with dozens or hundreds of chemical constituents. Often it is unclear which of these chemicals play an important role in the herb's pharmacologic activity. Some herbal products are standardized to contain a specified amount of one or two chemicals or chemical groups thought to be the active ingredients for the herb. Examples include ginkgo extracts standardized to 24 percent flavonoid glycosides and 6 percent terpenoids, and St. John's wort standardized to 0.3 percent hypericin. The latter is an example of a product standardized to a component that many experts believe is not the most important component for antidepressant activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27784?source=see_link\">",
"     \"Clinical use of St. John's wort\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even when herbal preparations are labeled \"standardized,\" there may be significant variation. One study of echinacea found that the content did not match the labeling in 47 percent of samples labeled \"standardized\" [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Purity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports of herbal medicines containing pharmaceuticals have occurred. Notable examples include the combination product PC-SPES used for prostate cancer that was found to contain DES,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/49\">",
"     49",
"    </a>",
"    ]. Reports of lead, mercury, and arsenic contamination in imported traditional Chinese [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/50\">",
"     50",
"    </a>",
"    ] and Indian [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/51-53\">",
"     51-53",
"    </a>",
"    ] herbal products have also occurred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link\">",
"     \"Adult lead poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8730?source=see_link\">",
"     \"Arsenic exposure and poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several well-defined herbal products have been evaluated in controlled trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ginkgo biloba extract has shown some promise in clinical trials for the treatment of dementia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/28/11720?source=see_link\">",
"       \"Clinical use of ginkgo biloba\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment of dementia\", section on 'Ginkgo biloba'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Soy products (Glycine max) have been found to have limited efficacy in treating hypercholesterolemia and menopausal hot flashes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link&amp;anchor=H3#H3\">",
"       \"Lipid lowering with diet or dietary supplements\", section on 'Soy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"       \"Menopausal hot flashes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ginger (Zingiber officinale) has been studied mostly for its antiemetic properties in various situations that can produce nausea and vomiting (eg, postoperative, chemotherapy, motion sickness, pregnancy). The majority show ginger to be more effective than placebo, although safety in pregnancy has not been adequately proven. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link&amp;anchor=H29#H29\">",
"       \"Prevention and treatment of chemotherapy-induced nausea and vomiting\", section on 'Complementary therapies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18824?source=see_link&amp;anchor=H20#H20\">",
"       \"Motion sickness\", section on 'Ginger'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29002?source=see_link&amp;anchor=H12#H12\">",
"       \"Treatment and outcome of nausea and vomiting of pregnancy\", section on 'Ginger'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safety issues for herbs include adverse effects and drug-herb interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our knowledge about adverse effects of herbs comes predominantly from case reports and clinical trials. Few systematic studies of safety have been completed. Several tables are prepared, reviewing the effects of commonly used herbal medications on glucose metabolism (",
"    <a class=\"graphic graphic_table graphicRef59340 \" href=\"UTD.htm?39/49/40732\">",
"     table 2",
"    </a>",
"    ), lipids (",
"    <a class=\"graphic graphic_table graphicRef72116 \" href=\"UTD.htm?23/31/24059\">",
"     table 3",
"    </a>",
"    ), hormones (",
"    <a class=\"graphic graphic_table graphicRef61831 \" href=\"UTD.htm?43/33/44571\">",
"     table 4",
"    </a>",
"    ), blood pressure (",
"    <a class=\"graphic graphic_table graphicRef68095 \" href=\"UTD.htm?35/47/36603\">",
"     table 5",
"    </a>",
"    ), and the heart (",
"    <a class=\"graphic graphic_table graphicRef62487 \" href=\"UTD.htm?37/41/38556\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Notable examples of adverse effects include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ephedra alkaloids (derived from Ephedra sinica or Ma huang) have been commonly combined with caffeine and marketed for weight loss and athletic enhancement [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/54\">",
"       54",
"      </a>",
"      ]. A review of adverse events possibly associated with ephedra use between 1997 and 1999 found episodes of hypertension, arrhythmias, myocardial infarction, stroke, and seizures [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/55\">",
"       55",
"      </a>",
"      ]. Ten events led to death and 13 led to permanent disability. Of these 23 reports, nine occurred at recommended ephedra doses in individuals without significant preexisting cardiovascular or neurologic risk factors. Although double-blind randomized controlled trials of ephedra-caffeine combinations have shown modest efficacy over placebo for weight loss [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/56,57\">",
"       56,57",
"      </a>",
"      ], data from 50 ephedra trials showed an estimated 2.2 to 3.6 fold increase in the odds of psychiatric, autonomic, cardiovascular, and gastrointestinal symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/58\">",
"       58",
"      </a>",
"      ]. There have also been case reports of heart failure in patients taking ephedra [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Despite ephedra products comprising only 0.8 percent of all dietary supplement sales in 2001, they were responsible for 64 percent of all herb-related adverse events reported to US Poison Control Centers during the same year [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/60\">",
"       60",
"      </a>",
"      ]. In part based upon these data, the FDA on April 12, 2004 banned manufacturers from the sale of products containing ephedra [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/61\">",
"       61",
"      </a>",
"      ]. Some manufacturers subsequently substituted bitter orange (citrus aurantium) for ephedra in weight loss products. Citrus aurantium contains synephrine, an adrenergic agonist similar to phenylephrine and ephedrine, that has been associated with serious cardiovascular and neurological side effects [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/62,63\">",
"       62,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Plants containing pyrrolizidine alkaloid constituents can lead to liver toxicity secondary to venoocclusive lesions, resulting in parenchymal necrosis, fibrosis, and even cirrhosis (",
"      <a class=\"graphic graphic_table graphicRef76400 \" href=\"UTD.htm?8/4/8269\">",
"       table 7",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/64\">",
"       64",
"      </a>",
"      ]. The precise mechanism of hepatic injury is unknown, but appears to result from the accumulation of toxic metabolites produced via the cytochrome system [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/65\">",
"       65",
"      </a>",
"      ]. The increased concentration of CYP enzymes in the centrilobular region of the liver correlates with the changes seen pathologically. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25642?source=see_link\">",
"       \"Hepatotoxicity due to herbal medications and dietary supplements\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some herbal treatments are known to be nephrotoxic and should be avoided [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/66\">",
"       66",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6933?source=see_link\">",
"       \"Nephropathy induced by aristolochic acid (AA) containing herbs\"",
"      </a>",
"      .) Aristolochia is a Chinese herb included in weight loss herbal formulas associated with over 100 cases of nephropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/67\">",
"       67",
"      </a>",
"      ]. It is also a probable human carcinogen associated with urothelial cancers [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/68\">",
"       68",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Herbal products can contain harmful contaminants including heavy metals. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Purity'",
"      </a>",
"      above.) These may be incidental contaminants from plant raw materials or the manufacturing process. However, they may be sometimes intended constituents of the product since several non-Western healing traditions such as traditional Indian (Ayurvedic) and Chinese medicine systems use heavy metals including lead for their purported therapeutic efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. Use of Ayurvedic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      traditional Chinese medicine herbs, as well as St. John's wort, has been associated with higher blood lead levels among women [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/69\">",
"       69",
"      </a>",
"      ]. At least 80 cases of heavy metal toxicity have been reported from traditional Indian (Ayurvedic) herbal medicine products that contain lead, mercury, and arsenic [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/51,70-72\">",
"       51,70-72",
"      </a>",
"      ]. The majority of these cases involve lead and involve products manufactured outside of the US. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link\">",
"       \"Adult lead poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8730?source=see_link\">",
"       \"Arsenic exposure and poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The belief among some patients that \"more is better\" leads to significant side effects and potential harm from ingesting large quantities of herbal products [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/73\">",
"       73",
"      </a>",
"      ]. Toxicities due to overuse have been documented with ginseng and licorice [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Asking patients about herbal medicine use and potential side effects will improve their recognition. In the US, adverse events related to herbal products can be reported to the FDA MedWatch program via telephone (800-FDA-1088), online (",
"    <a class=\"external\" href=\"file://www.fda.gov/safety/medwatch/\">",
"     www.fda.gov/safety/medwatch/",
"    </a>",
"    ), fax (800-FDA-0178), or mail.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Herb-drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing data show the potential for herbal medicines to interact with prescription and nonprescription pharmaceuticals. Several of these interactions have been documented to occur through case reports. Other interactions have been theorized through in vitro studies but not documented with case reports. Specific interactions of natural and alternative drugs with other medications may be determined using the drug interaction tool (Lexi-Interact&trade; Online). This can be accessed from the UpToDate online search page or through the individual drug information topics, section on Drug interactions.",
"   </p>",
"   <p>",
"    Several systematic reviews identified herb-drug pairs that have been reported to interact based on clinical data or in vitro studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    was the most frequent pharmaceutical implicated and St. John's wort had the most drug-herb interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/76\">",
"     76",
"    </a>",
"    ]. Herb-induced alteration in the metabolism of cytochrome P450 enzymes was the most common mechanism implicated in herb-drug interactions.",
"   </p>",
"   <p>",
"    Specific examples of documented herb-drug interactions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hyperforin component of St. John's wort induces the CYP3A4 system which metabolizes a number of drugs including protease inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , oral contraceptives,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      . Failure of anti-retroviral therapy, transplant rejection, and contraceptive failure have been reported. In addition, St. John's wort may produce the serotonin syndrome when taken with other serotonergic medications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27784?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical use of St. John's wort\", section on 'Herb-drug interactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ginkgo biloba has antiplatelet and antithrombotic effects and therefore has the potential to interact with anticoagulants such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , NSAIDs, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , leading to an increased risk for spontaneous hemorrhage and bleeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/28/11720?source=see_link&amp;anchor=H18#H18\">",
"       \"Clinical use of ginkgo biloba\", section on 'Interactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Concomitant ingestion of grapefruit juice and certain dihydropyridine calcium channel blockers may elevate the plasma concentration of the latter, possibly leading to hypotension [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/77\">",
"       77",
"      </a>",
"      ]. Grapefruit juice increases the bioavailability of certain calcium channel blockers by inhibiting the cytochrome P450 3A4 (CYP3A4) isoenzyme found in the liver and gut wall [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/78\">",
"       78",
"      </a>",
"      ]. The result of this inhibition is that more drug is absorbed and plasma concentrations increase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     INTERNET EVIDENCE-BASED RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of web-based resources aimed at providing health care practitioners and consumers with evidence-based information on herbal medicine.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Natural Medicines Comprehensive Database",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(www.naturaldatabase.com)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Natural Standard",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(www.naturalstandard.com)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consumer Lab",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(www.consumerlab.com)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medline Plus Drugs and Supplement Directory",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/druginformation.html\">",
"     www.nlm.nih.gov/medlineplus/druginformation.html",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NIH National Center for Complementary and Alternative Medicine Herb Fact Sheets (",
"      <a class=\"external\" href=\"file://nccam.nih.gov/health/herbsataglance.htm\">",
"       nccam.nih.gov/health/herbsataglance.htm",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      NIH Office of Dietary Supplements (",
"      <a class=\"external\" href=\"file://www.ods.od.nih.gov/\">",
"       www.ods.od.nih.gov",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     COUNSELING PATIENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Asking about use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveys have found that the majority of patients who use herbal medicines and other forms of complementary and alternative medicine do not disclose this to their health care providers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/79\">",
"     79",
"    </a>",
"    ]. Of complementary alternative medicine users who did not disclose such use to their physicians, 61 percent reported that a reason for not telling their physician was \"it wasn't important for my doctor to know\" and 60 percent also reported that \"the doctor never asked.\"",
"   </p>",
"   <p>",
"    There are several important reasons for asking patients about the use of herbal medicines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Herbs are pharmacologically active and therefore can positively and negatively impact patient health. Positive effects may include improvement of disease-specific outcomes. Negative effects may include adverse effects and drug-herb interactions. For these reasons, the Joint Commission on Accreditation of Healthcare Organizations in the US now requires that herb and supplement use be recorded as part of the medication list in the hospital medical record [",
"      <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Discussion of herbal medicine use may open dialogue about patient concerns that may be amenable to management with well-studied conventional therapies. For example, further questioning of a patient who uses multiple supplements such as garlic, Vitamin E, and Coenzyme Q-10 might reveal intense anxiety of myocardial infarction due to a family history of premature heart disease. Measuring cardiovascular risk markers and educating the patient about conventional cardiac risk factor reduction and therapy could then be initiated.",
"     </li>",
"     <li>",
"      Providers may need to consider herb-drug interactions when prescribing and dosing conventional medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Asking about herb use can be done during the medication history by asking: \"What prescription medications, over the counter medicines, vitamins, herbs, or supplements do you use?\"",
"   </p>",
"   <p>",
"    This encourages communication by demonstrating the practitioner's interest in the information and willingness to discuss herb and supplement use. It is also appropriate to put a question like this into medical intake questionnaires filled out prior to the appointment.",
"   </p>",
"   <p>",
"    When the ingredients of a commercial herbal product are unknown, practitioners can consult the",
"    <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/\">",
"     Dietary Supplement Labels Database",
"    </a>",
"    or the product's website.",
"   </p>",
"   <p>",
"    Patients who use herbs should be asked about their reasons for use. Motivation for herb use is often not based on scientific data [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/16\">",
"     16",
"    </a>",
"    ]. Of herbal users surveyed, 72 percent stated they would continue using supplements despite a negative government scientific study. Instead patients often get their information about herbs from family, friends, advertisements, and the Internet. Patients can be directed to Medline plus (see above) for free evidence-based information about many herbal products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Advising patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The schema in the table (",
"    <a class=\"graphic graphic_table graphicRef64011 \" href=\"UTD.htm?20/31/20987\">",
"     table 8",
"    </a>",
"    ), can be used to develop an approach to advising patients about an herbal product based upon the evidence for that product's quality, efficacy, and safety [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/49,54\">",
"     49,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there is strong evidence for an herbal product's quality, safety, and efficacy, it may be reasonable to proactively recommend that product and closely monitor the patient for effectiveness and safety. Given the frequent uncertainty in herbal product quality, which impacts the product's efficacy and safety, few (if any) herbal products currently fit these criteria.",
"   </p>",
"   <p>",
"    In contrast, it would be appropriate to discourage use of products when there is strong evidence for either lack of quality, inefficacy, or harmfulness. Examples of products that should be discouraged include traditional herbal medicines known to contain toxic heavy metals, St. John's wort when taken with medicines metabolized by CYP3A4, and ephedra-related products [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of herbal products do not fall into either the recommend or discourage category due to uncertain, insufficient, or contradictory evidence regarding quality, efficacy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    safety. For these products, physicians should counsel and caution patients regarding the uncertainty of the evidence. The impact of uncertain quality on efficacy and safety should be emphasized. If the patient chooses to proceed with an herbal product, a plan should be agreed on for ongoing monitoring for both benefits and adverse effects. These discussions should be documented clearly in the medical record.",
"   </p>",
"   <p>",
"    Physicians need to take into account patients' individual health conditions, concerns, and preferences [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/81\">",
"     81",
"    </a>",
"    ]. Patients seeking or already using herbal treatments should have an appropriate evaluation for their condition such that proven conventional treatments can be offered for any diagnosed conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the patient who decides to use an herbal product against the advice of his or her physician, a nonjudgmental attitude should be maintained. This will allow channels of communication to remain open for monitoring and future discussion. A patient's decision to pursue herbal therapy against medical advice or in lieu of conventional therapy is not an acceptable justification for a physician to terminate care of a patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Choice of brand",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who use herbs often ask their providers what brand should be used. Lack of regulatory reform in the herbal industry makes it difficult for the clinician to provide an informed response. One option is to recommend brands that have been tested by independent sources such as Consumer Labs (www.consumerlab.com) and found to meet minimum quality criteria. For ethical reasons, supplements sold through practitioners' offices or multilevel marketing plans should be discouraged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Pregnancy and nursing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few animal or human studies have been conducted on the safety of herbal medicines in pregnancy or while nursing. Given the current paucity of data for these populations as well as the uncertainty in product quality, women who are pregnant, contemplating pregnancy, or lactating should generally be discouraged from using herbal treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents should be cautioned about the relative lack of studies demonstrating efficacy and safety of herbal medicines in infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/83\">",
"     83",
"    </a>",
"    ]. Additional concerns are proper dosing in this age group, greater susceptibility to potential contaminants, and uncertainty of product quality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caution should be exercised in the use of herbs in older adults due to possible decreased renal and hepatic clearance of herb and drug metabolites. Additionally, for older individuals taking multiple medications, there is a greater potential for herb-drug interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Surgical patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;No large prospective study of the impact of perioperative herb use on surgical outcomes has been completed. Herbs may theoretically impact surgery through altered coagulation (eg, ginkgo, ginseng, garlic), cardiovascular stability (eg, ephedra), glucose control (ginseng), anesthesia (eg, valerian, kava), and increased metabolism of perioperative medication (eg, St. John's wort). Case reports of perioperative bleeding associated with ginkgo biloba [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/84\">",
"     84",
"    </a>",
"    ] and saw palmetto [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/85\">",
"     85",
"    </a>",
"    ] have been reported. Authors have recommended avoiding herbs for at least two weeks prior to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/4/20554/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herbal treatments are widely used by patients in the United States and elsewhere. They have the potential for both benefit and harm. (See",
"    <a class=\"local\" href=\"#H1060381973\">",
"     'Commonly used herbs and supplements'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be asked about use of herbal treatments in a nonjudgmental manner as part of the medication history. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Asking about use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients can be advised about herbal product use or avoidance based upon a product's quality, efficacy, and safety (",
"      <a class=\"graphic graphic_table graphicRef64011 \" href=\"UTD.htm?20/31/20987\">",
"       table 8",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Advising patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uncertainty in quality and the relatively few well-designed studies make it difficult for physicians to proactively recommend herbal therapies for most patients. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Advising patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When patients decide to use herbal therapies they should be monitored for evidence of benefits and harmful effects, including side effects. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Advising patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that pregnant and nursing patients be advised to avoid herbal therapies (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Pregnancy and nursing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An option for counseling patients who seek advice about what brand of herbal medicine to use is to recommend brands that have been tested by independent sources such as Consumer Labs (www.consumerlab.com). (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Choice of brand'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/1\">",
"      Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280:1604.",
"     </a>",
"    </li>",
"    <li>",
"     The ABC Clinical Guide to Herbs, Blumenthal M (Ed), American Botanical Council/Thieme, New York 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/3\">",
"      Kaptchuk TJ. Acupuncture: theory, efficacy, and practice. Ann Intern Med 2002; 136:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/4\">",
"      Farnsworth NR, Akerele O, Bingel AS, et al. Medicinal plants in therapy. Bull World Health Organ 1985; 63:965.",
"     </a>",
"    </li>",
"    <li>",
"     National Center for Complementary and Alternative Medicine. Expanding Horizons of Health Care: Strategic Plan 2005-2009. NIH publication no. 04-5568., National Center for Complementary and Alternative Medicine; NIH, Bethesda, MD 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/6\">",
"      Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 1993; 328:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/7\">",
"      Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998; 280:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/8\">",
"      Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/9\">",
"      American Botanical Council. Herbal Supplement Sales Experience Slight Increase in 2008. HerbalGram 2009; 82:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/10\">",
"      Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/11\">",
"      Kaptchuk TJ, Eisenberg DM. The persuasive appeal of alternative medicine. Ann Intern Med 1998; 129:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/12\">",
"      Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med 2001; 135:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/13\">",
"      Marcus DM, Grollman AP. Botanical medicines--the need for new regulations. N Engl J Med 2002; 347:2073.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine Committee. Use of Complementary and Alternative Medicine by the American Public. National Academies Press, Washington DC, 2005. Available at: www.iom.edu/project.asp?id=4829 (Accessed on September 13, 2005).",
"    </li>",
"    <li>",
"     Center for Science in the Pulic Interest (CSPI). CSPI Reacts to IOM Report on Dietary Supplements. Available at: www.cspinet.org/new/200404012.html (Accessed on August 16, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/16\">",
"      Blendon RJ, DesRoches CM, Benson JM, et al. Americans' views on the use and regulation of dietary supplements. Arch Intern Med 2001; 161:805.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Issues dietary supplements final rule. Available at: www.fda.gov/bbs/topics/NEWS/2007/NEW01657.html (Accessed on March 18, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/18\">",
"      McKenzie J, Keller HH. Vitamin-mineral supplementation and use of herbal preparations among community-living older adults. Can J Public Health 2001; 92:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/19\">",
"      Harrison RA, Holt D, Pattison DJ, Elton PJ. Who and how many people are taking herbal supplements? A survey of 21,923 adults. Int J Vitam Nutr Res 2004; 74:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/20\">",
"      Vaabengaard P, Clausen LM. [Surgery patients' intake of herbal preparations and dietary supplements]. Ugeskr Laeger 2003; 165:3320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/21\">",
"      Devesa Jord&agrave; F, Pellicer Bataller J, Ferrando Ginestar J, et al. [Consumption of medicinal herbs in patients attending a gastroenterology outpatient clinic]. Gastroenterol Hepatol 2004; 27:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/22\">",
"      Jamison JR. Herbal and nutrient supplementation practices of chiropractic patients: an Australian case study. J Manipulative Physiol Ther 2003; 26:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/23\">",
"      Delgoda R, Ellington C, Barrett S, et al. The practice of polypharmacy involving herbal and prescription medicines in the treatment of diabetes mellitus, hypertension and gastrointestinal disorders in Jamaica. West Indian Med J 2004; 53:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/24\">",
"      Clement YN, Williams AF, Aranda D, et al. Medicinal herb use among asthmatic patients attending a specialty care facility in Trinidad. BMC Complement Altern Med 2005; 5:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/25\">",
"      Ailinger RL, Molloy S, Zamora L, Benavides C. Herbal remedies in a Nicaraguan barrio. J Transcult Nurs 2004; 15:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/26\">",
"      Silva MI, Sousa FC, Gondim AP. Herbal therapy in primary health care in Maracana&uacute;, Cear&aacute;, Brazil. Ann Pharmacother 2005; 39:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/27\">",
"      Bland RM, Rollins NC, Van den Broeck J, et al. The use of non-prescribed medication in the first 3 months of life in rural South Africa. Trop Med Int Health 2004; 9:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/28\">",
"      Stewart MJ, Steenkamp V, Zuckerman M. The toxicology of African herbal remedies. Ther Drug Monit 1998; 20:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/29\">",
"      Ang HH. Herbal medicines in Malaysia. Clin Pharmacol Ther 2005; 77:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/30\">",
"      Shankar PR, Partha P, Shenoy N. Self-medication and non-doctor prescription practices in Pokhara valley, Western Nepal: a questionnaire-based study. BMC Fam Pract 2002; 3:17.",
"     </a>",
"    </li>",
"    <li>",
"     Major Herbs of Ayurveda, Williamson EM (Ed), Churchill Livingston, London 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/32\">",
"      Chan TY. The prevalence use and harmful potential of some Chinese herbal medicines in babies and children. Vet Hum Toxicol 1994; 36:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/33\">",
"      De Smet PA. Herbal medicine in Europe--relaxing regulatory standards. N Engl J Med 2005; 352:1176.",
"     </a>",
"    </li>",
"    <li>",
"     The Complete German Commission E Monographs: Therapeutic guide to herbal medicines, Blumenthal M (Ed), American Botanical Council, Austin 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/35\">",
"      Hesketh T, Zhu WX. Health in China. Traditional Chinese medicine: one country, two systems. BMJ 1997; 315:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/36\">",
"      Gogtay NJ, Bhatt HA, Dalvi SS, Kshirsagar NA. The use and safety of non-allopathic Indian medicines. Drug Saf 2002; 25:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/37\">",
"      Okpako DT. Traditional African medicine: theory and pharmacology explored. Trends Pharmacol Sci 1999; 20:482.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Essential Drugs and Medicines Policy. Available at: www.who.int/medicines/library/trm/nationalpolicy_globalsurvey.shtml (Accessed on September 09, 2005).",
"    </li>",
"    <li>",
"     National policy on traditional medicine and regulation of herbal medicines: report of a WHO global survey. WHO. Geneva 2005. Available at: file://apps.who.int/medicinedocs/en/d/Js7916e/ (Accessed on April 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/40\">",
"      Ernst E. Harmless herbs? A review of the recent literature. Am J Med 1998; 104:170.",
"     </a>",
"    </li>",
"    <li>",
"     Newall CA, Anderson LA, Phillipson JD. Herbal Medicines. A Guide For Health-Care Professionals, The Pharmaceutical Press, London 1996. p.6.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/42\">",
"      Crone CC, Wise TN. Use of herbal medicines among consultation-liaison populations. A review of current information regarding risks, interactions, and efficacy. Psychosomatics 1998; 39:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/43\">",
"      Harkey MR, Henderson GL, Gershwin ME, et al. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr 2001; 73:1101.",
"     </a>",
"    </li>",
"    <li>",
"     www.consumerlab.com (Accessed on September 07, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/45\">",
"      Garrard J, Harms S, Eberly LE, Matiak A. Variations in product choices of frequently purchased herbs: caveat emptor. Arch Intern Med 2003; 163:2290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/46\">",
"      M&uuml;ller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998; 31 Suppl 1:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/47\">",
"      Singer A, Wonnemann M, M&uuml;ller WE. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. J Pharmacol Exp Ther 1999; 290:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/48\">",
"      Gilroy CM, Steiner JF, Byers T, et al. Echinacea and truth in labeling. Arch Intern Med 2003; 163:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/49\">",
"      Weiger WA, Smith M, Boon H, et al. Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med 2002; 137:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/50\">",
"      Ko RJ. Adulterants in Asian patent medicines. N Engl J Med 1998; 339:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/51\">",
"      Saper RB, Kales SN, Paquin J, et al. Heavy metal content of ayurvedic herbal medicine products. JAMA 2004; 292:2868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/52\">",
"      Kew J, Morris C, Aihie A, et al. Arsenic and mercury intoxication due to Indian ethnic remedies. BMJ 1993; 306:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/53\">",
"      Saper RB, Phillips RS, Sehgal A, et al. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA 2008; 300:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/54\">",
"      Saper RB, Eisenberg DM, Phillips RS. Common dietary supplements for weight loss. Am Fam Physician 2004; 70:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/55\">",
"      Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/56\">",
"      Astrup A, Breum L, Toubro S, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord 1992; 16:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/57\">",
"      Boozer CN, Daly PA, Homel P, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord 2002; 26:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/58\">",
"      Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003; 289:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/59\">",
"      Peters CM, O'Neill JO, Young JB, Bott-Silverman C. Is there an association between ephedra and heart failure? a case series. J Card Fail 2005; 11:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/60\">",
"      Bent S, Ko R. Commonly used herbal medicines in the United States: a review. Am J Med 2004; 116:478.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration (FDA). Sales of Supplements Containing Ephedrine Alkaloids (Ephedra) Prohibited. Available at: www.fda.gov/oc/ (Accessed on August 16, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/62\">",
"      Nykamp DL, Fackih MN, Compton AL. Possible association of acute lateral-wall myocardial infarction and bitter orange supplement. Ann Pharmacother 2004; 38:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/63\">",
"      Bouchard NC, Howland MA, Greller HA, et al. Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. Mayo Clin Proc 2005; 80:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/64\">",
"      Larrey D. Hepatotoxicity of herbal remedies. J Hepatol 1997; 26 Suppl 1:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/65\">",
"      Huxtable RJ. New aspects of the toxicology and pharmacology of pyrrolizidine alkaloids. Gen Pharmacol 1979; 10:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/66\">",
"      Dammin GJ. Endemic nephropathy in Yugoslavia. Arch Pathol 1972; 93:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/67\">",
"      Cronin AJ, Maidment G, Cook T, et al. Aristolochic acid as a causative factor in a case of Chinese herbal nephropathy. Nephrol Dial Transplant 2002; 17:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/68\">",
"      Arlt VM, Stiborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 2002; 17:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/69\">",
"      Buettner C, Mukamal KJ, Gardiner P, et al. Herbal supplement use and blood lead levels of United States adults. J Gen Intern Med 2009; 24:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/70\">",
"      Centers for Disease Control and Prevention (CDC). Lead poisoning associated with ayurvedic medications--five states, 2000-2003. MMWR Morb Mortal Wkly Rep 2004; 53:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/71\">",
"      Ernst E. Heavy metals in traditional Indian remedies. Eur J Clin Pharmacol 2002; 57:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/72\">",
"      Kales SN, Christophi CA, Saper RB. Hematopoietic toxicity from lead-containing Ayurvedic medications. Med Sci Monit 2007; 13:CR295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/73\">",
"      Siegel RK. Ginseng abuse syndrome. Problems with the panacea. JAMA 1979; 241:1614.",
"     </a>",
"    </li>",
"    <li>",
"     Newall CA, Anderson LA, Phillipson JD. Herbal Medicines. A Guide For Health-Care Professionals, The Pharmaceutical Press, London 1996. p.9.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/75\">",
"      Brazier NC, Levine MA. Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am J Ther 2003; 10:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/76\">",
"      Shi S, Klotz U. Drug interactions with herbal medicines. Clin Pharmacokinet 2012; 51:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/77\">",
"      Bailey DG, Arnold JM, Spence JD. Grapefruit juice and drugs. How significant is the interaction? Clin Pharmacokinet 1994; 26:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/78\">",
"      Uesawa Y, Takeuchi T, Mohri K. Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol 2012; 13:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/79\">",
"      Eisenberg DM, Kessler RC, Van Rompay MI, et al. Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 2001; 135:344.",
"     </a>",
"    </li>",
"    <li>",
"     Joint Commission on Accreditation of Healthcare Organizations. 2005 National Patient Safety Goals FAQs. Available at: file://www.jointcommission.org/ (Accessed on August 16, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/81\">",
"      Ashar BH, Rowland-Seymour A. Advising patients who use dietary supplements. Am J Med 2008; 121:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/82\">",
"      Eisenberg DM. Advising patients who seek alternative medical therapies. Ann Intern Med 1997; 127:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/83\">",
"      Gardiner P. Dietary supplement use in children: concerns of efficacy and safety. Am Fam Physician 2005; 71:1068, 1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/84\">",
"      Destro MW, Speranzini MB, Cavalheiro Filho C, et al. Bilateral haematoma after rhytidoplasty and blepharoplasty following chronic use of Ginkgo biloba. Br J Plast Surg 2005; 58:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/85\">",
"      Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of Saw Palmetto herb: a case report and review of literature. J Intern Med 2001; 250:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/4/20554/abstract/86\">",
"      Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001; 286:208.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1392 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-F836DB8729-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_4_20554=[""].join("\n");
var outline_f20_4_20554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1060381973\">",
"      Commonly used herbs and supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      UNITED STATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Prevalence of use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Market sales",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Reasons for use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INTERNATIONAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Europe",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Asia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Developing world",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      QUALITY AND EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Quality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Plant species used",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Plant parts used",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Harvesting and storage conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Processing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Accuracy of labeling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Standardization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Purity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Herb-drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      INTERNET EVIDENCE-BASED RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      COUNSELING PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Asking about use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Advising patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Choice of brand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Pregnancy and nursing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Infants and children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Older adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/1392\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/1392|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/24/19851\" title=\"table 1\">",
"      Medications with plant origins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/49/40732\" title=\"table 2\">",
"      Herbs affecting glucose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/31/24059\" title=\"table 3\">",
"      Herbs affecting lipids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/33/44571\" title=\"table 4\">",
"      Hormonally active herbs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/47/36603\" title=\"table 5\">",
"      Hypertensive herbal ingredients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/41/38556\" title=\"table 6\">",
"      Cardioactive herbal ingredients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/4/8269\" title=\"table 7\">",
"      Herbal medicine hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/31/20987\" title=\"table 8\">",
"      Advising about herbs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=related_link\">",
"      Adult lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8730?source=related_link\">",
"      Arsenic exposure and poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17498?source=related_link\">",
"      Benefits and risks of caffeine and caffeinated beverages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31496?source=related_link\">",
"      Chinese herbal medicine for the treatment of allergic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27784?source=related_link\">",
"      Clinical use of St. John's wort",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23542?source=related_link\">",
"      Clinical use of echinacea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/28/11720?source=related_link\">",
"      Clinical use of ginkgo biloba",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33061?source=related_link\">",
"      Clinical use of saw palmetto",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7513?source=related_link\">",
"      Complementary and alternative remedies in rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6953?source=related_link\">",
"      Complementary and alternative therapies for allergic rhinitis and conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=related_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/263?source=related_link\">",
"      Dehydroepiandrosterone and its sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13242?source=related_link\">",
"      Emerging therapies for hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/52/15177?source=related_link\">",
"      Evaluation and management of colic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25642?source=related_link\">",
"      Hepatotoxicity due to herbal medications and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=related_link\">",
"      Investigational therapies for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7606?source=related_link\">",
"      Long-term management and prevention of urinary tract infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2536?source=related_link\">",
"      Mitochondrial myopathies: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18824?source=related_link\">",
"      Motion sickness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6933?source=related_link\">",
"      Nephropathy induced by aristolochic acid (AA) containing herbs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/19/9529?source=related_link\">",
"      Non-hormonal performance enhancement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=related_link\">",
"      Pharmacotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13034?source=related_link\">",
"      Physiology and clinical use of melatonin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18809?source=related_link\">",
"      Possibly effective emerging therapies for heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5514?source=related_link\">",
"      Recurrent urinary tract infection in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=related_link\">",
"      Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30537?source=related_link\">",
"      The common cold in adults: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29002?source=related_link\">",
"      Treatment and outcome of nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39221?source=related_link\">",
"      Unproven therapies for chronic systolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_4_20555="Betamethasone vs dexamethasone";
var content_f20_4_20555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relative risk of selected adverse outcomes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Betamethasone versus control",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dexamethasone versus control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory distress syndrome",
"       </td>",
"       <td>",
"        0.57*",
"       </td>",
"       <td>",
"        0.70*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraventricular hemorrhage",
"       </td>",
"       <td>",
"        0.27*",
"       </td>",
"       <td>",
"        0.60*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perinatal infection",
"       </td>",
"       <td>",
"        0.72",
"       </td>",
"       <td>",
"        0.99",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal death",
"       </td>",
"       <td>",
"        0.47*",
"       </td>",
"       <td>",
"        0.84",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stillbirth",
"       </td>",
"       <td>",
"        0.80",
"       </td>",
"       <td>",
"        0.95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal infection",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"       <td>",
"        1.17",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Difference between study drug and controls was statistically significant.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Jobe, AH, Soll, RF. Am J Obstet Gynecol 2004; 190:878.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_4_20555=[""].join("\n");
var outline_f20_4_20555=null;
var title_f20_4_20556="Maternal mortality ratio";
var content_f20_4_20556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Maternal mortality ratio (MMR), 2008",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Country",
"      </td>",
"      <td class=\"subtitle1\">",
"       MMR (maternal deaths per 100,000 live births)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asia-Pacific, high income",
"      </td>",
"      <td>",
"       8 to 9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asia, central",
"      </td>",
"      <td>",
"       45 to 52",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asia, east",
"      </td>",
"      <td>",
"       35 to 46",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asia, south",
"      </td>",
"      <td>",
"       232 to 444",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asia, southeast",
"      </td>",
"      <td>",
"       112 to 212",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Australasia",
"      </td>",
"      <td>",
"       5 to 7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Caribbean",
"      </td>",
"      <td>",
"       168 to 372",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Europe, central",
"      </td>",
"      <td>",
"       12 to 14",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Europe, eastern",
"      </td>",
"      <td>",
"       29 to 35",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Europe, western",
"      </td>",
"      <td>",
"       7 to 8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Latin America, Andean",
"      </td>",
"      <td>",
"       77 to 134",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Latin America, central",
"      </td>",
"      <td>",
"       51 to 63",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Latin America, southern",
"      </td>",
"      <td>",
"       36 to 45",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Latin America, tropical",
"      </td>",
"      <td>",
"       37 to 87",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       North America/Middle East",
"      </td>",
"      <td>",
"       61 to 94",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       North America, high income",
"      </td>",
"      <td>",
"       14 to 18",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Oceania",
"      </td>",
"      <td>",
"       174 to 434",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sub-Saharan Africa, central",
"      </td>",
"      <td>",
"       392 to 839",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sub-Saharan Africa, east",
"      </td>",
"      <td>",
"       430 to 610",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sub-Saharan Africa, southern",
"      </td>",
"      <td>",
"       288 to 496",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sub-Saharan Africa, west",
"      </td>",
"      <td>",
"       508 to 787",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hogan, MC, Foreman, KJ, Naghavi, M, et al. Maternal mortality for 181 countries, 1980-2008: a systematic analysis of progress towards Millennium Development Goal 5. Lancet 2010; 375:1609.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_4_20556=[""].join("\n");
var outline_f20_4_20556=null;
var title_f20_4_20557="Functional GI disorders child";
var content_f20_4_20557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rome III diagnostic criteria for functional gastrointestinal disorders of childhood (ages 4 to 18 years)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Functional dyspepsia (must include all of the following):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Within the preceding two months, at least weekly occurrence of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Persistent or recurring pain or discomfort in the upper abdomen,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No evidence of inflammatory, anatomic, metabolic, or neoplastic process to explain the symptoms,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pain or discomfort not relieved by defecation or associated with the onset of a change in stool frequency or form",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Irritable bowel syndrome (must include all of the following):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Within the preceding two months, at least weekly occurrence of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Abdominal discomfort or pain associated with &ge;2 of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Relieved with defecation,",
"        <strong>",
"         and/or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Onset associated with a change in frequency of stool,",
"        <strong>",
"         and/or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Onset associated with a change in form (appearance) of stool,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        No evidence of inflammatory, anatomic, metabolic, or neoplastic process to explain the symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Functional abdominal pain (must include all of the following):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Within the preceding two months, at least weekly occurrence of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Episodic or continuous abdominal pain,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Insufficient criteria for other functional gastrointestinal disorders,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No evidence of inflammatory, anatomic, metabolic, or neoplastic process to explain the symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Childhood functional abdominal pain syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Within the preceding two months, at least weekly occurrence of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Childhood functional abdominal pain at least 25 percent of the time and &ge;1 of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Some loss of daily functioning,",
"        <strong>",
"         and/or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Additional somatic symptoms such as headache, limb pain, or difficulty sleeping",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Abdominal migraine pain (must include all of the following):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Within the preceding 12 months, &ge;2 episodes of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paroxysmal episodes of intense, acute, periumbilical pain that lasts for &ge;1 hour,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intervening periods of usual health lasting weeks to months,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The pain interferes with normal activities,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        The pain is associated with &ge;2 of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Anorexia,",
"        <strong>",
"         and/or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Nausea,",
"        <strong>",
"         and/or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Headache,",
"        <strong>",
"         and/or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Photophobia,",
"        <strong>",
"         and/or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Pallor,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        No evidence of inflammatory, anatomic, metabolic, or neoplastic process to explain the symptoms",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Rasquin A, Di Lorenzo C, Forbes D, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 2006; 130:1527. Copyright &copy;2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_4_20557=[""].join("\n");
var outline_f20_4_20557=null;
var title_f20_4_20558="Overview of the medical therapy of Crohns disease";
var content_f20_4_20558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Overview of the medical therapy of Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 349px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_4_20558=[""].join("\n");
var outline_f20_4_20558=null;
var title_f20_4_20559="Monophasic arterial Doppler waveform";
var content_f20_4_20559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Monophasic arterial Doppler waveform",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The monophasic Doppler signal has a slow upstroke, rounded peak, slow downstroke, no flow reversal and is non-pulsatile.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Division of Vascular Surgery at OHSU.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_4_20559=[""].join("\n");
var outline_f20_4_20559=null;
      